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ABSTRACT 
A series of chromone-3-carbaldehydes have been prepared using Vilsmeier-Haack 
methodology while a corresponding series of chromone-2-carbaldeydes have been 
synthesized via the Kostanecki-Robinson reaction. Baylis-Hillman reactions have 
been conducted on both series of chromone carbaldehydes using three different 
catalysts, viz., 1,4-diazabicyclo(2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]-
undec-7-ene (DBU) and 3-hydroxyquinuclidine (3HQ), and acrylonitrile, methyl 
acrylate and methyl vinyl ketone as the activated alkenes. These reactions have 
typically (but not always!) afforded both normal Baylis-Hillman and dimeric 
products. Attention has also been given to the use of 1-methyl-2-pyrrolidine (1-NMP), 
an ionic liquid, to replace normal organic solvents, and it has been found that, in the 
presence of DABCO, chromone-3-carbaldehydes afford the dimeric products alone. 
Reactions of chromone-3-carbaldehydes with methyl vinyl ketone have yielded 
unexpected, novel adducts, which appear to arise from preferential attack at C(2) in 
the chromone nucleus. Research on chromone-2-carbaldeydes under Baylis-Hillman 
conditions has also resulted in the formation of some interesting products instead of 
the expected Baylis-Hillman adducts. 
The Baylis-Hillman products have been explored as substrates for aza-Michael 
reactions using various amino derivatives including protected amino acids in the 
presence of the tetrabutylammonium bromide (TBAB) and the ionic liquid, 3-butyl-1-
methylimidazoleboranetetrafluoride (BmimBF4), as catalysts. The aza-Michael 
products have been targeted as truncated ritonavir analogues for investigation as 
potential HIV -1 protease inhibitors, and representative compounds have been 
subjected to enzyme inhibition assays to explore the extent and type of inhibition. 
Lineweaver-Burk and Dixon plots have indicated competitive inhibition in one case 
as well as non-competitive inhibition in another, and the inhibition constants (Ki) have 
been compared with that of the ritonavir. 
Computer modelling studies have also been conducted on selected chromone-
containing derivatives, using the ACCELRYS Cerius2 platform. Interactive docking 
of the chromone-containing ligands into the HIV -1 protease receptor site, using the 
Ligandfit module, has indicated the importance of hydrogen-bonding interactions 
mediated by bridging water molecules situated in the receptor cavity. 
NMR spectroscopy has been used to elucidate complex and competing mechanistic 
pathways involved in the Baylis-Hillman reactions of selected 2-nitrobenzaldehydes 
with MVK in the presence of DABCO - reactions which afford the normal Baylis-
Hillman product, the MVK dimer and syn- and anti-Baylis-Hillman type diadducts. 
The kinetic data confirm the concomitant operation of two pathways and reveal that, 
in the initial stage of the reaction, the product distribution is kinetically controlled, 
whereas in the latter stage, thermodynamic control results in the consumption of the 
normal Baylis-Hillman product and predominance of the anti-diadduct. 
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Introduction 
1. INTRODUCTION 
1.1 The Human Immunodeficiency Virus 
Human immunodeficiency virus subtypes 1 and 2 (HIV -1 and HIV -2) are the two forms 
of HIV that are recognized as the cause of the pandemic called Acquired 
Immunodeficiency Syndrome (AIDS). 1-4 However, since the HIV -2 pathogen has a 
longer latent period prior to the development of the disease and the virus is not easily 
transmitted, the AIDS infections found in humans is typically caused by HIV -1 _3 These 
two subtypes were found to originate from two African monkeys; the chimpanzee (Pan 
troglodytes troglodytes) for HIV-1 and the sooty mangabay (Cercocebus atys) for HIV-
2. s-6 HIV -1 was first isolated from a patient with multiple lymphadenopathies, a 
condition associated with AIDS.7 Initially, various names were given to the virus 
isolated from AIDS patients, viz., human T lymphotropic virus III (HTLV-IJI), 
immunodeficiency associated virus (IDA V), lymphadenopathy-associated virus (LA V), 
and AIDS-associated retrovirus (ARV).8-12 However, in 1986, human immunodeficiency 
virus, HIV, was the name approved for this type of virus.9 HIV belongs to the 
Retroviridae family, in which genetic information flows from RNA to DNA; 13-14 it also 
belongs to the Lentivirus subfamily, 15-16 members of which are able to infect non-
dividing cells.17 In this review the focus will be on HIV -1. 
1.1.1 HIV-1 Structure and function 
HIV -1 is composed of nine known genes with the ends being flanked by long terminal 
repeat sequences (L TR), which are crucial for the initiation of viral gene expression 
(Figure 1).18-19 These genes are classified into three major coding domains:- (i) the three 
standard core genes: gag, a gene coding for a protein which forms the viral core and 
which is also involved in the assembly of the virion in the host cell membrane; pol, 
which codes for the enzymatic proteins, viz., protease (PR), reverse transcriptase (R T), 
and integrase (IN); and env, which directs the formation of the surface envelope, 
glycoproteins gp 120 and gp41 ;4' 17-18 (ii) the two regulatory genes (tat, rev); and (iii) 
1 
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four accessory genes (vpr, vpu, nef, vij) which are essential for viral replication and host 
pathogenesis.4' 18•20-21 
Vif Nef Ncl:l 
-Vpr 
Figure 1. Genetic organisation of HlV-1. The asterisked genes together with the central 
DNA flap are involved in I-IIV-1 nuclear import. [Adapted from ref. 18] 
The HIV-1 virion (Figure 2) is enveloped by a lipid bilayer membrane with two types of 
glycoprotein attached to the surface, viz. , the surface (SU) envelope protein (gp 120), 
located on the external face, and the transmembrane (TM) envelope protein (gp41 )_22-23 
In mature virions, the matrix (MA) proteins line the inner surface of the membrane, 
while the capsid (CA) protein forms a cone-shaped core which contains two copies of 
identical, single-stranded RNA (diploid genomic RNA) complexed with nucleocapsids 
(NC), and the replicative enzymes: reverse transcriptase (RT), protease (PR) and 
integrase (IN). 18•21•23-25 Immature virions have a spherical capsid which collapses to a 
conical shape during replication and maturation to the virion.23-24•26-27 
~--~~~-----p6 
cA--~~-.--------~ 
RNA ---,,.---3----,.;:--\---t 
Dimer 
~--- MA 
Nef(core) 
VU'al protein. R IN 
RT ---->.i~--~ ~~-FI---- PR (Vpr) .._....., ... 
Figure 2. Organisation ofthe matured HIV-1 virion. [Adapted from ref. 25] 
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1.1.2 Replication cycle of HIV-1 
The HIV -1 life cycle illustrated in Figure 3, begins when the envelope glycoprotein 
(gp 120) of the virus binds with a surface CD4 receptor of the host cell (Stage 1).28 This 
interaction results in the conformational change of gp 120 which activates the envelope 
protein (gp41) to mediate fusion of the viral and cellular membrane resulting in the 
"microinjection" of the capsid contents (Stage 2). The capsid (Stage 3) undergoes 
uncoating followed by reverse transcription in Stage 4, where the viral single-stranded 
RNA is transcribed into viral DNA. Stage 4 also involves the pre-integration complex 
(PIC) which comprises viral RNA/DNA, reverse transcriptase (RT), integrase (IN), 
matrix (MA) and viral protein R (Vpr). However, various core proteins are lost during 
the formation of the PIC. 29-30 
8 
t CD4 *ptor 
Viral DNA 
HIV virion 
Figure3. HIV-1 life cycle. [Adapted from ref. 29] 
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The PIC crosses through the lipid bilayer of the nuclear membrane where the viral DNA 
is integrated into the host cell DNA (Stage 5). The viral RNA synthesized from the 
integrated DNA is then transported back to the cell cytoplasm for translation to 
polypeptides and further protein synthesis (Stage 6).4'29 Newly synthesized viral 
proteins, the intermediate gag-pol polypeptide and two strands of viral RNA migrate to 
the cell membrane where assembly of the virion occurs (Stage 7).31 As the immature 
virion buds off from the host cell taking cell membrane with it, HIV -1 PR cleaves the 
gag-pol polypeptide into major structural proteins thus producing infectious and mature 
HIV -1 virions (Stage 8)?6' 32'33-34 
1.1.3 The HIV-1 Protease Enzyme 
1.1.3.1 HIV Protease structure 
HIV -1 PR, an aspartic protease, is a 22 kDa homodimeric endopeptidase comprismg two 
identical 99 amino acid polypeptides.35-39 The active site of HIV-1 PR is a hydrophobic 
cavity of about lOA in diameter.40 Inside the cavity, Asp-Thr/Ser-Gly triad sequence 
residues and an aspartate from each monomer, together with structural water molecules 
are involved in the cleavage of substrate amide bonds.4144 The X-ray crystal structure 
of HIV -1 PR (Figure 4) reveals a symmetric structure with each monomer contributing 
an extended glycine-rich fi-sheet region known as the flap. Each monomer has a 
hydrophobic core consisting of two loops, one of which includes the active site aspartic 
acid. The enzyme-binding cavity is capable of accommodating a minimum of seven 
consecutive amino acid residues in the substrate.46,47 The amino acid residues found in 
the binding pockets (or subsites) of HIV -1 PR are specified m Table 1. 
4 
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Flap 
Active Site 
Beta Sheet 
·- _....., 
Figure 4. X-ray crystal structure ofHIV-1 PR dimer. [Adapted from ref. 46] 
Table 1. Amino acid sequences forming the HIV -1 protease subsites. 41 
Subsite HIV-1 PR 
s4 Asp30' Ile50' lle54' 
s 3 Arg8 Asp29'Leu23 Val82 Arg87' 
s 2 Ala28 Val82 Phe53' Ile54' Leu 76' Thr80' Ile84' 
s, Leu23 Asp25* Phe53 Pro81 Val82 Ile84 
s, . Leu23 ' Asp25'* Phe53' Ile84' 
S2· Ala28 Asp30 Val32 Phe53 Ile54 Leu 76 Ile84 
S3· Arg8 Asp29 lle50 Pro81 ' Arg87 
Primes (')distinguish the residues from the two subunits in the dimer ofHIV-1 PR. 
* Catalytic Asp residue. 
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1.1.3.2 HIV -1 Protease Function 
HIV -1 PR is one of the viral enzymes essential for the HIV -1 life cycle, 39•4849 selectively 
cleaving viral polyproteins at specific peptide bonds. 50-51 Figure 5 depicts how HIV -1 PR 
functions as a "molecular pair of scissors", by hydrolyzing the viral gag-pol precursor 
proteins to produce structural proteins.16 Hydrolysis of the amide carbonyl group, by a 
water molecule accommodated between the side-chains of the aspartic acid residues 25 
and 125, is believed to involve a tetrahedral intermediate.16•44 
Peptide substrate 
.Y).H 0 
~0-------- h. ____ __ g~ . 
Asp 25 . u Asp 125 
Acids 
R, 
Products 
,Z~~OH 
0 
,...H 
~0 
Asp 25 . 
Amine 
Asp 125 
Tetrahedral intermediate 
AN~It,Jl, 
H 0 0 T l 
(/
H/ I R2 
. H 
' 
' 
(to------ H,o~ 
Asp 25 · Asp 125 
1! 
Figure 5. Catalytic mechanism of HIV -1 Protease. [Adapted from ref. 16] 
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1.1.4 HIV-1 Protease Substrates 
HIV -1 PR polypeptide substrates contain various amino acid sequences, which may 
dictate cleavage at different substrate sites (Table 2).31 Such sequences comprise 
approximately seven amino acids?6•31 
Table 2. Amino acid sequences forming the substrate sites cleaved by HIV Protease.31 
Site Amino acid sequences at cleavage site 
1 Ser.Gln.Asn.Tyr*Pro.Ile.Val.Gln 
2 Ala.Arg.V al.Leu* Ala.Glu.Ala.Met 
3 Ala.Thr.Ile.Met*Met.Gln.Arg.Gly 
4 Pro.Gly.Asn.Phe*Leu.Gln.Arg.Gly 
5 Ser.Phe.Asn.Phe*Pro.Gln.Ile.Thr 
16 The.Leu.Asn.Phe*Pro.Ile.Ser.Pro 
: 7 Ala. Glu. Thr.Phe*Tyr.Val.Asp. Gly I [8 Arg.Lys.Ile.Leu*Pro.Leu.Asp.Gly 
* Signifies the scissile bond location 
In 1967, Schechter and Berger47 developed the nomenclature now used for the HIV-1 
protease- substrate complex and which is illustrated in Figure 6, where S 1, S2,. .••• ,Sn and 
S1·, S2·, ..•.. ,Sn· denote the amino acid residues constituting the subsites in the enzyme 
active site. The corresponding groups in the substrate are denoted by P 1, P2, ..... ,Pn and 
Pl',P2·, ..... ,Pn· with the scissile bond being situated between P 1 and P 1•.31•47 The amino 
acid residues found in the binding pockets of HIV-1 PR are specified in Table 1.41 
Preliminary studies have shown that the S 1 and S ,. (S2 and S2· etc.) sites are structurally 
equivalent.47 Furthermore, the two S, and S2 subsites are more hydrophobic than S341•47 
Mutagenesis of the active site Asp to Asn in PR hinders the processing of polyprotein, 
and results in the formation of immature, non-infectious virions thereby preventing the 
spread of the virus to other cells.48•49•50-51 
7 
sl. 
Scissile~ 
bond
1 0 p Ol pI 0 pI 
Y~JY~yt~JY~0~JY 
p3 0 pt ! 0 P2' 
"---../ "---../ "---../ 
Figure 6. Standard nomenclature for HIV -1 PR and the substrate complex. 
[Adapted from ref. 47] 
1.1.5 Acquired ImmunoDeficiency Syndrome (AIDS) 
Introduction 
AIDS is the severe immunosuppressive condition which is caused by the increase of 
HIV replication.3'31 '52 This results in the depletion of CD4+ T -cells, with symptoms 
beginning to appear when the CD4+ T-cell concentration fal.ls below 500/~-tL; full-blown 
AIDS is indil:ated when the CD4+ T-cell concentration falls below 200/~-tL (Figure 7).3 
The time for progression to AIDS following HIV infection is variable but averages 
approximately 10 years. Apparently, the first documented case of AIDS occurred in 
Central Africa in 1959.53 
AIDS has become a pandemic which is escalating at an alarming rate. 54 At the end of 
2006, about 39.5 million people, globally, were found to be living with HIV/AIDS; of 
these, 4.3 million people were newly infected, and more than 2.9 million had died in that 
year from the disease (Figure 8). 55 In some countries the AIDS epidemic statistics are 
very low, but that does not mean they are not affected. Some recent studies have 
suggested that by the end of 2010 another 45 million people will have been infected with 
HIV if no effective preventive measures are taken globally. 28 
8 
1200 
:::r 1000 
E 
11 800 Qj 
~ 
!!!. 600 
Qj 
t,) 
I 
~ 400 
+ ~ 
0 200 (.) 
0 
0 
Primary 
Infection 
Anti-HIV immune 
2 4 6 
AIDS 
/symptoms 
8 10 
Time after infection (Years) 
Introduction 
12 
Figure 7. Progression ofHIV to AIDS over time.[Adapted from ref. 3] 
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Figure 8. Global HIV/AIDS pandemic statistics for 2006. [Adapted from ref. 55] 
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1.1.6 Designing HIV-1 Protease Inhibitors 
Computational studies have been used to design HIV-1 PR inhibitors (Pis). This 
approach explores structural compatibility between the inhibitor and the HIV PR active 
site. 13•56-57 The conformation of both the HIV PR active site and the substrate are critical 
factors in the biocatalytic process, and it is therefore crucial to understand the role of 
each specific amino acid within the active site in the presence of the substrate or 
inhibitor. 58 Enzyme kinetic studies are crucial in identifying what type of enzyme 
inhibitiot:J. occurs, and this can be described in terms of competitive inhibition, non-
competitive inhibition or uncompetitive inhibition. 59 
When designing HIV -1 PR inhibitors (Pis) various characteristics need to be considered. 
They should: (i) be effective against various HIV clinical isolates; (ii) be specific for 
HIV -1 PR (compared with other mammalian aspartic acid pro teases) to minimize 
possible adverse effects; (iii) have good oral bioavailability and duration in humans; (iv) 
be more effective in the suppression of the wild-type virus through increased efficacy 
and higher plasma levels; (v) be active against PI -resistant variances of HIV -1; and (vi) 
and be safe to use and well tolerated. 60-62 
There are currently nine HIV PR inhibitors clinically approved for use in the treatment 
of AIDS; they may be classified as peptidomimetic or non-peptidomimetic 
inhibitors.55•63 These Pis are usually administered as one or two drugs in combination 
with two nucleoside reverse transcriptase inhibitors.64-70 The peptidomimetic Pis 
are: 16•62-69 Invirase® [Saquinavir, Hoffman-La Roche, Dec. 1995] (1); Norvir® [ 
Ritonavir, Abbott Laboratories, March 1996] (2); Crixivan® [Indinavir, Merck, March 
1996] (3); Viracept® [Nelfinavir, Pfizer, March 1997 ] (4); Agenerase® [Amprenavir, 
GlaxoSmithKline, May 1999] (5); Kaletra® [Lopinavir, Abbott Laboratories, September 
2000] (6); Reyataz® [Atazanavir, Bristol-Myers Squibb, June 2003] (7); Lexiva® 
10 
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[Fosamprenavir, GlaxoSmithKline, October 2003] (8). The non-peptidomimetic PI is: 
Aptivus® [Tipranavir, Boehringer Ingelheim, June 2005] (9).63· 70 
9'1 
:::-... 
N 
0, 
:p" 
HO OH 
5 6 
9 
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Most clinically approved HIV -1 PR inhibitors (PI) contain a non-hydrolyzable 
hydroxyethylamine (10) or hydroxyethylene dipeptide (11) isostere at would otherwise 
be the scissile site. These inhibitors have a particular configuration at the hydroxyl-
bearing asymmetric centre, which is crucial for their inhibitory activity.71 
Hydroxyethylene dipeptide isosteres (11) have an S-configuration, at the hydroxyl 
bearing centre,71-74 while hydroxyethylamine isosteres (10) show a preference for an R-
configuration. 74-75 The hydroxyl group concerned participates in hydro.gen bonding 
interactions with the catalytic aspartic acid residues in the HIV PR active site, and its 
orientation plays a crucial role in the binding.76 
OH 
0 I 
Ph 
11 0 
H 
I 
N....._ 
Hydroxyethylamine isostere Hydroxyethylene dipeptide isostere 
1.2 Enzyme Kinetics and Inhibition 
Enzyme kinetic studies are crucial for discovering the kinetic parameters involved 
during the reversible interaction of the free enzyme (E) with the substrate (S) to form an 
enzyme-substrate complex (ES), which then decomposes to form the enzyme and the 
reaction product (P). These studies provide an understanding of the rate and specificity 
of biological processes.77 This can be described in terms of the steady state mechanism 
for a one-substrate reaction, 78 
kl 
(E] + (S]~==:!:: [ES] 
k_l 
(E) + (P] ... ........ .. (1) 
12 
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where k1, k_1 are the forward and reverse rate constants which describe the enzymatic 
process for the formation of ES, while k2 is the rate constant for the decomposition of ES 
to form product, the assumption being that second step is irreversible.79 The rate can be 
expressed in terms of the kinetic parameter known as the Michaelis constant, Km: 
Km = (kt + k2) 
kt 
The Michaelis constant (Km) measures the binding affinity between the substrate and 
enzyme and also determines the substrate concentration at which the reaction rate is half 
of its maximum value (V max), which occurs at a sufficiently high substrate concentration 
such that the enzyme is saturated.77-79 
However, when the inhibitor is introduced in the enzymatic reaction, it affects the 
binding of the substrate to the enzyme and this effect can be described in terms of 
competitive, non-competitive or uncompetitive inhibition. 80-82 In competitive inhibition, 
the inhibitor is assumed to bind to the active site of the free enzyme without forming any 
product thus reducing the concentration of free enzyme available to bind with the 
substrate. Competitive inhibition can be expressed by the following model.80•82 
[E] + [S] k1 '"" [ES] [E] + [P] 
+ 
.... . ........ (2) 
[EI] + [S] ---.. NO REACTION 
In the case of non-competitive inhibition, the inhibitor is presumed to bind at a site 
distinct from the substrate active site in either the free enzyme or the enzyme-substrate 
(ES) complex. Such inhibition can be represented as follows.80•82 
13 
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[E)+ [S] kl '"" (ES] k2 ... [E] + [P] 
+ k_) + 
[I] [I] 
1l K; 
............. (3) 
K'. I 
[EI] [ESI] NO REACTION 
In uncompetitive inhibition, the inhibitor is presumed to only bind to the ES complex at 
a site distinct from the substrate active site and this can be represented by the following 
model. 80,82 
[E] + [S] kl - [ES] Is ,.. [E] + [P] 
k_l + 
[I] 
... . ......... (4) 
1lK; 
[ESI] NO REACTION 
The Km, V max values and the inhibition constant (Ki), which measures the binding affinity 
between the enzyme and the inhibitor, are the kinetic parameters which determine the 
effect of an inhibitor on a catalytic reaction between an enzyme and a substrate. 8 I-83 
1.3 Chromones 
Chromone 12 is the parent structure for the benzannulated oxygen-containing 
heterocyclic compounds which contain a y-pyrone ring 13.84•85 Bloch and Kostanecki86 
used the name "chromone" when describing several coloured, naturally occurring 
compounds which contain the benzopyran-4-one moiety. Xanthone 14, a chromone 
derivative, is doubly benzannulated, while other common derivatives include flavones 
15 (2-phenylchromones), and isoflavones 16 (3-phenylchromones).87 Chromone 
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derivatives are widely distributed in plants, and their biological activity and 
pharmacological properties have prompted research into their chemical properties.88•89 
The pyran analogues 17 and 18 have no carbonyl group, while coumarin 19 is isomeric 
with chromone, differing only in the location ofthe carbonyl group.87• 90 
12 
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0 
03-----___ ..,. 
0 2 
1 
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y-pyrone 
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1.3.1 Structure and Spectroscopic Properties of chromone systems 
The n-electronic structure has been used to rationalize general chromone properties,87 
with the y-pyrone ring assuming the aliphatic dienone structure 13a rather than the 
pyrylium betaine structure 13b. However, certain properties, such as lack of normal 
ketonic behavior and the tendency to form salts with acids, has been attributed to a 
contribution by the pyrylium betaine structure 13b.91 These properties are consistent 
with Amdt's92 suggestion, made in 1924, that they-pyrone ether oxygen could interact 
electronically with the carbonyl group, thus modifying the properties of the latter. The 
"aromaticity" of the y-pyrone is evidenced by the failure to form a Diels-Alder adduct 
when 2,3-dimethylbuta-1 ,3-diene is treated with y-pyrone.93 The aromaticity of the y-
pyrone ring is also supported by the results of semi-empirical calculations (ab initio and 
DFT).85 
While molecular orbital delocalization energy (M.O.D.E), dipole moment and 1H- and 
13C-NMR data also indicate that they-pyrone ring in chromone possesses a significance 
degree of aromaticity,91•94 some spectroscopic properties of chromone derivatives are 
better explained in terms of the aliphatic dienone structure 13a. For example, the IR 
carbonyl stretching frequency for chromone 12 (vc=o ~ 1660 cm-1) is higher than for y-
pyrone (ve=o~ 1650 cm-1), but lower than for the isomeric coumarin 19 (vc=a~ 1710 cm-
1 ).95-97 
The 1H-NMR spectrum of chromone 12 in CDCh reveals that the 2-H and 3-H nuclei 
resonate at o 7.88 and 6.34 ppm, respectively.95 These values are almost the same as 
those found for y-pyrone 13a (o 7.88 and 6.38 ppm respectively),98 which implies that 
benzannulation has relatively little effect on the ring current of the heterocyclic ring. In 
the 13C-NMR spectra of chromones, the carbonyl carbon (C-4) signal always resonates at 
low field (o 177 ppm) and is relatively unaffected by substitution in the system. 
Substitution at C-2 or C-3 of the chromone nucleus, on the other hand, has a major effect 
16 
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on the chemical shifts of these carbon atoms. For example, substitution with either 
methyl or phenyl groups induces a downfield shift for the carbon to which they are 
attached, but an upfield shift for the adjacent carbon atom.98 
In electron-impact mass spectrometry, chromone 12 fragments via two main pathways, 
which involve either elimination of carbon monoxide or ring cleavage by a retro-Diels-
Alder (RDA) reaction as depicted in Scheme 1.90 While these transformations appear to 
be general in chromone systems, A-ring substitution may divert the fragmentation 
pattern.90 
12 
rnlz 146 
21 
rn/z118 
Scheme 1 
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1.3.2 Biological activity of chromone systems 
I"!" 
C)=c=o 
rnlz92 
J -CO 
Since the chemistry of chromones has been comprehensively studied,87 this review 
focuses mainly on the more recent literature (since 1980) on synthetic and naturally 
occurring chromone derivatives, which exhibit pharmacological activity. The collective 
term chromones will also be used in reference to chromone derivatives. 
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Many naturally occurring chromones contain a methyl group at C-2, a phenyl group at 
C-2 or C-3 and a hydroxyl group at C-5 and/or C-7.87 These features are exemplified by 
the polyoxygenated chromones, 5,7-dihydroxy-2-methylchromone 22 and 5,6-
dihydroxy-7 -methoxy-2-methylchromone 23, both of which were isolated from the bulb 
of Pancratium biflorum Roxb. when the plant still had flowers,99 by quercategetin 24, a 
flavone isolated from Sculletaria baicarensis and by the isoflavone 25, isolated from the 
roots of Salsola somalensis (synonyms: Halotamnus somalensis and S. bottae).100-102 
OH·-- 0 
HO Me 
22 
OH 0 
OH 
HO 
24 OH 
HO 
MeO 
MeO 
OH--- 0 
23 
OMe 
25 
Me 
OH 
The chromone moiety constitutes an important component of the pharrnacophore of a 
number of biologically active molecules. For example, the extracts of the bulb and the 
flowers of P. biflorum are used for the treatment of ear-ache, chest ailments and fungal 
diseases. 102 Compound 24 is known as the most potent HIV -1 integrase (IN) inhibitor, 
with the activity being attributed to the numerous hydroxyl groups. 100•103 The extract of 
the root of S. somalensis is used for the treatment of tapeworm infestations, while root 
parts are utilised as tooth sticks; the fibrous roots slowly disintegrate in the mouth and 
the juice is swallowed resulting, it is claimed, in the expulsion of parasites. 102 
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The synthetic 3 'R,4' R -di-0-(-)-camphanoyl-2' ,2' -dimethyldihydropyrano [2,3-
j)chromone (DCP) analogues 26 and 27 have been found to exhibit extremely high anti-
HIV activity.104 A hydrophobic moiety, either aliphatic or phenyl, at position 2 appears 
to be significant for anti-HIV activity by increasing binding to a putative hydrophobic 
cleft on the surface of the target thereby increasing affinity and the desired 
pharmacogical response. The extremely high anti-HIV activity of 27 indicates that C-2 
ethyl group probably fits well into the putative hydrophobic cleft. Substitution at 
position 3 with methyl group, as in compound 26, also appears to increase activity 
against the multi-RT inhibitor resistant strain while decreasing cytotoxicity.104 
26 27 
The synthetic chromone derivatives 28-31 have also shown some anti-HIV-1 protease 
(PR) activity with inhibition efficiencies of 93.6%, 93,3%, 92.2% and 92.02%, 
respectively. 105 Docking studies of these compounds has revealed that the bulky 
3-benzoyl and 2-phenyl substituents interact with the hydrophobic S 1 subsite, whereas 
the 7- or 8-hydroxyl groups interact with Asp 25 and Asp 25 ' in the receptor cavity. The 
hydroxyl groups act as hydrogen-bond donor moieties, forming hydrogen bonds with the 
carbonyl oxygen of Asp 25 and Asp 25' .105 The chromone xanthone derivatives 32 and 
33 are found in Penicillium glabrum (Wehmer) Westling extract. These compounds 
exhibit CD4 binding activity in an enzyme-linked immunosorbent assay (ELISA) on the 
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binding ofthe monoclonal antibody, anti Leu 3a, to soluble recombinant CD4.106 CD4 is 
a glycoprotein expressed on the surface of mature helper/inducer T -lymphocytes; it has a 
crucial role in many immune responses and functions as a cellular receptor for HIV. Anti 
Leu 3a blocks both CD4 dependent T-cell responses and the binding of HIV to the T-
cells. These compounds thus have potential as immunosuppressive and anti-HIV 
agents.106 
HO 
HO 
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Me 
HO 
HO 
HO 
HO 
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29 
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Me 
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Biflorin 34, a polyoxygenated chromone-C-glucoside isolated from the roots of P. 
biflorum, has been found to inhibit phosphodiesterase. This property of biflorin reflects 
its general ability to activate phosphokinase enzymes which are important for active 
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growth of the producer organism.107 6-~-C-Glucopyranosyl-5, 7 -dihydroxy-2-
isopropylchromone 35 is a chromone derivative isolated from Baeckea frutescens L. 
(Myrtaceae) the leaves of which are used as a medicinal tea for fever diseases in 
China.108 Aloesin 36 is a chromone derivative isolated from the dried leaves of Aloe 
excelsa A. Berger, which is widely distributed in Southern Africa. These leaves are 
commonly used in traditional medicine to treat venereal sores, asthma and abdominal 
pains.109 Schumanniofioside A 37 and Schumanniofioside B 38 are chromone glycosides 
isolated from the root bark of Schumanniophyton magni.ficum, a small tree that grows in 
the tropical zone of West and Central Africa. In Cameroon, the bark decoction is used as 
a remedy for dysentery and also as an enema, while other tribes use it after 
circumcision. 110 
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Gin.kgetin 39 is a biflavone extracted from Selaginella moellendorffii Hieron 
(Selaginellaceae), which has been found to possess an inhibitory effect on the growth of 
the cancer cell line, hwnan ovarian adenocarcinoma (OVCAR-3). This plant, S. 
moellendorffii, has been used as a remedy for jaundice, gonorrhea, bleeding and acute 
hepatitis.1 11 Cromoglycic acid 40, the first drug to have the ability to prevent asthmatic 
attacks has stimulated medicinal chemical research on anti-asthmatic drugs. 112, 113 
OH 
MeO 
39 
40 
Robustaflavone 4' -methyl ether 41 is a new biflavone, which was isolated from 
Selaginella delicatula Desv. Alston (Selaginellaceae), a perennial herb found in a 
Taiwanese mountain forest. This compound 41 was found to possess cytotoxic activity 
on various human tumor cell lines where it suppresses the growth of Raji and Calu-1 
tumor cell lines. 114 V ariabiloside B 42, a quercetin found in the leaves of Strychnos 
variabilis Wildem, appears to alleviate the symptoms of cerebrovascular insufficiency 
and poor arterial circulation. 1 15 
The chromone derivatives, 5-hydroxy-6-methoxy-2-(2-phenylethyl)chromone 43 and 6-
hydroxy-2-(2-hydroxy-2-phenylethyl)chromone 44, were isolated from an extract of 
withered wood of Aquilaria senensis (Thymelaeaceae).116 The decay or injury of A 
senensis results in the formation of resinous agarwood, a famous incense which is used 
as a sedative, analgesic and digestive in KampoY6 Eryvarins F 45 and G 46 are 3-
phenoxychromones isolated from the roots of Erythrina variegate L. (Legwninosae). 
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This plant is found in many tropical and subtropical regwns and is used as an 
antibacterial, anti-inflammatory, antipyretic and antiseptic agent; however, in China it is 
used as a collyrium. 117 
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Hormothamnione 47 was the first naturally occurring styrylchromone to be isolated from 
the marine cryptophyte, Chrysophaeum taylori. Hormothamnione 47 has been found to 
be potent cytotoxin to several human leukemia cell lines; it appears to operate via 
selective inhibition of RNA synthesis, 118 but lacks the catechol moiety characteristic of 
other flavone derivatives which cleave the DNA material. The isoflavones 48-50 were 
isolated from the roots of Sa/sola somalensis found in drier parts of Asia, Europe and 
Africa and, as indicated earlier, S. somalensis is used in local medicine. 102 
MeO 
MeO 
OH 0 
47 
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48 R1 = R2 = OH; R3 = H; R4 = R5 = OMe 
49 R1 = R2 = OH; R3= R4 = OCH20; R5 = H 
50 R1 = R2 = OH; R3 = R4 = R5 = OMe 
1.3.3 Synthesis of chromone derivatives 
There are two commonly used methods for preparing chromone derivatives. The first, 
which is more preferable, is known as the Kostanecki-Robinson86 reaction, and involves 
the condensation of o-hydroxyacetophenone 51 with an acylating agent to form a P-
diketone derivative 52, which on acidification spontaneously cyclises to the chromone 
derivative 53 (Scheme 2). This reaction is actually the reverse of chromone hydrolysis. 
The second method is the Simonis reaction, 86 which involves the acid-catalysed 
condensation of a phenol 54 with a P-ketoester to give a chromone 53 (Scheme 3). The 
formation of a coumarin 55 under these conditions is known as the Pechmann 
condensation. Chromone formation is favoured provided the phenol contains a 
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deactivating group, such as chlorine, the ~-ketoester is a-substituted and phosphorus 
pentoxide is used as the condensing agent.92 
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Reagents: i) NaOEt, CH3C02Et; ii) ft. 
0 
~C02R Me 
+ 
~ ~OH 
54 
Scheme3 
Me 
0 
53 
Reagents: i) Condensing agent (H2S04 or P20s). 
0 
cXl ii 0 Me 
53 
Me 
and/ or 
Me 
55 
Recently, it has been discovered that chromones 58 can be synthesized by reacting 
substituted phenols 56 with Meldrum's acid 57 in the presence of the catalyst, Yb(OTf)3, 
(Scheme 4). During the reaction, two distinct multibond-forming reactions, known as 
Friedel-Crafts C-alkylation/0-acylation and Friedel-Crafts C-acylation/0-alkylation, are 
involved and the degree of substitution on the alkylidene moiety 57 controls the 
regioselectivity of the annulation reaction. 118 
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5-Hydroxy-2-isopropyl-7-methoxychromone 64 has been synthesized via the 
Konstanecki-Robinson method (Scheme 5). Thus, methylation of 2'4'6' -
trihydroxyacetophenone 59 with dimethyl sulfate affords 2' -hydroxy-4' ,6' -
dimethoxyacetophenone 60, which undergoes acylation to form an enolate which reacts 
with a carboxylate ester to give a mixture of compounds 61 and 62. Treatment of this 
mixture with acetic and sulfuric acids gives the 5,7-dimethoxychomone derivative 63, 
which undergoes selective demethylation at the C-5 position to afford 5-hydroxy-2-
isopropyl-7-methoxychromone 64.119 
·rtl MeO~OH 
60 
j 
I ii,iii 
I 
OH OMe 
~ Me 
Me 
Me MeO MeO 61 
Me 
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Me Me MeO MeO 
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Scheme 5 
Reagents: (i) Me2S04 (2eq.), K2C03 (2eq.), acetone; (ii) NaOEt, EtOH; 
(iii) Me2CHC02Et; (iv) AcOH, H2S04; (v) Ac20, HI, ll5°C, 30min. 
2-Methyl-3-nitrochromone 67, which is used for preparation of analgesics, has been 
obtained in a one-pot reaction via nitration of a-hydroxybenzoylacetone 65 with acetic 
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anhydride, which permits direct cyclization of the P-diketone 66 as depicted in Scheme 
6.12° Kaye et al. have reported another method for the synthesis of 2-
( dimethlamino )chromone 70, which involves the reaction of 2-ethylsulfinylchromone 69 
obtained, in turn, from the thiolactone 68 (Scheme 7). 121 
~Me___.!._ cx:iMe -o&NO, 
0 Me 
65 
Scheme 6 
66 
Reagents: (i) HN03, (Me-C0)20. 
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Reagents: (i) K2C03, Eti, (CH3)2CO; (ii) MCPBA, Cl(CH2)2Cl; (Me)2NH. 
5,7-Dihydroxychromone 72, has been prepared by condensation of 2',4',6'-
trihydroxyacetophenone monohydrate 71 with ethyl oxalyl chloride, followed by 
hydrolysis, acidification and decarboxylation (Scheme 8).122 Treatment of 2',4'-
dihydroxyacetophenone 73 or 2',4'-dihydroxypropiophenone 74 with triethyl 
orthoformate and 70% perchloric acid, followed by hydrolysis in boiling water afforded 
7-hydroxychromone 75a or 7-hydroxy-3-methylchromone 75b, respectively (Scheme 
9). 123 Nishinaga et al. 124 published a convenient method for synthesizing 2,3-
dialkylchromones. This approach involves the base-catalyzed rearrangement of o-
acetoxypropiophenone 76 to give the diketone 77 which undergoes cyclisation to afford 
2,3-dimethylchromone 78 (Scheme 10).124 Recently, a modified Baker-Venkataraman 
reaction for the synthesis of 3-acyl chromones and flavones has been published by 
Ganguly et al. 125 This involves the reaction of2 ' ,4' ,6' -trihydroxyacetophenone 79 with 
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acyl chlorides 80 in the presence of DBU and pyridine to afford 3-acyl chromone 
derivatives 81 (Scheme 11).125 3-Acyl chromones have been shown to be useful 
precursors for the formation of other chromone derivatives. 
OH 0 Et02COCO 0 
£C HO ~ OH Et02COCO C02Et 
71 j ii, ili 
OH 0 
ro iv HO ~ 0 HO COOH 
72 
Scheme 8 
Reagents: (i)EtOOCCOCl, pyridine; (ii) oH·; (iii) I-t; (iv) heat. 
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74 R= CH3 
Scheme 9 
Reagents: (i) 70% perchloric acid, triethyl orthoformate, 40min; (ii) H20, reflux, 40min. 
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Reagents: (i) KOBu\ DMF, r.t.; (ii) Com(salpr)(OH), CF3CH20H, 60°C. 
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Reagents: (i) DBU, Pyridine. 
Chromone-3-carbaldehyde 83 was first synthesized in relatively low yield (:S 30%) by 
the reaction of the ketoaldehyde 82 with ethyl formate or acetic acid (Scheme 12).126 
However, application of Vilsmeier-Haack methodology has permitted significant 
improvement in this yield. A one-pot synthesis, in which o-hydroxyacetophenone 84 is 
treated with phosphorus oxychloride in dimethylformamide has been reported to afford 
chromone-3-carbaldehyde 83 in 61-85% yields (Scheme 13).127 
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Treatment of the 2,4-dihydroxyphenyl ketone 85 with methanesulfonyl chloride in dry 
DMF has been shown to afford 7-hydroxy-3-phenylchromone 86 (Scheme 14),128 while 
Dawood et al. 129 have recently reported that heating chromanone 87 with 4-
chlorobenzaldehyde 88 in the presence of a catalytic quantity of piperidine resulted in 
the formation of 3-(4-chlorobenzyl)chromone 89 as depicted in Scheme 15129 Selenium 
dioxide has been recognized as an effective reagent for the incorporation of an oxygen 
functionality at allylic positions and, recently, chromone-2-carbaldehydes 91 have been 
synthesized by selenium dioxide oxidation of2-methylchromones 90 (Scheme 16).130-131 
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Reagents: (i) Se02, xylene. 
Hom1othamnione 97, which is a potent cytotoxin for several types of human leukemia 
cells, has been synthesized by treating 2,3,4,5-tetramethoxyphenol 92 with 2-butynoic 
acid and Eaton's reagent (phosphorus pentoxide in methanesulfonic acid) to afford the 
alkynyl ketone 93, which undergoes cyclization to form the 5,6,7,8-
tetramethoxychrornone 94. Condensation of the chromone 94 with 3,5-
bis(benzyloxy)benzaldehyde yields the styrylchromone 95, which undergoes C-3 
methylation to afford 3-methyl-2-[3,5-bis(benzyloxy)styryl]-5,6,7,8-
tetramethoxychromone 96. Selective demethylation of the methyl ether at C-5 and 
debenzylation leads to the styrylchromone, hormothamnione 97 (Scheme 17).132 
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Scheme 17 
Reagents: (i) P20s/CH3S03H, 0°C, 4h, Ar; (ii) K2C03, Acetone; (iii) 3,5-
bis(benzyloxy)benzaldehyde, EtONa, EtOH; (iv) THF, LDA, CF3S03CH3 
-78 °C; (v) CH2Ch, BCh 
1.3.4 Reactivity of chromone derivatives 
Chromones have intrigued many researchers due to the spectrum of reactivity with 
nucleophiles, electrophiles and other reagents to give various derivatives, examples of 
which are provided below. 
1.3.4.1 Reactions with Nucleophiles 
Chromones normally undergo nucleophilic attack at the C-2 and C-4 positions of the 
heterocyclic ring. 133 However, nucleophilic attack at C-2 in chromone derivatives has 
been found to result in either pyrone ring opening or loss of the C-(2)-C-(3) n-bond.134 
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Thus, reaction of chromone-3-carboxylic acid 98 with piperidine, a nitrogen nucleophile, 
affords an enamino ketone 100. In this reaction, the chromone substrate 98 undergoes 
1 ,4-addition to form ~-keto-P' -amino acid 99, which then undergoes decarboxylative 
ring opening to afford the enamine derivative 100 (Scheme 18).135 In this reaction the o-
carbonylphenoxy group behaves as nucleofugal group.133 It has been noted that similar 
reactions occur with chromone-3-carbaldehyde 83. 
~COOH+ HN8 
Scheme 18 
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With tertiary ammes, 1 ,4-addition to the chromone-3-carboxylic acid 98 affords a 
reactive zwitterionic substrate 101, which then undergoes spontaneous decarboxylative 
Hofmann elimination, instead of ring opening, to form chromone 12. This is attributed to 
the greater nucleofugality of the positively charged quaternary ammonium cation 
(Scheme 19).135 
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Reagents: (i) Triethylamine, EtOH, reflux, 2-3h. 
Reaction of chromone-3-carbaldehyde 83 with aminopyrazole 102 has been shown to 
afford pyrazolo[1,5-a]pyrimidine 103. This reaction occurrs via a conjugate addition of 
the endocyclic nucleophilic nitrogen of the aminopyrazole 102, followed by the ring-
opening of the resulting adduct (Scheme 20).136 It has also been shown that refluxing 
chromone-3-carbaldehyde 83 with ethyl glycinate hydrochloride 104 in aqueous 
acetonitrile, in the presence of triethylamine, affords the C-2 substituted product 105. 
Further heating in aqueous acetonitrile, in the presence of potassium carbonate, gave the 
tricyclic compound 106 (Scheme 21).137 
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Reagents: (i) Aq. acetonitrile, TEA; (ii) Aq. acetonitrile, K2C03. 
It is interesting to note that the reaction of chromone-3-carbaldehyde 83 with 6-
aminopyrimidin-4-ones 107 by heating in absolute ethanol or by microwave irradiation 
in the absence of solvent resulted in the unexpected pyrido[2,3-d]pyrirnidines 112 
instead of the expected pyridopyrirnidines 108. This was attributed to the regiospecific 
cyclocondensation of amine 107 with the aldehyde 83, to give the pyrido(2,3-
d]pyrirnidine 109. The intermediate derivative 109 can either be converted into the 
aromatic pyrylium species 110 or, alternatively, undergo nucleophilic attack by water, 
released in the previous step to afford the dihydroxy species 111. Either of the 
intermediates 110 or 111 afford ·compound 112, via nucleophilic addition of hydroxide 
ion or elimination of water, respectively (Scheme 22).136 
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Reagents: (i) Microwave irradiation, 2-3 min, solvent free conditions; (ii) EtOH, reflux, 
2-3h. (R = H, CH3; R' = CH30, CH3S, NH2, OH, SH) 
Reaction of chromone-3-carbaldehyde 83 with the 1,3-bis-(silyl enol ether) derivative 
113, in the presence of TMSOTf, has been reported to afford the benzoyl substituted 
benzophenone 118 as shown in Scheme 23. The formation of 115 can be explained by 
the TMSOTf-catalysed domino 'Michael-retro-Michael-aldol' reaction, outlined in 
Scheme 23. 138 
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Chromones typically undergo ring-opening when treated with aqueous alkali. The 
nucleophilic hydroxide ion attacks C-2 in a rate-determining step, the rate constant of 
which varies with the ground state electron density at that centre. 133 Thus, chromone 12 
in aqueous alkali undergoes the nucleophilic addition of hydroxide ion at C-2 resulting 
in the formation of the enolate 119, which can undergo fission of the r-prone ring to give 
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a mixture of enolate species 120a-c (Scheme 24). 139 The chromone-2-carboxylate 
derivative 121 similarly undergoes ring-opening when treated with aqueous sodium 
hydroxide under reflux, affording 2,4-dibromo-3,6-dihydroxyacetophenone derivative 
122 as depicted in Scheme 25. 140 
~0-H--~---- 0 cc\ 0 -OH 
12 119 120b 
c6 0 
120c -
Scheme24 
Reagents: (i) alkaline medium. 
0 
COOEt 
COOEt 
121 122 
Scheme 25 
Reagents: (i) aqueous NaOH. 
However, if a substituent attached to the chromone is more electrophilic than C-2 or C-4, 
then the nucleophile will attack at that position. Acrylic acid derivates 123, for example, 
have been synthesized, in high yield, by reacting chromone-3-carbaldehydes 122 with 
38 
Introduction 
malonic acid (Scheme 26). 141 Reaction of 3-nitrochromone 124 with diazomethane, a 
carbon nucleophile, under mild conditions affords cyclopropabenzopyrans 125 (Scheme 
27), reflecting ring-forming rather than ring-opening.142 
H i 
R 
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Scheme 26 
Reagents: (i) CH2(C02H)2, pyridine 
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Reaction of chromone-3-carbaldehyde 83 with a binucleophile (Nu1-Nu2) may result in 
the formation of a new heterocyclic ring. The first nucleophile attacks the formyl carbon 
(C-1 '), to give an intermediate 126, which then undergoes intramolecular attack by the 
second nucleophile (e.g. NH2) at the reactive C-2 position, leading to ring-closure and 
concomitant ring-opening of the pyrone system. This method has been used to prepare 
products such as 4-(2-hydroxybenzoyl)pyrazole 127a (Scheme 28). 143 
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Reaction of 3-substituted chromones 83 with the allene-derived 1,3-dipolar species 128 
gave 3a,9a-dihydro-1-ethoxycarbonyl-1-cyclopenteno[5,4-b ]benzopyran-4-one 129 
(Scheme 29).144 During the reaction, the dipolar species 128 adds regioselectively to the 
C2-C3 n-bond and deforrnylation results in the formation of the product 129 in good 
yield.144 
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40 
R 
J 
R 
129 
Introduction 
The direct nucleophilic introduction of perfluoroalkyl and especially, trifluoromethyl 
moieties is very important for synthesizing compounds with applications in the 
pharmaceutical industry. Treatment of the chromone derivative 12 with 
(trifluoromethyl)trimethylsilane and a three-fold excess of the nucleophilic initiator, 
Me4NF, afforded a mixture of the 1 ,4-addition product 130 and the 1 ,2-addition product 
131 (Scheme 30). 145 
0 
i ' ii 
12 130 131 
Scheme 30 
Reagents: (i) CF3SiMe/Nu; (ii) W 
Reaction of 3 -( dimethoxyphosphoryl)-2-methylchromone 132a or 3 -(methoxycarbonyl)-
2-methylchromone 132b with N-methylhydrazine resulted in the formation of isomeric, 
highly substituted pyrazole derivatives 133 and 134, the former as the major product in 
each case. Intramolecular transesterification of 133a,b and 134a,b under basic 
conditions afforded the corresponding tricyclic derivatives 135 and 136, respectively, as 
shown in Scheme 31.146 
Chromone-3-carbaldehyde 83 possess a highly polarized C2-C3 n-bond and annulation 
across this bond can be anticipated, and reaction of 3-(N-aryliminomethyl)chromones 
137, which resemble chromone-3-carbaldehyde 83, with the 1,3-dipolar allenic ester 128 
gave the cyclopentanochromones 144.144 During the reaction, the dipolar species 128 
adds regioselectively to the C2-C3 n-bond resulting in the intermediates 140. 
Subsequent thermal opening of the chromone ring affords the phenoxide species 141, 
internal rotation, recyclization and a 1 ,5-hydride shift then leads to the tricyclic products 
144 (Scheme 32). Reaction of 3-methylchromone 145 with vinyl magnesium bromide 
resulted in the direct formation of the open-chain product 146 (Scheme 33).147 
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1.3.4.2 Reactions with Electrophiles 
Chromones are slightly basic and form salts with strong acids, with protonation normally 
occurring at 0-1, C-3 or the carbonyl oxygen. 134 Although the pyran ring in chromone 
derivatives is relatively unreactive towards electrophiles, an electron-releasing 
substituent at C-2 or C-3 activates the adjacent vacant position. 148 Vilsmeier formylation 
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of 2-(dimethylamino)-8-isopropyl-5-methylchromone 147, for example, furnishes the 
2-formylchromone derivative 148 (Scheme 34).144 
Me 0 
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Reagents: (i) POCh, DMF; (ii) H20. 
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The elements of hypobromous acid are added across the 2,3-double bond when 
chromone 12 is treated with NBS in aqueous DMSO to form 3-bromo-2-
hydroxychromanone 149 (Scheme 35).142 
c6° ~Br 0 llAO~OH 
12 149 
Scheme 35 
Reagents: (i) NBS, aq. DMSO. 
When the electrophilic reagents are either strong acids or produce strong acids during the 
reaction, protonation of the pyran ring may be expected to inhibit further attack by the 
electrophile. 142 However, aminomethylation under Mannich reaction conditions is often 
achieved under less acidic conditions, resulting, for example, in the formation of 3-
aminodimethylchromone 151 from 8-methoxychromone 150 (Scheme 36). 142 
Me 
150 
Scheme 36 
Me 
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1.3.4.3 Other reactions 
While the enone moiety of the parent chromone system does not function as dienophile 
in cycloaddition reactions, an electron-withdrawing substituent at C-3 enhances the 
dienophilicity of the 2,3-double bond, permitting such reaction to occur. Cycloaddition 
of chromone-3-carbaldehyde 83, reacting as the dienophile, and ortho-
benzoquinodimethane 152, a highly reactive diene, resulted in the expected adduct 153 
which is susceptible to deformylation under the reaction conditions to afford a mixture 
of the diastereomeric cycloadducts 154 and 155. Oxidation of these diastereomeric 
cycloadducts with dimethyl sulfoxide in the presence of iodine afforded the novel 
benzo[b ]xanthones 156 (Scheme 37).149 
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Reagents: (i) 1,2,4-Trichlorobenzene, 250°C; (ii) Me2SO, h. 
Reaction of chromone-3-carbonitrile 157 with a-phenylenediamine 158 (an aromatic 
1,2-diamine) under reflux, resulted in the amidine derivative 159, which also exists as 
the tautomeric form 160. Further heating in glacial acetic acid afforded a fused diazepine 
derivative 162 (Scheme 38). 150 During this reaction the aromatic 1 ,2-diamine 
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nucleophile 158 adds 1,2 to the nitrile function of compound 157 to afford the ami dine 
159, which undergoes cyclisation and air oxidation to furnish compound 162. 
~CN 
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161 
J;; 
0 
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NH2 
-..; N 
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Reagents: (i) Ethanol, reflux; (ii) glacial acetic acid, reflux, air. 
However, when chromone-3-carbonitrile 157 was heated under reflux with 
ethylenediamine 163 (an aliphatic 1,2-diamine) in ethanol, 2-amino-3-formylchromone 
169 was obtained together with a minor product 170 (Scheme 39).150 The mechanism 
for the formation of the products 169 and 170 involves 1 ,4-addition by the nucleophile 
which results in the intermediate adducts 164-166. The intermediate 165 cyclizes to the 
aldimino derivative 167, which undergoes hydrolysis to afford the aminochromone 169. 
This hydrolysis occurs partially in ethanolic medium and is completed during 
crystallization from acetic acid. The intermediate 166, on the other hand, loses a 
molecule of hydrogen cyanide, and the resultant intermediate 168 undergoes 
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intramolecular 1 ,4-addition with concomitant opening of the pyrone ring to form the 
tetrahydroimidazole 170. 
Scheme 39 
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Reagents: (i) Ethanol, reflux; (ii) glacial acetic acid, reflux, air. 
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The acetal 171 can be metalated with lithium 2,2,6,6-tetramethylpiperidine (LTMP) at 
the electrophilic centre C-2. The 2-lithiated derivative can then be trapped with 
acetaldehyde to give furan derivative 172. The unmasking of the acetal moiety proceeds 
rapidly when a trace ofTsOH in warm toluene is used, as illustrated in Scheme 40.151 
2-Carboxamido chromones 176-179 have been synthesized from ethyl chromone-2-
carboxylate 175, by reacting the ester 175 with alkyl amines, as shown in Scheme 41. 
These chromone derivatives are used in hair-conditioning agents, as they bind to human 
hair and protect it from UV -radiation which damages hair fibre. 84 
0 0:) 
0 i , ii 
171 172 Me 
0 
Me 
174 
Scheme 40 
Reagents: (i) LTMP, THF, -78°C; (ii) MeCHO; (iii) TsOH (cat.), PhMe, ca. 50°C. 
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1.4 Previous work done in the group 
Introduction 
Chromone chemistry has been the subject of investigation in our research group for 
many years, and this investigation has provided a context for the present study. 
In previous years, infrared carbonyl band doubling exhibited by substituted chromone-2-
carboxylate ester was observed to be solvent-, substituent- and temperature dependent 
and was explained in terms of rotameric equilibria between syn-s-trans and anti-s-trans 
forms. 152 A synthesis of N,N-dimethylchromone-2-carboxarnides has been developed, 153 
and dynamic NMR studies of such compounds revealed a temperature dependent 
splitting of the N-alkyl 1H and 13C NMR signals, which was attributed to internal 
rotation ofthe amide group.154 
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The amine-mediated ring-opening of substituted chromone-2-carboxamides has been 
explored to clarify the susceptibility of chromone derivatives to ring-opening via 
nucleophilic attack at C-2, 155 and kinetic mechanistic studies have illustrated the 
influence of substituents on the ring-opening process. 156 Mass spectrometric analysis of 
the ring-opened, polyfunctional acrylamide derivatives permitted elucidation of their 
major fragmentation patterns, 157 while dynamic NMR analysis of rotational isomerism in 
these systems permitted the calculation of internal rotational barriers.158 
Dynamic 1H NMR spectroscopic methods were also used to study the effect of 
substituents on the internal rotation of the ammo group m 2-(N,N-
dialky lamino )chromones; 159 delocalisation of the nitrogen lone pair was presumed to 
inhibit rotation about the N-C(O) bond - a property which influences the basicity of 
these compounds. The effect of various substituents on the electron density at C-2 and, 
hence, on the acidity of a series of chromone-2-carboxylic acids has also been 
investigated. 16° Chromone systems have also been used in the construction of ritanovir 
analogues as potential HIV -1 protease inhibitors.161 
Research in our group has also focused on applications of the Morita-Baylis-Hillman 
reaction, in the synthesis of 2-substituted indolizines, 162 quinoline derivatives, 163 
chromenes,164 thiochromenes165 and coumarins/66 while chromone-3-carbaldehydes 
have been employed as Baylis-Hillman substrates, affording unprecedented dimeric 
products. 167 
1.5 Aims of the current investigation 
The present investigation has been focused on the application of Baylis-Hillman 
methodology to chromone systems with a view to preparing compounds with HIV -1 
protease inhibition potential. The inhibitors currently in clinical use (see p. 11) are 
relatively large and structurally complex molecules. The intention in our approach was 
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to prepare and elaborate truncated analogues which are not only structurally simpler but 
also synthetically more accessible. The research has included the following specific 
objectives: 
1. The synthesis of substituted chromone-3-carbaldehydes and chromone-2-
carbaldehydes and their use as substrates in Morita-Baylis-Hillman reactions 
using acrylonitrile, methyl acrylate and methyl vinyl ketone as activated alkenes. 
2. Exploring the effect of varying the catalyst and solvent system on reaction 
efficiency and product selectivity. 
3. Aza-Michael reactions of the Baylis-Hillman products usmg various ammo 
derivatives with a view to generating readily accessible derivatives as potential 
HIV -1 protease inhibitors. 
4. Enzyme kinetic studies of representative derivatives to investigate their inhibition 
capabilities. 
5. Computer-modelling studies of representative derivatives using an interactive 
docking programme to explore their binding to the HIV -1 protease active site. 
6. Kinetic mechanistic studies of the DABCO-catalysed Baylis-Hillman reaction of 
a series of substituted 2-nitrobenzaldehyde derivatives with MVK using NMR 
methods. 
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2. RESULTS AND DISCUSSION 
In line with the identified aims, the discussion covers:- the preparation of chromone 
carbaldehydes (Section 2.1); their use as substrates in Baylis-Hillman reactions (Section 
2.2); aza-Michael reactions of the Baylis-Hillman products (Section 2.3); HIV-1 protease 
enzyme inhibition assays (Section 2.4); computer modelling studies of the aza-Michael 
products and the chromone dimers (Section 2.5); and finally kinetic-mechanistic study of 
the Baylis-Hillman reaction involving selected 2-nitrobenzaldehydes with MVK (Section 
2.6). 
Ritanovir 2, a drug in clinical use, was used as a template in the design of potential HIV-
1 protease inhibitors, with the intension of developing chromone derivatives as scaffolds 
for the construction of HIV -1 protease inhibitors. It was hoped that chromone dimers of 
type 222 could be elaborated to afford products which, like ritonavir 2, contain termini 
linked by a peptidomimetic chain. (In the event, time did not permit such elaborations of 
the dimeric products). Monochromone derivatives, on the other hand, would be 
elaborated to afford truncated analogues of ritonavir 2 such as compound 260 (See 
below). 
N\1 H, O / Ph 0 Me NS»-/ ~s~ol(o ~ ~ ~I(~~J~ \ 
Ph/ / ~ O 
Hydroxyethylene 2 
Isostere 
eterocyclic ring 
Heterocyclic ring 222 
I 
II 
Heterocyclic ring 
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2.1 Preparation of chromone carbaldehydes 
2.1.1 Synthesis of chromone-3-carbaldehydes using the Vilsmeier-Haack 
reaction 
A series of substituted chromone-3-carbaldehydes 83 and 184-187 were prepared as 
Baylis-Hillman precursors using the Vilsmeier-Haack reaction in which the 
corresponding o-hydroxyacetophenones 84 and 180-183 were treated with phosphorus 
oxychloride (POCh) in dry DMF at -20°C (Scheme 42). 127 The mechanism of the 
Vilsmeier-Haack reaction involves double fmmylation of the acetophenone enolate 189 
by the Vilsmeier-Haack "complex" 188a-c with structures b and c being the 
predominant tautomers (Scheme 43). 168 Subsequent hydrolysis gave the desired 
chromone-3-carbaldehydes 83 and 184-187 (Scheme 44). The approach thus provides a 
one-pot conversion of o-hydroxyacetophenones to chromone-3-carbaldehydes. 
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Recrystallisation of the crude chromone-3-carbaldehydes from acetone afforded the pure 
products 83 and 184-187 in yields of 43-85% (Table 3). The products were fully 
characterized by spectroscopic (IR, 1H and 13C NMR) and elemental (HREIMS) 
analysis. 
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Table 3. Comparative yields for chromone-3-carbaldehydes 83 and 184-187. 
R Compound No. Yield(%) 
H 83 71 
Cl 184 81 
Br 185 83 
F 186 85 
OMe 187 43 
The 1H NMR spectrum (Figure 9) of the parent system 83 reveals an overlapping triplet 
and doublet at ca. 7.50 ppm corresponding to the 6-methine and 8-methine protons, 
respectively, a singlet at 8.54 ppm corresponding to the 2-methine proton, and a singlet 
corresponding to the formyl proton at I 0.38 ppm. The 13C NMR spectrum (Figure 1 0) 
shows the expected 10 carbon signals, with the 2-methine carbon resonating at 160.6 
ppm and the carbonyl carbon signals at 176.0 and 188.6 ppm. 
' 
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Figure 9. 400 MHz 1H NMR spectrum of chromone-3-carbaldehyde 83 in CDCh. 
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Figure 10. 100 MHz 13C NMR spectrum of chromone-3-carbaldehyde 83 in CDCh. 
2.1.2. Synthesis of chromone-2-carbaldehydes 
Due to the reactivity of the 2-formyl group, chromone-2-carbaldehydes are well known 
intermediates in the synthesis of a variety of interesting products.130-131 A series of 
chromone-2-carbaldehydes were prepared in order to explore their behaviour under 
Morita-Baylis-Hillman conditions and their elaboration to potential HIV -1 inhibitors. 
The chromone-2-carbaldehydes 91 and 201-204 were synthesized via selenium dioxide 
(Se02) oxidation of the appropriate 2-methylchromones 90 and 197-200, which were 
obtained using the Kostanecki-Robinson method.86•129-131 This approach involves the 
condensation of suitable o-hydroxyacetophenone 84, 188-191 with ethyl acetate to form 
the corresponding P-diketo derivatives 192-196. On acidification these intermediates 
cyclised spontaneously to the 2-methylchromones 90 and 197-200 (Scheme 45). The 
mechanism (Scheme 46) for Se02 oxidation of the 2-methylchromones is considered to 
involve deprotonation of the methyl group to form a resonance stabilized enolate (step 
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a), which undergoes selenation at C-3 (step b). A [2,3]-sigmatropic rearrangement (step 
c) followed by deselenation affords the chromone-2-carbaldehydes 91 and 201-204.169-
176 The selenium oxidation reaction has been reported to proceed in poor yield (ca. 
40%), but in this case, the yields ranged from 45-65% (Table 4). Optimization was 
achieved by washing the selenium residue thoroughly with hot xylene after observing 
that some of the expected products remained in the selenium residues. It was also 
noticed that extending the reaction time from 12hrs to 20 hours enhanced the product 
yields as shown in Table 4. Further optimization was attempted by using 1-
chloronaphthalene or dioxane instead of xylene. However, use of 1-chloronaphthalene 
and dioxane gave compound 91 in yields of 36% and 7.5%, respectively, much lower 
than the 65% obtained using xylene. These results confinned that xylene was the best of 
the solvents used in these reactions. 
Recrystallisation of the crude 2-methylchromones 90 and 197-200 from hexane afforded 
the pure products in yields ranging from 43 to 86% (Table 4). These products were fully 
characterized by spectroscopic (IR, 1H and 13C NMR) and elemental (HREIMS) 
analysis. The 1H NMR spectrum (Figure 11) of compound 198 reveals a singlet at 2.38 
ppm corresponding to the 2-methyl protons, while the 3-methine proton resonates as 
singlet at 6.17 ppm. The 13C NMR spectrum (Figure 12) shows the expected 10 carbon 
signals, with the 2-methyl carbon resonating at 20.6 ppm and the carbonyl carbon signal 
at 178.0 ppm. 
Purification of crude chromone-2-carbaldehydes 91 and 201-204 usmg flash 
chromatography on silica gel afforded yields ranging from 46 to 65% and 50 to 70%, 
depending on the reaction period (Table 4). The 1H NMR spectrum (Figure 13) of 
compound 202 reveals a singlet at 6.91 ppm corresponding to 3-methine proton, while 
the singlet corresponding to the aldehyde proton resonates at 9.78 ppm. The 13C NMR 
spectrum (Figure 14) shows the expected 10 carbon signals, with the aldehydic carbonyl 
carbon (CHO) resonating at 185.0 ppm. 
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Reagents: (i) NaOEt, dry EtOH, dry CH3COzEt; (ii) AcOH, conc.H2S04; 
(iii) Se02, xylene/ naphthalene/ dioxane, reflux. 
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Table 4. Isolated yields(%) of the 2-methylchromones 90 and 197-200 and the 
chromone-2-carbaldehyde 91 and 201-204. 
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Figure 11. 400 MHz 1H NMR spectrum of 6-bromo-2-methylchromone 198 in CDC~). 
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Figure 12. 100 MHz 13C NMR spectrum of6-bromo-2-methylchromone 198 in CDCh. 
CHO Br 3-H 
1 ~ 
/I ~· )\ II J\. l'i 
y y y y y 
8 § 8 Sf ~ 
~~----~r~~-r~~~~~~~-~--~~~7-. ~~ 
m (tl) 10.00 9.50 9.00 8.50 8.00 7.50 7.00 
PP I 
Figure 13. 400 MHz H NMR spectrum of 6-bromochromone-2-carbaldehyde 202 in 
CDC h. 
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Figure 14. 100 MHz 13C NMR spectrum of 6-bromochromone-2-carbaldehyde 202 in 
CDC~). 
2.2 Morita-Baylis-Hillman reactions 
The Morita-Baylis-Hillman reaction, or more simply, the Baylis-Hillman reaction, is a 
very useful method for carbon-carbon bond formation between an activated alkene and 
an aldehyde in the presence of a tertiary amine catalyst. 177- 179 The reaction typically 
results in polyfunctional products with a new chiral centre.177-182 The rate of reaction has 
often been found to be sluggish when 1,4-diazabicyclo[2.2.2]octane (DABCO) is used as 
the catalyst. This was confirmed by preliminary studies performed in our laboratory by 
Sabbagh166 on Baylis-Hillman reactions between chromone-3-carbaldehydes and the 
activated alkenes, methyl acrylate, acrylonitrile and methyl vinyl ketone. In the presence 
of DAB CO, reactions took several weeks to afford the expected Baylis-Hillman products 
together with unexpected chromone dimers in very low yields ranging from 8 to 17% 
and 2 to 15%, respectively. 3-Hydroxyquinuclidine (3-HQ), a nucleophilic catalyst, and 
1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU), a non-nucleophilic catalyst, have, however, 
been shown to be very efficient catalysts in some cases.179' 183-185 The generally accepted 
mechanism186 is illustrated for the 3-hydroxyquinuclidine-catalyzed reaction of acrylate 
esters with pyridine-4-carboxaldehyde 208 in (Scheme 47). The reaction is initiated by 
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the nucleophilic addition of the tertiary amine catalyst, e.g. 3-hydroxyquinuclidine 205, 
to the activated alkene, e.g. methyl acrylate 206 to form a zwitterionic enolate 
intermediate 207 that subsequently attacks the electrophilic aldehyde 208 to form a 
second zwitterionic intermediate 209 (Scheme 47). 186-187 Proton transfer then results in 
the resonance-stabilized species 210, which collapses to the product 211 via an ElcB 
elimination, releasing the catalyst.186-187 
C)jo'H wo, ())o'H 
N+ OJH 
N N+ 0 -~205 '~/ 
'Xo/ ( 0 207 
~0" -o Rl 
0) RI H 209 
206 lP l 208 
R 1 = 4-pyridyl C)jo'H 
())o'H OH 0 N+ 0 
+ R'yo/ ·~~X>/ N 
205 HO RI 211 
210 
Scheme 47 
2.2.1. Reaction of chromone-3-carbaldeydes under Baylis-Hillman 
conditions 
2.2.1.1. Reaction of chromone-3-carbaldehydes with acrylonitrile 
The series of chromone-3-carbaldehydes 83 and 184-187 were reacted with acrylonitrile 
using 3-hydroxyquinuclidine as a nucleophilic catalyst, in a minimal volume of 
chloroform at 25°C for 24hours (Scheme 48). Purification of the crude products using 
flash clu-omatography afforded the desired Baylis-Hillman products 212-216 in yields 
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ranging from 60 to 98% (Table 5), i.e. significantly higher than the yields previously 
obtained by Nchinda 53-67%. 166 The chromatographic purification was optimized by 
increasing the polarity of the mobile phase (hexane:EtOAc: 2:3) and adding a few drops 
of dichloromethane immediately after loading the sample on to the silica column. Use of 
DBU as the catalyst gave the corresponding Baylis-Hillman products 212-216 in yields 
ranging from 50 to 60% and 63 to 80% in 6 and 24 hours, respectively (Table 5). It was 
also observed that when DABCO was used as catalyst in the presence of the ionic liquid, 
1-methyl-2-pyrrolidine (1-NMP), the Baylis-Hillman products were obtained in yields 
ranging from 45 to 60% in 24 hours (Table.S). When DABCO is used alone, such yields 
are nonnally only obtained after several weeks. These results indicate that DBU is a very 
acceptable catalyst, m terms of reaction rate, when composed with 
3-hydroxyquinuclidine, the previously favoured catalyst. 185 The structures of these 
catalysts are shown in Table 5. The products were fully characterized by spectroscopic 
(IR, 1- and 2-dimensional NMR) and elemental (HREIMS) analysis. 
The 1H NMR spectrum (Figure 15) of the Baylis-Hillman product 216 reveals a singlet 
at 3.89 ppm corresponding to the methoxy group, broad signals at 4.41 ppm and at 5.28 
ppm corresponding to the 3 '-hydroxyl group (OH) and 3 '-H respectively, and two 
distinct singlets at 6.14 and 6.34 ppm corresponding to the diastereotopic 1 ' -methylene 
protons. The 13C NMR spectrum (Figure 16) reveals 14 carbon signals as expected. The 
methoxy carbon resonates at 55.9 ppm, the 3' -methine carbon at 69.6 ppm, the 1 ' -
methylene carbon at 130.0 ppm and the carbonyl carbon at 177.6 ppm. The DEPT 135 
spectrum (Figure 17) confirms assignment of the methylene carbon to the signal at 130.0 
ppm. Data from the 2-D spectra (COSY, HMQC and HMBC) were used to facilitate 
assignment of the signals. 
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R CN 
R 
212 H 
213 Cl 
214 Br 
215 F 
216 OMe 
Table 5. Isolated yields (%) of Baylis-Hillman products 212-215 using various catalysts. 
R 
3HQ DBU DBU DAB CO 
R Compound After After After After 
24 hours 6 hours 24 hours 24 hours 
H 212 98 60 80 60 
Cl 213 85 56 71 50 
Br 214 73 52 63 55 
F 215 60 50 60 48 
MeO 216 71 55 77 45 
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Figure 15.400 MHz 1H NMR spectrum of the Baylis-Hillman product 216 in CDCh. 
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Figure 16. 100 MHz 13C NMR spectrum of the Baylis-Hillman product 216 in CDCh. 
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Figure 17. DEPT 135 NMR spectrum of the Baylis-Hillman product 216 in CDCb. 
2.2.1.2. Reaction of chromone-3-carbaldehydes with methyl acrylate 
The series of chromone-3-carbaldehyde 83 and 184-187 were reacted with methyl 
acrylate using 3-hydroxyquinuclidine as the catalyst in chloroform for 24hours (Scheme 
49). Purification of the crude products using flash chromatography afforded the desired 
Baylis-Hillman products 217-221 and the corresponding chromone dimers 222-226 in 
yields ranging from 63 to 80% and 5-25%, respectively (Table 6). When DBU was used 
as the catalyst, the Baylis-Hillman products 217-221 were obtained alone in yields 
ranging from 50 to 65% (Table 6). Furthermore, when DABCO was used in the presence 
ofthe ionic liquid, 1-methylpyrrolidine (1-NMP), the Baylis-Hillman products 217-221 
were again obtained as the sole products in yields ranging from 30 to 50% (Table 6). 
These products were fully characterized by spectroscopic (IR, 1- and 2-dimensional 
NMR) and elemental (HREIMS) analysis. NMR data are illustrated for the Baylis-
Hillman product 218 in Figures 18-20 and for the dimeric products 222 in the Figures 
21-23. 
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Table 6. Isolated yields(%) ofthe Baylis-Hillman products 217-221 and chromone 
R 
H 
Cl 
Br 
F 
Meo 
{ 
dimers 222-226 obtained using various catalysts. 
B-H 3HQ 
product 
217 80 
218 68 
219 70 
220 63 
221 75 
0 OH 
Cl 
6'::/" 
4a 4 
I I 3 
3' 
7:::::::.... 
8a 0 2 8 1 
218 
{f t 1'-H r 
OMe 
DBU 
65 
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Figure 18. 400 MHz 1H NMR spectrum of the Baylis-Hillman product 218 in CDC13• 
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Figure 19. 13C NMR spectrum of the Baylis-Hillman product 218 in CDCh. 
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Figure 20. 400 MHz DEPT 135 NMR spectrum ofthe Baylis-Hillman product 218 in 
CDCl3. 
70 
Results and Discussion 
1' 
• I 
Y Y Y YW W 
_. o - o-~ pp 
8 ~ ~ ~~~ ~ 
..----.-r-----.--.-,.-.---. -.- ·r-.---.---.--,--,---,--.,.----,--,---,---,--,--,--,---.---.----r--T-,-f--,-,-
ppm (tl) 8.0 7.0 6.0 5.0 4.0 3.0 
Figure 21. 400 MHz 1H NMR spectrum of the dimeric product 222 in CDCi]. 
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Figure 22. 100 MHz 13C NMR spectrum of the dimeric product 222 in CDCh. 
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Figure 23. DEPT 135 NMR spectrum of the dimeric product 222 in CDCI3. 
The 1H NMR spectrum (Figure 18) of the Baylis-Hillman product 218 reveals a very 
broad signal at 2.90 ppm corresponding to the 3'-hydroxyl proton, a singlet at 3.74 ppm 
corresponding to the methoxy group, a singlet at 5.60 ppm corresponding to 3'-methine 
proton and two distinct singlets at 6.14 and 6.44 ppm corresponding to the diastereotopic 
I' -methylene protons. The 13C NMR spectrum (Figure 19) reveals 14 carbon signals as 
expected. The methoxy carbon resonates at 52.0 ppm, the C-3' methine carbon at 67.4 
ppm, the C-1' methylene carbon at 127.0 ppm and the two carbonyl carbons at 166.5 and 
176.6 ppm. The DEPT 135 spectrum (Figure 20) confirms assignment of the methylene 
carbon at 127.0 ppm, while the data from the COSY, HMQC and HMBC spectra were 
also used to assign the signals. 
The 1 H NMR spectrum (Figure 21) of the chromone dimer 222 reveals two distinct 
doublets at 3.12 and 3.3 7 ppm corresponding to the diastereotopic 13-methylene protons, 
two singlets at 3.61 and 3.65 ppm corresponding to the two methoxy groups, a doublet 
of doublets at 4.51 ppm corresponding to the 2-methylene protons, a singlet at 5.05 ppm 
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corresponding to the 9a proton and a triplet at 6.69 ppm corresponding to the 4-methine 
proton reflecting coupling with the 13-methylene protons. The 13C NMR spectrum 
(Figure 22) reveals the expected 28 carbon signals and 3 additional signals due to 
residual ethyl acetate. The C-13 and C-2 methylene carbons resonate at 28.4 and 65.8 
ppm, respectively, while the C-9a methine carbon resonates at 99.8 ppm. The DEPT 135 
spectrum (Figure 23) confirms the assignment of the C-13 and C-2 methylene carbons to 
the signals at 28.4 and 65.8 ppm, respectively, while the data from COSY, HMQC and 
HMBC spectra were also used to facilitate the assignment of the signals. 
It was interesting to discover that the highest rates for Baylis-Hillman reactions using 
DABCO can be achieved at lower temperature.177•187- 188 Consequently, a series of 
chromone-3-carbaldehydes 83 and 184-185 were reacted with methyl acrylate in the 
presence of DABCO using a minimal volume of solvent (either CHCb or CH2Ch or 
THF or DMF) at 0°C for 12hours (Scheme 50). Purification of the crude products using 
flash chromatography did not afford the dioxanone derivatives 227-229 as expected but 
afforded the chromone dimer 222-224 in yields ranging from 5 to 45% (Table 7). While 
no Baylis-Hillman products 217-219 were observed after 12hours, however it is 
presumed that, in fact, they may well have been formed from dioxanone derivatives 227-
229 and then converted to chromone dimers 222-224. The dimeric products 222-224, 
first isolated by Sabbagh, 166 are presumed to form via the mechanistic sequence outlined 
in Scheme 51. 166 This involves the intermolecular reaction between two molecules of 
the Baylis-Hillman product 217 which results in intermediate 230. Attack of the hemi-
acetal hydroxyl oxygen on the a, P-unsaturated carbonyl moiety results in intramolecular 
cyclisation via an SN2' or conjugate addition-elimination process (as illustrated in 
structure 230a), to produce the dimeric product 222. These products 222-224 were fully 
characterized by spectroscopic (IR, 1- and 2-dimensional NMR) and elemental 
(HREIMS) analysis. 
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Table 7. Isolated yields(%) of chromone dimer 222-224. 
R Chromone Dimer Using Using Using Using 
THF CH2Ch CHCh DMF 
H 222 5 22 45 15 
Cl 223 12 35 25 20 
Br 224 17 37 30 27 
2. 2.1. 3. Reaction of chromone-3-carbaldehydes with methyl vinyl ketone 
The series of chromone-3-carbaldehydes 83 and 184-187 were reacted with methyl vinyl 
ketone using of 3-hydroxyquinuclidine as catalyst in chloroform for 24hours (Scheme 
52). Purification of the crude products afforded the novel tricyclic adducts 231-235 and 
the chromone dimers 241-245 in yields ranging from 60 to 80% and 20 to 35%, 
respectively (Table 8). When DABCO was used as the catalyst and 1-methylpyrrolidine 
was employed as an ionic solvent, the adducts 231-235 were isolated alone in lower 
yield ranging from 30 to 45%. There were no Baylis-Hillman products 236-240 observed 
in these reactions after 24 hours but it is assumed that they had been to be converted into 
the corresponding chromone dimers 241-245. When DBU was employed as catalyst, 
however, the reaction did not take place, confirming the observation by Aggarwal eta!. 
that MVK is not reactive in the presence of DBU .185 Th~1£Mmation of the n:w tricyclic 
adducts 231-235 can be rationalized as indicated in Scheme 53. The zwitterionic enolate 
D, formed from reaction of the catalyst and MVK, attacks the chromone-3-carbaldehyde 
83 at position 2 to afford intermediate 246. Proton transfer, followed by elimination of 
the catalyst, yields the intermediate 247. Cyclisation via an intramolecular conjugate 
addition and a tandem intermolecular Michael reaction then provide access to the novel 
tricyclic system 231. These tricyclic products 231-235 were fully characterized by 
spectroscopic (IR, 1 and 2-dimension NMR) and elemental (HREIMS) analysis. 
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Table 8. Comparative yields (%) of novel chromone adducts 231-235 and chromone 
dimer 241-245 obtained using 3-hydroxyquinuclidine and DABCO as catalyst. 
0 
I I~ 
,;; 
R 
0 
R 
R COMe 
0 
R Compound Using Using Chromone Using 
3HQ DAB CO dimer 3HQ 
H 231 69 45 241 25 
Cl 232 80 40 242 18 
Br 233 63 33 243 28 
F 234 60 30 244 23 
MeO 235 73 37 245 20 
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The 1H NMR spectrum (Figure 24) of the tricyclic adduct 231 reveals two multiplets at 
1.98 and 2.25 ppm corresponding to the diastereotopic 13-methylene protons, two 
singlets at 2.07 and 2.39 ppm corresponding to the 16- and 12-methyl groups, two 
multiplets at 2.40 and 2.60 ppm corresponding to the diastereotopic 14-methylene 
protons, a doublet of doublets at ca. 4.7 ppm corresponding to 10-methylene protons, a 
singlet at 5.13 ppm cmTesponding to the 8a-methine proton and a triplet at 7.30 ppm 
corresponding to the 2-methine proton which couples with the 1 0-methylene protons. 
The 13C NMR spectrum (Figure 25) reveals 18 carbon signals. The C-13 methylene 
nucleus resonates at 24.9 ppm, the C-12 and C-16 methyl nucleus at 25.5 and 30.0 ppm, 
the C-14 methylene nucleus at 3 7.8 ppm, the quaternary carbon C-9 at 49.1 ppm, the C-
10 methylene nucleus at 65.9 ppm, the C-8a methine at 99.9 ppm, the vinylic carbon C-2 
at 135.4 ppm and the three carbonyl carbons at 192.6, 196.6 and 206.7 ppm. The DEPT 
90 spectrum (Figure 26) confirms that there are only 6 methine carbon signals as 
expected. The DEPT 135 spectrum (Figure 27) confirms the presence ofthree methylene 
carbons, C-13, C-14 and C-10, which resonate at 55.9, 37.8 and 65.9 ppm, respectively; 
the absence of the C-9 signal, which resonates at 49.1 ppm, confirms that it is a 
quaternary carbon. The COSY spectrum (Figure 28) reveals long range couplings (A) 
between the 2-methine proton and the diastereotopic 1 0-methylene protons. The HMQC 
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and HMBC spectra (Figures 29 and 30) were used to assign the aromatic signal and also 
to confirm the other signal assignments. 
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Figure 24.400 MHz 1H NMR spectrum of the tricyclic adduct 231 in CDCh. 
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Figure 25. 100 MHz 13C NMR spectrum the tricyclic adduct 231 in CDC13. 
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Figure 26. DEPT 90 NMR spectrum of the tricyclic adduct 231 in CDC13. 
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Figure 27. DEPT 135 NMR spectrum of the tricyclic adduct 231 in CDCh. 
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Figure 28.400 MHz COSY NMR spectrum of the tricyclic adduct 231 in CDCh. 
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Figure 29.400 MHz HMQC NMR spectrum of the tricyclic adduct 231 in CDCI3• 
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Figure 30.400 MHz HMBC NMR spectrum of the tricyclic adduct 231 in CDC~). 
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The 1H NMR spectrum (Figure 31) of the chromone dimer 241 reveals two singlets at 
2.29 and 2.42 ppm corresponding to the 12- and 16-methyl groups, a singlet at 3.23 ppm 
corresponding to the 13-methylene protons, a doublet of doublets at 4.52 ppm 
corresponding to the 2-methylene protons, a singlet at 5.00 ppm corresponding to the 9a 
proton and a singlet at 7.17 ppm corresponding to the 4-methine proton. The 13C NMR 
spectrum (Figure 32) reveals the expected 28 carbon signals. The C-13 and C-2 
methylene carbons resonate at 30.9 and 65.9 ppm, respectively, the C-4a quaternary 
carbon at 50.1 ppm and the C-9a methine carbon at 99.8 ppm. The data from DEPT 135, 
COSY, HMQC and HMBC spectra were also used to facilitate the assignment of the 
signals. 
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Figure 31.400 MHz 1H NMR spectrum of the dimeric product 241 in CDCh. 
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Figure 32. 100 MHz 13C NMR spectrum of the dimeric product 241 in CDCh. 
2.2.2 Reaction of chromone-2-carbaldehydes with Michael acceptors 
2.2.2.1. Reaction of chromone-2-carbaldehydes with methyl vinyl ketone 
The chromone-2-carbaldehydes 91, 202 and 204 were reacted with methyl vinyl ketone 
using 3-hydroxyquinuclidine, as catalyst, in chloroform at room temperature for 24hours 
(Scheme 54). Purification of the crude products using flash chromatography afforded the 
MVK dimer 246 and the new adducts 247-249 in ca. 2:3 mixtures of syn- and anti-
diastereomers in yields of23-40% and 55-70%, respectively (Table 9a and b) and similar 
adducts have been reported for Baylis-Hillman reactions involving benzaldehyde 
substrates (see Section 2.7, p 157). None of the normal Baylis-Hillman product was 
found in the reaction mixtures after 24 hours. The mechanism for the formation of the 
adducts 247-249 has yet to be fully established, but it is likely that the normal Baylis-
Hillman product 250 is formed first (see Scheme 46, p 63), and then undergoes the 
conjugate addition by the MVK zwitterion D (Path I; Scheme 55) to form the 
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intermediate zwitterion 251; elimination of the catalyst then results in the adduct 247. 
Since there is an excess of MVK in the reaction mixture, dimerization occurs to form the 
dimer 246 (path II). 190-195 When these reactions were repeated using DABCO as catalyst, 
the MVK dimer 246 and the adducts 247-249 were obtained in yields of25-35% and 40-
55%, respectively. When dichloromethane was used as the solvent and 3HQ as the 
catalyst, the MVK dimer 246 and adducts 247-249 were obtained in lower yields (15-
27% and 50-65%, respectively). Furthermore, when DABCO was used as the catalyst 
but dichloromethane was used as the solvent, instead of chloroform, the MVK dimer 246 
and the adducts 247-249 were obtained in even lower yields (15-23% and 30-45%, 
respectively). However, when DBU was employed as catalyst, in either chloroform or 
dichloromethane, there was no reaction at all, confirming that MVK is not a good 
substrate for DBU.185 Its appears that the excess MVK favours the formation of Baylis-
Hillman adducts 247-249 as the Baylis-Hillman product 250, once formed, acts as an 
electrophile and reacts with the zwitterionic enolate D as depicted in Scheme 55. 
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The diastereomeric adducts 247-249 appeared as single spots on thin layer 
chromatography plates and even when HPLC was applied following flash 
chromatography, the syn and anti-diastereomers could not be separated. These products 
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were, however, characterized by spectroscopic (IR, 1- and 2-dimensional NMR) and 
elemental (HREIMS) analysis. The signal assignments in the representative 1H- and 13C-
NMR spectrum (Figures 34 and 35) of the parent system 247 were based on a careful 
analysis of the DEPT 135, HSQC and HMBC spectra. 
0 
250 
Scheme 55 
OH o-
251 
0 
247 
Table 9a. Isolated yields(%) ofMVK the dimer 246 at different solvents and catalysts. 
~ 
3HQ Catalysis DABCO Catalysis 
CHCh CH2Ch CHCh CH2Ch 
40 35 27 23 
37 28 19 17 
23 25 15 15 
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Table 9b. Isolated yields (%) of the adducts 247-249 using different solvents and 
catalysts. 
R 
R Product 3HQ Catalysis DABCO Catalysis 
CHCh CH2Ch CHCh CH2Ch 
H 247 70 65 55 45 
Br 248 63 50 47 35 
MeO 249 55 57 40 30 
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Figure 34. 400MHz 1H NMR spectrum of the diastereomeric adducts 247 in CDCb, 
with signals due to syn isomer denoted by (s) and the signals due to anti by 
(a). 
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Figure 35. lOOMHz 13C NMR spectrum of the diastereomeric adducts 247 in CDCh, 
with signals due to syn isomer denoted by (s) and the signals due to anti by 
(a). 
The 1H NMR spectrum (Figure 34) of the diastereomeric syn and anti- Baylis-Hillman 
adducts 247 reveals two singlets at 2.05 and 2.31 ppm, which correspond to the 7'- and 
9' -methyl protons, respectively, of the anti-isomer, and another two singlets at 2.18 and 
2.35 ppm which correspond to the 7' and 9' -methyl protons, respectively, of the syn-
isomer. The overlapping multiplets between 2.51 and 2.78 ppm correspond to the 
diastereotopic 3 '-methylene protons of both syn- and anti-isomers, the remaining signals 
maybe similarly assigned to the syn (s)- and anti (a)-diastereomers as indicated in 
Figure 34. The 13C NMR spectrum (Figure 35) reveals 36 carbon signals as expected 
with the anti- and syn-isomers each containing 18 different carbon atoms. The remaining 
13C signals have been assigned (s) or (a) in Figure 35, the assignments being based on 
careful examination of the 2-D NMR data. 
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2.2.2.2. Reaction of chromone-2-carbaldehyde with methyl acrylate 
The chromone-2-carbaldehyde 204 was reacted with methyl acrylate usmg 3-
hydroxyquinuclidine as catalyst in a minimal volume of chloroform at room temperature 
for 24hours (Scheme 56). Purification of the crude product using flash chromatography 
afforded the interesting product 250 in 45% yield, but none of the expected Baylis-
Hillman product 251. When dichloromethane was used as solvent this interesting 
product 250 was obtained in lower yield of 12%. The proposed mechanism for the 
formation of this product is in Scheme 57, and involves the displacement of the 
aldehyde group at position 2. It is apparent that instead of attacking the aldehydic 
carbonyl carbon, the zwitterionic enolate attacks electrophilic C-2 centre on the 
chromone system. Furthermore, when either DABCO or DBU were used, the reaction 
did not take place. Increasing the reaction time to 5 days and monitoring the progress 
every 24 hours failed to provide any evidence of the formation of the Baylis-Hillman 
product. The product 250 was fully characterized by spectroscopic (IR, 1- and 2-
dimensional NMR) and elemental (HREIMS) analysis. The 1H NMR spectrum (Figure 
36) of compound 250 reveals a doublet at 1.51 ppm corresponding to the 3'-methyl 
protons, a singlet at 3.93 ppm corresponding to the 1 '-methoxy protons, a quartet at 4.26 
ppm corresponding to the 2'-methine proton, and a singlet at 7.00 ppm corresponding to 
the 3-methine proton. The 13C NMR spectrum (Figure 37) reveals 14 carbon signals as 
expected. The 3' -methyl carbon resonates at 12.6 ppm, the 2' -methine carbon signal at 
48.0 ppm, the 3-methine carbon at 111.1 ppm, and the ester carbonyl carbon at 190.4 
ppm. The DEPT 135 spectrum (Figure 38) confirms the assignment of the 3' -methyl 
carbon to the signal at 12.6 ppm, the 2'-methine carbon to the signal at 48.0 ppm; the 
two methoxy carbons C-1 ' and C-6 resonate at 52.8 and 56.0 ppm, respectively. The 
COSY, HMBC (Figures 39-40) and elemental (HREIMS) analysis confirmed these 
results. 
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Figure 37. I 00 MHz 13C NMR spectrum of the compound 250 in CDCJ3• 
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Figure 38. DEPT 135 NMR spectrum of the compound 250 in CDCh. 
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Figure 40. 400 MHz HMBC NMR spectrum of the compound 250 in CDC b. 
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2.2.2.3. Reaction of chromone-2-carbaldehydes with acrylonitrile 
The chromone-2-carbaldehydes 91, 202 and 204 were also reacted with acrylonitrile 
using 3-hydroxyquinuclidine as catalyst in a minimal volume of chloroform at room 
temperature for 24 hours (Scheme 58). Purification of the crude products using flash 
chromatography failed to produce the expected Baylis-Hillman products 251-253 but, 
instead, afforded the interesting products 255-257 in yields ranging from 40 to 55% 
(Table 1 0). The proposed mechanism (Scheme 59) for the formation of these products 
255-257 involves nucleophilic attack of the cyanide nitrogen in the zwitterionic enolate 
at the electrophilic C(2) centre instead of the aldehydic carbonyl carbon, followed by the 
cyclisation to yield product 254a which tautomerises to 254b. Hydration then affords 
product 254. When either DABCO or DBU was used as the catalyst, the reaction did not 
take place, and when dichloromethane was used as solvent these interesting products 
(255-257) were obtained in lower yields ranging from 15 to 25%, but when either THF 
or DMF was used as solvent, the reaction did not take place at all. The reactions were 
repeated and monitored for 5 days but still did not afford the expected Baylis-Hillman 
products 251-253. The isolated products 255-257 were characterized by spectroscopic 
(IR, 1- and 2-dimensional NMR) and elemental (HREIMS) analysis. 
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Table 10. Isolated yields (%) of compounds 255-257 using different solvents. 
R Compound CHCh CH2Cb 
H 255 47 22 
Br 256 40 15 
MeO 257 55 25 
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Figure 43. DEPT I 35 NMR spectrum of compound 255 in CDC13. 
For example, the 1H NMR spectrum (Figure 4I) of compound 255 reveals a triplet at 
1.43 ppm which corresponds to the 2'-methyl protons, a quartet at 4.46 ppm which 
corresponds to the I' -methylene protons, a singlet at 7.11 ppm which corresponds to the 
5-methine proton and a broad signal at 7.36 ppm corresponding to the hydroxyl proton. 
The 13C NMR spectrum (Figure 42) reveals 12 carbon signals as expected. The methyl 
carbon C-2' resonates at 14.1 ppm, the methylene carbon C-I' at 63.0 ppm, the methine 
carbon C-5 at 114.8 ppm, the imine carbon C-4 at 124.4 ppm and the carbonyl carbon at 
178.4 ppm. The DEPT 135 spectrum (Figure 43) confirms the presence of the methyl 
carbon C-2' , the methylene carbon C-1 ' and the presence of four five methine carbons 
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with C-5 resonates at 114.8 ppm. The COSY spectrum (Figure 44) reveals the vicinal 
coupling (at the cross peak A) between the 2 ' methyl and the 1 ' -methylene protons. The 
HMQC spectrum (Figure 45) reveals that in cross peak A that the 2 ' -methyl protons are 
bonded to the carbon that resonates at 14.1 ppm, cross peak B reveals that the 1 '-
methylene protons are bonded to the carbon that resonates at 63.0 ppm, and cross peak C 
reveals that the 5-methine proton is bonded to the carbon that resonates at 114 ppm. The 
HMBC spectrum (Figure 46) was also used to support the structural assignment with 1 ' -
methylene protons connects to C-4 and 5-methine proton connects to C-4, C-2 and 
carbonyl carbon. 0 
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Figure 44. 400 MHz COSY NMR spectrum of the compound 255 in CDC h. 
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Figure 45. 400 MHz HMQC NMR spectrum of the compound 255 in CDCh. 
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2.3 Aza-Michael reactions of Baylis-Hillman products with 
amine derivatives 
These reactions involve the intermolecular addition of nitrogen-centered nucleophiles to 
a suitably activated alkenes, under strongly basic conditions either in the presence or 
absence of a catalyst.189 They provide a convenient method for the formation of P-amino 
carbonyl compounds and for generating carbon-nitrogen bonds. 190-194 In the present 
study, the approach has been applied to Baylis-Hillman derived a., P-unsaturated 
carbonyl compounds or nitriles. 
2.3.1 Reactions of Bay/is-Hillman products with (S)-benzylcysteamine 
hydrochloride 
The series of Baylis-Hillman products 212-216 were treated with (S)-benzylcysteamine 
hydrochloride and sodium acetate in EtOH at 25°C for 6 weeks (Scheme 60). 
Purification of the crude products using flash chromatography afforded the 
corresponding aza-Michael products 258-262 in yields ranging from 35 to 51% (Table 
11). It was observed that (S)-benzylcysteamine hydrochloride was insoluble in most 
organic solvent and it was decided to explore use of the amine. This was first achieved 
by treating the hydrochloride salt with aqueous sodium hydroxide and extracting the free 
amine into diethyl ether. Evaporation of organic solvent afforded the free amine, (S)-
benzylcysteamine, as an oil, some of which crystallized to give white needles. The 
reactions (Scheme 60) were repeated under similar conditions but employing the free 
amine, (S)-benzylcysteamine. The same products 258-262 were obtained but, 
surprisingly, the yields were lower, ranging from 15 to 45%. It was then decided to 
neutralize the (S)-benzylcysteamine hydrochloride in situ. Thus, the Baylis-Hillman 
products 212-216 were treated with (S)-benzylcystearnine hydrochloride and sodium 
acetate (NaOAc) in the presence of tetrabutylammonium bromide, (TBAB), as catalyst, 
in EtOH at 25°C. It was found that the reaction time could be effectively reduced to 5 
days, but still afford the chromatographed aza-Michael products 258-262 in yields 
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rangmg from 40 to 60% (Table 11). When the ionic liquid, 3-butyl-1-
methylimidazoleboranetetrafluoride (BmimBF4) was employed as catalyst in the 
presence of water, the reaction did not take place since the substrates 212-216 were 
insoluble in water. When the reactions were attempted in organic solvents such as 
chloroform, dichloromethane, THF, methanol and DMF, the substrates 212-216 were 
recovered unchanged due, it seems, to the fact that BmimBF 4 failed to dissolve. 
However, when the EtOH was used as the solvent, even though the 3-butyl-1-
methylimidazolium tetrafluoroborate (BmimBF4) appeared to be immiscible, the 
reaction took place and yielded products in purified yields ranging from 50 to 68% 
(Table 11). From the results summarized in Table 11 that the highest yields were 
obtained using BmimBF 4 in EtOH. The novel aza-Michael products 258-262 were fully 
characterized by spectroscopic (IR, 1- and 2-dimensional NMR) and elemental 
(HREIMS) analysis. The nitrile function in these compounds is, of course, capable of 
elaboration to, for example, amine or carboxylic acid groups. Such functional groups 
could hydrogen-bond with amino acid residues in the HIV -1 protease binding site. It 
should also be noted that a number of nitrile-containing compounds have been shown to 
exhibit useful pharmacological properties. 
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Table 11. Isolated yields(%) of the aza-Michael adducts 258-262 obtained under 
various conditions. 
R Compound A B c 
(6 weeksl (6 weeks) (5 days) 
H 258 51 45 51 
Cl 259 46 40 48 
Br 260 42 33 43 
F 261 35 15 40 
MeO 262 47 27 60 
A= usmg the usmg hydrochlonde amme salt; B = usmg the free amme; 
C= using TBAB; D= using [bmim]BF4 
D 
(5 days) 
68 
64 
56 
50 
66 
The 1H NMR spectrwn (Figure 47) of the aza-Michael product 258 reveals a triplet at 
2 .64 ppm which corresponds to the diastereotopic 6'-methylene protons, a multiplet at 
3.15 ppm which corresponds to the 2 ' -methine proton, a multiplet at 3.21 ppm which 
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corresponds to the diastereotopic 5'-methylene protons, a doublet of doublets at 3.24 
ppm corresponding to one hydrogen of the diastereotopic 4 '-methylene group, a broad 
peak at 3.53 ppm which corresponds to the 4'-amine proton, a doublet of doublets at 
3.57 ppm corresponding to another hydrogen ofthe 3'-methylene diastereotopic protons, 
a broad singlet at 3.73 ppm which corresponds to the diastereotopic 8' -methylene 
protons and a doublet at 4.98 ppm which corresponds to the 1 ' -methine proton. The 
series of signals in the region 7.21-7.27 ppm correspond to the aromatic protons and a 
broad signal at 10.93 ppm corresponds to the 1 'hydroxyl proton. The 13C NMR 
spectrums reveals 22 carbon signals as expected, and are assigned as indicated in (Figure 
48). 
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Figure 46. 400MHz 1H NMR spectrum of the aza-Michael product 258 in CDCh . 
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Figure 47. IOOMHz 13C NMR spectrum ofthe aza-Michael product 258 in CDCh. 
The DEPT 135 spectrum (Figure 48) confirms the presence of four methylene carbons, 
C-6', C-8', C-3' and C-5' which resonate at 30.1, 30.2, 43.2 and 55.9 ppm, respectively. 
In the HMQC spectrum (Figure 49) the cross peak A reveals that the 2' -methine proton 
is bonded to the carbon at 30.2 ppm, while cross peak B reveals that the diastereotopic 
3'-methylene protons are bonded to the carbon that resonates at 43.2 ppm, cross peak C 
reveals that the 1 '-methine proton is bonded to the carbon resonating at 61.1 ppm. In the 
HMBC spectrum (Figure 50), the cross peak A reveals that the diastereotopic 2' -methine 
proton is COUpling With 3'-methylene carbon through a two-bond COnnectivity eJc,H ), 
while the cross peak B reveals that the diastereotopic 3 '-methylene protons are coupling 
with the 1, -methine carbon through three-bond COnnectivity e Jc,H ). 
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Figure 48. DEPT 135 NMR spectrum of the aza-Michael product 258 in CDCI3. 
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Figure 49. HMQC NMR spectrum of the aza-Michael product 258 in CDCI3. 
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2.3.2 Reactions of Baylis-Hillman products with ethyl glycinate 
hydrochloride 
The Baylis-Hillman products 212, 213 and 215 were reacted with ethyl glycinate 
hydrochloride and sodium acetate in EtOH at 25°C for 6 weeks (Scheme 61). 
Purification of the crude products using flash chromatography afforded the aza-Michael 
products 263-265 in yields ranging from 15 to 45% (Table 12). The hydrochloride salt 
was again insoluble in most organic solvents and, as with the reaction with (S)-
benzylcysteamine hydrochloride, alternative approaches were explored. When reactions 
(Scheme 61) were repeated under similar conditions using free amine, ethyl glycinate 
(produced by neutralizing ethyl glycinate hydrochloride salt), the same products 263-265 
were obtained in yields ranging from 41 to 54%. It was also decided to neutralize the 
(S)-benzylcysteamine in situ. Thus, the Baylis-Hillman products 212, 213 and 215 were 
treated with ethyl glycinate hydrochloride and sodium acetate in the presence of 
tetrabutylammonium bromide (TBAB) as catalyst, in EtOH at 25°C for 5 days. 
Purification using the flash chromatography afforded the aza-Michael products 263-265 
in yields ranging from 50 to 60% (Table 12). When an ionic liquid, 3-butyl-1 -
methylimidazolium tetrafluoroborate (BmimBF4), was employed as catalyst in the 
presence of sodium acetate in EtOH, the yields ranged from 56 to 68% (Table 12). When 
MeOH or THF were used as the solvent in the presence ofBmimBF4 the reaction did not 
take place. These novel aza-Michael products 263-265 were fully characterized by 
spectroscopic (IR, 1- and 2-dimensional NMR) and elemental (HREIMS) analysis. 
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Table 12. Isolated yields(%) of the aza-Michael products 263-265 under various 
conditions. 
R Compound A B c 
after after after 
6 weeks 6 weeks 5 days 
H 263 45 48 58 
Cl 264 37 54 65 
F 265 15 41 50 
A = usmg the usmg hydrochlonde amme salt; B = usmg the free amme; 
C= using TBAB; D= using [bmim]BF4 
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Figure 51.400 MHz 1H NMR spectrum of the aza-Mjchael product 263 in CDC~]. 
The 1H NMR spectrum (Figure 51) of the aza-Michael 263 reveals a triplet at 1.29 ppm 
which corresponds to the 2 " - methyl protons, a multiplet at 3.21 ppm corresponding to 
the 5'-methine proton, a doublet of doublets at 3.38 ppm corresponding to one of the 4' -
methylene protons, a broad singlet at 3.6 I ppm which corresponds to NH, another 
doublet of doublets at 3.79 corresponding to the second 4' -methylene proton, a doublet 
at 4. 99 ppm corresponding to the 6' -methine proton and a broad signal at I 0.9 ppm 
which corresponds to the 6' -hydroxyl proton. The 13C NMR spectrum (Figure 52) 
reveals I 7 carbon signals as expected. The 5' -methine carbon resonates at 30.3 ppm, the 
4' -methylene carbon at 44.2 ppm, the 6' -methine carbon at 61.0 ppm and the 1 '- and 4-
carbonyl carbons at 167.9 and 195.9 ppm, respectively. The DEPT 135 spectrum (Figure 
53) confirms the presence ofthree methylene carbons, C-2', C-4' and C-1 ",which 
resonate at 57.1 , 44.2 and 62.2 ppm, respectively, and the two 5' - and 6'-methine 
carbons at 30.3 and 61.0 ppm. 
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Figure 52. 100 MHz 13C NMR spectrum of the new aza-Michael product 263 in CDCh. 
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Figure 53. DEPT 135 NMR spectrum ofthe aza-Michael product 263 in CDCh. 
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Figure 54. COSY NMR spectrum of the aza-Michael product 263 in CDCh. 
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Figure 55. HMQC NMR spectrum of the aza-Michael product 263 in CDCh. 
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The COSY spectrum (Figure 54) reveals vicinal coupling (A) between the 2"-methyl 
protons and the diastereotopic 1 ''-methylene protons, and also another vicinal coupling 
(B) between the 5' -methine proton and the 6' -methine proton .. In the HMQC spectrum 
(Figure 55) the cross peak A reveals that the 5' -methine proton is bonded to the carbon 
that resonates at 62.2 ppm, cross peaks B reveal that 4' -methylene diastereotopic protons 
are bonded to carbon that resonates at 44.2 ppm, and the cross peak C reveals that the 6'-
me thine proton is bonded to carbon that resonates at 61.0 ppm. 
2.3.3 Reaction of Baylis-Hillman products with D-serine methyl ester 
hydrochloride 
The Baylis-Hillman products 212, 213 and 216 were reacted with D-serine methyl ester 
hydrochloride and sodium acetate in EtOH at 25°C for 6 weeks (Scheme 62). 
Purification of the crude products using flash chromatography afforded the aza-Michael 
products 266-268 in yields ranging from 15 to 31% (Table 13). However, when these 
reactions were run for 5 days using similar conditions and TBAB as catalyst the aza-
Michael products 266-268 were obtained in yields ranging from 20 to 40% (Table 13). 
The aza-Michael products 266-268 were fully characterized by spectroscopic (IR, 1- and 
2-dimensional NMR) and elemental (HREIMS) analysis. 
R 
212 H 
213 Cl 
216 MeO 
R 
R 
266 H R 
267 Cl 
268 MeO 
Scheme 62 
OH _/OH 
CN _ + · 
+ CIH3N ............... C02Me 
EtOH, NaOAc, 6weeks 
or 
EtOH, NaOAc, TBAB, 5 days 
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Table 13. Isolated yields (%) of the aza-Michael compounds 266-268 obtained under 
various conditions. 
R Compound After 6 weeks 
using NaOAc 
H 266 31 
Cl 267 15 
MeO 268 27 
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Figure 56. 400MHz 1H NMR spectrum of the aza-Michael product 266 in CDCI3• 
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Figure 58. DEPT 135 NMR spectrum of the aza-Michael product 266 in CDCh. 
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The 1H NMR spectrum (Figure 56) of the aza-Michael product 266 reveals a broad 
signal at 2.21 ppm corresponding to the 2' -methylene hydroxyl proton, two triplets at 
2.21 and 3.02 ppm corresponding to the diastereotopic 4'-methylene protons, a broad 
singlet at 3.16 ppm which corresponds to NH, a multiplet at 3.21 ppm which 
corresponds to the 5'-methine proton, a broad singlet at 4.98 ppm corresponding to the 
6 '- methine proton, and a broad singlet at 10.98 ppm which corresponds to the 6'-
hydroxyl proton. The 13C NMR spectrum (Figure 57) reveals 17 carbon signals as 
expected with the extra signals due to the diastereomers. The 5' -methine carbon 
resonates at 31.3 ppm, a 4 ' -methylene carbon resonates at 43.1 ppm, a 6' -methine 
carbon resonates at 55.5 ppm, a methoxy carbon resonates at 59.8 ppm, the signal 
marked with an asterisk, which resonates at 128.8 ppm, indicates that there are four 
methine carbons which are overlapping which implies the presence of four isomers. The 
DEPT 135 spectrum (Figure 58) confirms the presence oftwo diastereotopic 4'- and 8' -
methylene carbons which resonate at 43.1 and 55.5 ppm respectively. 
2.3.4 Reaction of Baylis-Hillman products with L-serine ethyl ester 
The Baylis-Hillman products 212, 213 and 216 were reacted with L-serine ethyl ester 
hydrochloride ar1d sodium acetate NaOAc in EtOH at 25°C for 6 weeks (Scheme 63). 
Purification of the crude products using flash chromatography afforded the aza-Michael 
products 269-271 in yields ranging from 26 to 45% (Table 14). However, when these 
reactions were reacted using L-serine ethyl ester hydrochloride, sodium acetate (NaOAc) 
and tetrabutylammonium bromide (TBAB), as catalyst, in EtOH at 25°C for 5 days they 
gave yields ranging from 28 to 40%. The products 269-271 were fully characterized by 
spectroscopic (IR, 1- and 2-dimensional NMR) and elemental (HREIMS) analysis. The 
1H NMR spectrum (Figure 59) of the aza-Michael product 269 reveals a triplet at 1.33 
ppm corresponding to the 8'-methyl protons, a broad singlet at 3.19 ppm which 
corresponds to the 3' -amine proton, a multiplet at 3.57 and 3.79 ppm corresponding to 
the diastereotopic 4 ' -methylene protons, a multiplet at 3.80 ppm corresponding to the 
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5'-methine proton, a singlet at 5.02 ppm corresponding to the 6'-methine proton, and a 
broad singlet at 11.4 ppm which corresponds to 6' -hydroxyl proton. The 13C NMR 
spectrum (Figure 60) reveals 17 carbon signals as expected. The 5' -methine carbon 
resonates at 47.4 ppm, the 4' -methylene carbon at 53.4 ppm, and the 6' -methine carbon 
at 68.4 ppm. The DEPT 135, COSY, HSQC and HMBC and elemental (HREIMS) 
analysis data were all used to facilitate the assignment of signals in of these compounds. 
R 
212 H 
213 Cl 
216 
R 
R 
269 H 
270 Cl 
271 MeO 
Scheme 63 
0 
R 
EtOH, NaOAc, 6weeks 
or 
EtOH, NaOAc, TBAB, 5 days 
CN OH 
NrC02Et 
H 
Table 14. Isolated yields (%) of the aza-Michael compounds 269-271 obtained under 
various conditions. 
R Compound After 6 weeks After 5 days 
usingNaOAc usingTBAB 
H 269 26 30 
Cl 270 29 45 
MeO 271 27 33 
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Figure 59. 400MHz 1H NMR spectrum of the aza-Michael product 269 in CDCh. 
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Figure 60. 1 OOMHz 13C NMR spectrum of the aza-Michael products 269 in CDC b. 
2.3.5 Reaction of Baylis-Hillman products with L-threonine methyl ester 
hydrochloride 
The Baylis-Hillman products 212 and 213 were reacted with L-threonine methyl ester 
hydrochloride and sodium acetate in EtOH at 25°C for 6 weeks (Scheme 64). 
Purification of the crude products using flash chromatography afforded the aza-Michael 
products 272 and 273 in relatively low yield (25-31 %; Table 15). However, repetition of 
these reactions using L-threonine methyl ester hydrochloride and sodium acetate 
(NaOAc) and tetrabutylammonium bromide, as catalyst, in EtOH at 25°C for 5 days 
gave improved yields (37-45%). 
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OH 
Table 15. Isolated yields of aza-Michael compounds 272 and 273 obtained 
at various reaction times. 
R Compound After 6 weeks After 5 days 
using NaOAc usingTBAB 
H 272 25 37 
Cl 273 31 45 
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Figure 61. 400MHz 1H NMR spectrum of the aza-Michael product 273 in CDCh. 
While the 1H NMR spectra of the corresponding benzyl cysteamine, glycine and serine 
derivatives exhibit relatively sharp signals, the 1H NMR spectrum (Figure 61) ofthe aza-
Michael product 273 is characterized by poorly resolved signals attributed to the 
presence, in this case, of diastereomeric products. The 13C NMR spectrum (Figure 62) 
reveals more than 18 carbon signals, which was expected, which confirms the presence 
of diastereomeric products. The DEPT 135, COSY, HMBC (Figures 62-64) and 
elemental (HREIMS) analysis data were used to facilitate the assignment of signals in 
these compounds. 
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F igure 63. DEPT 135 NMR spectrum of aza-Michael product 273 in CDCh. 
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Figure 64. 400 MHz COSY NMR spectrum of aza-Michael product 273 in CDC13• 
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Figure 64. 400 MHz HMQC NMR spectrum of aza-Michael product 273 in CDCh. 
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2.4 HIV -1 Protease Kinetics 
Enzyme kinetics studies were undertaken in order to explore the catalytic activity of 
HIV -1 protease in the presence of the commercially available "HIV substrate III" and 
the representative chromone derivatives 258, 263 and 266, our inhibitors (Figure 65). 
The chromone derivatives 258, 263 and 266 were selected for examination as potential 
inhibitors as they possess some features in common with ritonavir, a clinically approved 
HIV -1 protease inhibitor. Km, V max and Ki are the parameters typically used to measure 
changes in catalytic activity. The Michaelis constant, Km, reflects the binding affinity 
between the HIV substrate III and HIV-1 protease, while Vmax, the maximum velocity, 
corresponds to the maximum catalytic activity. These parameters provide measures of 
the catalytic activity of the enzyme, in the presence of substrate, informing the 
intermediate HIV-1 protease-HIV substrate III complex. It is assumed that the 
interaction between the enzyme and substrate in this case is reversible (Equation 5), but 
that the decomposition of the HIV -1 protease-HIV substrate III complex to form product 
and free enzyme is sufficiently slow to be considered negligible. 
[lllV-1 protease]+ [lllV substrate lli] [lllV-1 protease-mv substrate 1[[1] ....... (5) 
CN ~ 
s ~ I N~ 
H 
258 263 
266 
Figure 65. Chromone derivative selected for examination as potential HIV -1 protease 
inhibitors 
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The rate of the enzy!Tie-catalysed reaction is therefore directly proportional to the 
concentration of the enzyme and this linearity is important for accurate measurement of 
the enzyme activity.79 This requires that the enzyme concentrations used during the 
assay should lie within the linear region and that the pH and temperature be kept 
constant. Km, the substrate concentration at which the HIV -1 protease receptor sites are 
half filled (IN max), and Vmax, the rate at which the HIV -1 protease activity is saturated, 
can be determined using Michaelis-Menten, Lineweaver-Burk, and Hanes and Wool 
plots, as described in the Introduction. 
Normally, the units of initial velocity, vo, are expressed as ~-tmoles of substrate cleaved 
per minute. 77 But in this section, the units used to express vo are defined as the amount of 
enzyme that will cause a change in absorbance at 300nm of 0.00001 per minute, under 
the assay conditions described. 
2.4.1 HIV-1 Protease Linearity 
The linear range of the HIV -1 protease was determined from assays in which the enzyme 
concentrations were varied while keeping the HIV substrate concentration constant at 
18.5 ~-tM (Figure 66). 
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Figure 66. Plot of vo versus HIV -1 protease concentration for determining the linearity 
dependence of HIV -1 PR. This assay was generated from duplicate assays in 
which [HIV-1 protease] was varied from 0 to 0.093 ~-tM using a constant HIV 
protease substrate III concentration of 18.5 ~-tM, at 25°C and pH 4.9. 
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A plot of the resulting data (Figure 66) reveals reasonable linearity up to ca. 0.05 11M in 
the concentration ofHIV-1 protease. An HIV-1 protease concentration of0.039 11M was 
therefore selected for all subsequent assays, while the pH and temperature were kept 
constant at 4.5 and 25 °C, respectively. 
2.4.2 HIV-1 Protease Substrate Dependence 
The substrate dependence assays involved collecting kinetic data for a series of substrate 
concentrations ranging from 0 - 73.96 11M while keeping the HIV-1 protease 
concentration constant at 0.037 11M. Figure 67 illustrates the graphical determination of 
Km and Vmax using (a) a Michaelis-Menten plot, (b) a Lineweaver-Burk plot, and (c) a 
Hanes and Woolf plot. These assays were run in triplicate at constant temperature 25 °C 
and a pH of 4.5. Comparison of the Km and V max values obtained with those reported in 
literature. 
The Michaelis-Menten plot, Figure 67a, was constructed using the following equation: 
Km + [HIV PR substrate III] 
....... (6) 
v = Vmax x [HIV PR substrate III] 
This plot clearly shows that at low substrate concentrations the rate of reaction, vo, 
increases more or less linearly with the substrate concentration while, at higher substrate 
concentrations the rate becomes constant. The Michaelis constant, Km, can be obtained 
by interpolation since it is the substrate concentration at which the reaction rate is half of 
its maximum value (V max/2), which is the reason why Km is also called the half-
saturation value.80 However, it is difficult to specify the exact substrate concentration 
corresponding to Km from this hyperbolic plot. Consequently, the linear Lineweaver-
Burk and Hanes-Woolf plots were constructed (Figures 67b and c), thus permitting 
accurate measurements of the values of both Km and V max even at higher substrate 
concentrations. 78 The Lineweaver-Burk plot (Figure 67b) was constructed using equation 
7, 75• 80 while the Hanes-Woolf plot was constructed using equation 8. 
132 
Results and Discussion 
1 -----------~~----------+ 
V max * [HIV protease substrate III] 
1 
....... (7) = 
v 
vmax 
[HIV protease substrate III] = _1 * [HIV protease substrate III] + ~ ....... (S) 
v vmax vmax 
From these plots, Km and V max were found to be 27.97 11M and 322.58 units.min' 1, 
respectively. The Km obtained for HIV PR substrate III lies in the same range as the Km 
value found in literature, viz. 28.00 11M.84 The catalytic efficiency ofHIV-1 protease was 
found to be 311.7 min-1, and was obtained by dividing V max by the Km value. 
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Figure 67. Kinetic analysis ofHIV Protease substrate dependence: (a) Michaelis-
Menten plot; (b) Lineweaver-Burk plot (r2 = 0.954); (c) Hanes-Woolf plot 
(r2 = 0.969). 
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2.4.3 HIV -1 Protease Inhibition Studies 
2. 4. 3.1 Effect of Inhibitors 
Results and Discussion 
The chromone derivatives 258, 260 and 266 were then examined in a series of HIV -1 
protease inhibition assays. In triplicate runs exploring the effect of varying the 
concentration of the potential inhibitors on the activity of HIV -1 protease at pH 4.5 and 
25°C, it became apparent that compounds 258 and 266 exhibit some inhibitory effect 
(see Figure 68). In the case of chromone derivative 260, however, no inhibition was 
observed even at a concentration as high as 44.23 ~LM. 
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Figure 68. (a) Effect of chromone derivative 258 and (b) chromone derivative 266 on 
HIV-1 protease activity. The assays were run in triplicate at pH 4.5 and 
25°C. 
The observed decrease in enzymatic activity implies interaction between the HIV -1 
protease enzyme and these inhibitors. 78 In the case of chromone derivative 258 (Figure 
68a), the remaining enzyme activity was ca. 52% at 20 J..lM decreasing to ca. 33% at 25 
~-tM and then remaining constant ca. 26% at 32.7 J..lM. However, in the case of chromone 
derivative 266 (Figure 68b) the residual enzyme activity was ca. 52% at 14.5 !lM and 
decreased to ca. 48% at 21.7 J..lM. The fact that neither of these inhibitors resulted in zero 
residual enzyme activity implies that they don't fill the entire receptor cavity of the HIV-
1 protease enzyme. In order to establish the type of inhibition involved, Lineweaver-
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Burk and Dixon plots were constructed using concentrations of the inhibitors that gave 
up to ca. 50% residual enzyme activity. 
2.4.3.2 Determination of the Krm Vmax and K; values 
Inhibition assays for the chromone derivative 258 were performed using inhibitor 
concentrations of 0 to 22!lM, while concentrations ranging from 0 to 21.75!lM were 
used for the chromone derivative 266. The Km and V max values were obtained from 
Lineweaver-Burk plots, while the Ki values were obtained from Dixon plots. The 
corresponding plots for the chromone derivatives 258 and 266 are illustrated in Figures 
69 and 70, respectively. 
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Figure 69. (a) Lineweaver-Burk plots for the inhibition ofHIV-1 protease by chromone 
derivative 258 using the concentrations of O!lM (r2 = 0.989), +, 1 011M 
(r2 = 0.935), •, and 22!lM (r2 = 0.847), A, in the presence ofHIV protease 
substrate III. (b) Dixon plots for the effect of chromone derivative 258 on 
HIV -1 protease activity when the HIV protease substrate III concentration 
was 9.25 11M (r2 = 0.896), +,and 18.25!lM (r2 = 0.960), A. 
Figure 69 reveals the chromone derivative 258 to be a non-competitive inhibitor. The 
Lineweaver-Burk plot, Fig. 69a, indicates that different concentrations [0.00!-iM 
(standard), 10!lM and 22!lM] give straight lines with Km values of 23.02, 25.04 and 
28.07 1-1M, respectively. The Km values in the presence of the inhibitor are higher than 
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the Km value in its absence (23.02 J..tM), meaning that the chromone derivative 258 does, 
in fact, interfere with the catalytic activity of HIV -1 protease. Furthermore, use of the 
different concentrations (0.00 JlM, 25.04 JlM and 28.07 J..tM) afforded V max values of 
294.12, 250.0 and 175.4 units.min.-1, respectively. The progressive decrease in V max on 
increasing the concentration are features which describe non-competitive inhibition.80 
The Dixon plot (Figure 69b) confirms that the chromone derivative 258 is a non-
competitive inhibitor; the straight lines intersect at abscissa indicating an inhibition 
constant (Ki) of ca. 3.2 llM (0.0032nM). However, with a Ki value of O.OlSnM, 91 
ritonavir has higher binding affinity for HIV -1 protease than chromone derivative 258. 
The results indicate that the chromone derivative 258 interferes with both the binding of 
the HIV protease substrate III and HIV -1 protease catalytic activity. This may be 
attributed to the chromone derivative 258 binding either to the free enzyme or to the 
protease-HIV protease substrate III (ES) complex (Equation 3, p. 13). 
.... 0.04 
.... 
0.05 
._ 
·-
(b) .... 
"7'= 0.04 'c 0.03 
·s ... e 0.03 
,f!j 0.02 ,f!j 
·; 
·; 0.02 
= 
'-" 0.01 = '-" 
;::. ~ 0.01 ...... 
.-( 0 
- 0 
-0.1 0 0.1 0.2 
-20 0 20 40 
-1 11 [HIV protease substrate III] (J.!.M ) [Chromone derivative 266] (J.!.M) 
Figure 70. (a) Lineweaver-Burk plots for the inhibition ofHIV -1 protease by chromone 
derivative 266 with concentrations of O!lM (r2 = 0.820), +, 7.03 llM 
(r2 = 0.997), •. and 14.5JlM (r2 = 0.9197), A, in the presence ofHIV 
protease substrate III. (b) Dixon plot for the effect of chromone derivative 
266 in HIV -1 protease activity when the HIV protease substrate III 
concentration was 18.25 J..tM(r2 = 0.896) +, and 27.73J..tM(r2 = 0.960) A. 
Figure 70 shows the chromone derivative 266 is a competitive inhibitor as deftned in 
Equation 2 (p. 13). The Lineweaver-Burk plot (Fig. 70a) reveals that the assay data for 
136 
Results and Discussion 
different concentrations (0.00 , 7.03 and 14.5 f!M) afford the straight lines, (with the Km 
values of 12.45, 32.50 and 23.44 f!M, respectively) which intersect at the same 11 V max 
value of about 188.7 units.min.-1 (Figure 70b). It is also evident that the Km values (32.5 
and 23.44 f!M) in the presence of this chromone derivative 266 are much higher than the 
Km value (12.45 f!M) in its absence. This implies that the chromone derivative 266 has a 
higher binding affinity than the HIV protease substrate III and thus competes with the 
protease substrate for binding to HIV -1 protease enzyme. The Dixon plot (Figure 70b) 
confirms that the chromone derivative 266 is a competitive inhibitor since plots of the 
different concentrations ( 0.00 , 7.03 and 14.5 f!M) of compound 266 at constant 
substrate concentrations (18.5 and 27.73 f!M) gave Ki values of 6.4 f!M (0.0064 nM) 
and 13.3 f!M (0.00133 nM), respectively. However, these values are lower than for the 
ritonavir Ki value of 0.015 nM,91 which means that the binding affinity of chromone 
derivative 266 for HIV -1 protease is lower than for the ritonavir. The various kinetic 
parameters determined in the enzyme kinetic studies are summarized in Table 16. 
Table 16. Kinetic parameters obtained during the kinetic studies. 
[Chromone derivative 258] Km (f!M) Vmax Ki (nM) 
(f!M) (units.min-1) 
0 23.01 294.12 0.015 
10 25.04 250.0 
22 28.07 175.4 
[Chromone derivative 266] 
(f!M) 
0.00 12.45 0.0064 
7.03 32.50 188.7 
14.5 23.44 
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2.5 Computer Modelling Studies of Chromone Derivatives as 
Potential HIV -1 Protease Inhibitors 
Computer modelling has become a crucial drug-designing technique. 13 Such studies 
typically involve modelling of the putative inhibitor and exploring its docking into a 
known enzyme receptor cavity, permitting elucidation of the interactions involved in the 
enzyme receptor-inhibitor complex. 57 The structure of the receptor cavity of the HIV-1 
protease enzyme has been well established by X-ray crystallography and the structure 
reported by Kempf et al. 195 was used in our investigation. The structure of this 
homodimeric enzyme is illustrated in Figure 71 with the orange ribbon denoting 
monomer A and the blue ribbon denoting the monomer B. 195 
Monomer A Monomer B 
Receptor cavity Structural water molecule 
Figure 71 . X-ray crystal structure ofHIV-1 protease. 195 
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The chromone-containing derivatives 222, 241, 258, 260, 266, 269, 272, and 274 
developed as truncated ritonavir analogues and the dimers 222 and 241 were selected as 
representative structures of several series of compounds prepared in this study, and were 
docked into this HIV-1 protease receptor cavity, using the ACCELRYS Cerius2 module, 
LigandFit. Conformational space was explored for each structure using molecular 
dynamics and the ten highest and ten lowest energy conformations in the resulting 
trajectory were subjected to energy minimization. The common minimum energy 
structure was then presumed to correspond to the global minimum. The resulting 
structures, illustrated in Figures 72-73, represent the global minimum in each case. The 
intention was to:- i) compare the minimum energy conformations of ritonavir 2 and 
each of the chromone derivatives 222, 241, 258, 260, 266, 269, 272, and 274; ii) explore 
the docking of ritonavir 2 and the chromone derivatives into the enzyme receptor cavity; 
and iii) compare the favoured binding conformation of each of the compounds with their 
respective minimum energy conformations. 
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Figure 72. Structtrres of compounds 2, 222, 241, 258,260, 266, 269, 272 and 274. 
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Compound 258 Compound 260 Compound 266 
Compound 269 Compound 272 Compound 274 
Compound 222 
Compound 241 
Ritonavir 2 
Figure 73. Energy-minimized conformers of the truncated, chromone-containing 
compounds 222, 241, 258, 260, 266, 269, 272 and 274 and ritonavir 2. 
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The Cerius2 SITE SEARCH module was used to define the binding site of HIV -1 
protease (Figure 74). The inhibitor is expected to be able to interact with the receptor 
provided it is situated within the vicinity of the site and, ideally, fills the entire region. 
Overlaying the energy-minimized structure of ritonavir 2 on this binding site reveals that 
this clinically useful inhibitor does not, in fact, encompass the entire space of the site nor 
is it completely accommodated within it (Figure 75). However, when overlaying both 
ritonavir 2 and lopinavir 5, a mixture of which comprises the combination drug, 
kaletra,72 it is apparent that more space in the binding site is occupied (Figure 76). This 
illustrates a possible advantage of using HIV protease inhibitors as combination drugs. 
Alignment of the chromone-derivatives 222, 241, 258, 260, 266, 269, 272 and 274 also 
revealed, not unexpectedly, that these compounds are not long enough to occupy the 
entire binding site (Figure 77). What is critical, of course, is the nature and strength of 
the interactions between the ligand and the receptor, and their effect on the relative 
receptor binding and plasma solvation energies. 
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It should be noted, however that Figures 75-77 illustrate in vacuo rather than binding 
conformations of the compounds examined. The binding conformations were explored 
using a docking routine (see below). 
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Figure 77. Overlay of energy-minimized in vacuo structures of the chromone-containing 
analogues 222, 241, 258, 260, 266, 269, 272 and 274. 
Since the chromone containing-analogues 222, 241, 258, 260, 266, 269, 272 and 274 
were expected to exhibit some structural similarity with ritonavir 2, their in silica 
alignment with ritonavir 2 was examined. This involved matching, where possible, 
corresponding groups, such as the characteristic 3-hydroxyl group in compounds 222, 
241, 258, 260, 266, 269, 272 and 274, the amide group in compound 274 as well as the 
aromatic groups. 
There are numerous reports on X-ray crystal structures of complexes of linear inhibitors 
with the HIV -1 protease dimer.47•195•196 Two important common features have been 
observed in the binding of peptidomimetic inhibitors and these are illustrated for the 
model isostere in Figure 78.16•73•196 The first feature involves linkage of the inhibitor to 
the flexible glycine-rich "flaps" through hydrogen-bonding with a structural water 
molecule. This water molecule interacts with the amide hydrogens of the isoleucine 
residues, lie 50A-NH and lie 508-NH and carbonyl oxygens of the inhibitor molecule. 
The second feature is the hydrogen-bonding between the inhibitor hydroxyl group and 
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the catalytic aspartic acid residues Asp 25A-COOH and Asp 25B-Coo-, situated in the 
S 1 and S 1, binding pockets of the enzyme. The bond marked with an asterisk (*) in 
Figure 78 corresponds to the cleavage site in an enzyme substrate. The inhibitor residues 
P t, P2, P3 etc. bind to the S~, S2, S3 etc. pockets of the HIV-1 protease enzyme situated in 
monomer A (Figure 79), while the P 1·, P2·, P3· residues bind to the St ·, S2·, S3· enzyme 
binding pockets situated in monomer B. Table 1 summarizes the amino acid residues 
which form the specific enzyme binding pockets. 
Catalytic Asp25A-COOH 
Flap lie 50A-NH 
-ooc-Asp25B 
H, ...-H 
,Q~-----
, ' 
,' ' 
Structural water 
Flap 'HN-Ile 50B 
Figure 78. Schematic representation of the hydrogen-bonding interactions observed 
when typical peptidomimetic inhibitors, such as ritonavir, bind to the HIV -1 
protease active site.16• 204 
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Table 1. Amino acid sequences forming the HIV -1 Protease subsites.41 
Subsite HIV-1 PR 
s4 Asp30' Ileso· Ile54' 
s 3 Arg8 Asp29'Leu23 Val82 Arg87' 
s2 Ala28 Val82 Phe53, Ile54' Leu76' Thr80' Ile84' 
St Leu23 Asp25* Phe53 Pro81 Val82 Ile84 
St · Leu23' Asp25'* Phe53' Ile84' 
S2· Ala28 Asp30 Val32 Phe53 Ile54 Leu76 lle84 
s 3' Arg8 Asp29 Ile50 Pro81 ' Arg87 
Primes ( ') distinguish the residues from the two subunits in the dimer of HIV -1 PR. 
* Catalytic Asp residue. 
'Ue-56 B;-
Pro 81 A 
lle 54 B 
Figure 79. X-ray crystal structure of HIV -1 protease with the amino acid residues that 
form the enzyme binding pockets in both monomers A and B.41· 195 
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The interaction between compounds 222, 241, 258, 260, 266, 269, 272 and 274 and the 
HIV -1 protease receptor cavity was explored using the Cerius2 docking module, 
"LigandFit". In this approach, the docking of various conformations of the ligand into 
the receptor site is examined while the enzyme remains rigid. Initially, the active 
binding site of the HIV -1 protease (Figure 71) was exposed by removing the ligand 
occupying the receptor cavity in the enzyme-ligand complex in the structure reported by 
Kempf et a/?03 Figure 80 shows the complex of the HIV -1 protease enzyme with 
ritonavir 2, covered by a Connoly surface, and it is evident that this inhibitor occupies a 
significant volume of the receptor cavity. 197 The van der Waals energy of interaction 
between ritonavir and the receptor cavity was found to be 903.5 kcal mor1• The van der 
Waals binding energy reflects the stability provided by hydrophobic interactions 
between the enzyme and the inhibitor. The ligand scoring option was used to select the 
conformation with the best binding based on both hydrogen-bonding and van der Waals 
interactions. Twenty conformers were so scored in each case with conformer 1 having 
the best interaction since it exhibits the highest binding energy of the set. This ranking is 
supported by the hydrogen-bonding distances, which are shorter and, hence, stronger in 
conformer 1 than in conformer 20. Figure 81 illustrates the interactions observed 
between conformer 1 of the docked ritonavir 2 molecule and the HIV -1 protease receptor 
cavity-interactions which include some of the common features characteristic of 
peptidomimetic inhibitors. 198 
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Figure 80. Structure of ritonavir 2 docked into the HIV -1 protease receptor cavity. 
Ile50A-N~ .. _2·042 A ...... HN-Ile50B 
Asp25A-COO- HOOC-Asp25B···... . .. ·<2·090 A 
···... / ,....0, ..,__Bridging water molecule 
A. : A .. ·H H 2.327 ··.. ... 2.178 .... 
N ·· ... H ..... /,. _.........,Ph ••• •••••• 1.679 A S 
1 ~ 0 - 0 Me F~ ~:~0 ~~ ~~ ~~r/-S ~: N:~ N 
.· 
.. ··· 
II = H = II 
.. o / /-......... 0 
/ Ph 
H, ,....H 
: 0 .. +-- ----Bridging water molecule 
2.042 A/ \ 
,..... \._2.090 A 
.... ·., 
Ile50A-NH HN-Ile50B 
Figure 81. Schematic representation of hydrogen-bonding interactions between ritonavir 
2 and the HIV -1 protease receptor cavity in the presence of bridging, 
structural water molecules. 
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The docking of compound 258 revealed water-mediated interactions with the HIV -1 
protease receptor cavity (Figures 82 to 85). Hydrogen-bonding interactions (~ 2.1 A) 
were predicted between the isoleucine residues, Ile 50A-NH and Ile 50B-NH, a bridging 
water molecule, and both the amino nitrogen and hydrogen atoms in compound 258. 
Hydrogen bonding interaction was also apparent between the same bridging water 
molecule and the nitrile nitrogen (C=N), and between the hydroxyl hydrogen and the 
catalytic aspartic acid residue (Asp 25A-COO} Compound 258 appears to interact with 
the S1, S3· and S4 enzyme-binding pockets with a van der Waals binding energy of -45.29 
kcal mor1, which is far lower than for ritonavir 2 (903.5 kcal mor1). Clearly, compound 
258 seems to exhibit fewer hydrogen-bonding interactions inside the receptor cavity and 
a much lower overall receptor binding energy (164.2 kcal mor1) than ritonavir 2. 
Compound 258 also occupies 0.336 A.3 of the receptor cavity whereas ritonavir 2 
occupies 0.612 A.3. Comparison of the interactions for conformer 1 with the highest 
binding energy (Figures 82 and 83) and conformer 20 with the lowest binding energy 
(Figures 84 and 85), reveals that the latter exhibits weaker binding interactions. 
Attempts to dock compound 258 into the enzyme receptor cavity in the absence of a 
water molecule failed to show any hydrogen-bond interactions with the amino acid 
residues forming the enzyme binding pockets, indicating the absence of direct 
interaction between the ligand and the amino acids residues situated in the enzyme 
binding pocket. Table 17 details the overall binding energies for the twenty conformers 
scored for compound 258. 
149 
1/_ "" --- \' I . 
} 
' 
lu 
I \ .. ........... . ' ' , ,, II\\ 
\ 
_/ 
•' 
I ( 
v \ 
..... " /' 
Results and Discussion 
·--
\ 
I 
\ / 
/ / \ 
// \ ........ 
-
.· 
/ 
.,-..... 
Figure 82. Complex of compound 258 (conformer 1) with the HIV -1 protease receptor 
cavity showing interactions with a structural water molecule. (Asterisk 
indicates structural water molecule.) 
lle50A-NH 
I 
Asp 25A-COO~, 2_0 11 A 
', ..... H 
'0 
2.090 A/ 
,' ,/ HN-IIe50B 
I 
1.228 A --H-o/'2.042 A 
- - \ 
=N---;.458',{ /·H 
.,."' ......... 
Figure 83 Schematic representation of hydrogen-bonding interactions between 
compound 258 (conformer l) and the HIV -1 protease receptor cavity in the 
presence of a structural water molecule. 
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Table 17. The binding energies for the twenty scored conformers of 
compound 258. 
Conformer no. Binding energy for compound 258 
(kcal.mor') 
1 164.2 
2 133.1 
3 104.3 
4 97.3 
5 73.1 
6 60.5 
7 53.7 
8 53.3 
9 52.8 
10 50.3 
11 45.8 
12 40.0 
13 30.6 
14 22.1 
15 22.0 
16 21.9 
17 21.8 
18 18.5 
19 17.3 
20 17.1 
The docking of compound 263 (conformer 1) revealed water-mediated interactions with 
the HIV -1 protease receptor cavity (Figures 86 to 88). Hydrogen-bonding interaction 
was observed between a bridging water molecule and the amino hydrogen (NH) in 
compound 263. Comparison of conformer 1, with lowest energy (Figures 86 and 87) and 
conformer 20 (Figure 88), with highest energy, shows that the latter exhibits longer 
NH-H20 separation meaning a weaker interaction. Compound 263 appears to interact 
with the S4-S3'enzyme binding pockets with a van der Waals energy of -16.73 kcalmor' 
and overall binding energy of 156.4 kcalmor' again far lower than for ritonavir 2 and 
also appears to occupy 0.320 A3 of the receptor cavity. Attempts to dock this compound 
in a receptor cavity in the absence of structural water revealed no hydrogen-bonding 
interaction. 
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Figure 86. Complex of compound 263 (conformer 1) with the HIV -1 protease receptor 
cavity showing interactions with a structural water molecule. (Asterisk 
indicates structural water molecule.) 
Ile50A-NH 
0 
· HN-IIe50B 
_..H 2.042 X·. •· 
0 \ ./2.090 A 
CN .·H_ ... :o,H 
N6y~..........-
H 0 
Figure 87. Schematic representation of hydrogen-bonding interactions between 
compound 263 (conformer 1) and the HIV -1 protease receptor cavity in the 
presence of a structural water molecule. 
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Ile50A-NH 
HN-Ile50B 
,.H 2.042k·. .· 
0 -.. ./2.o9oA 
eN ..... :o, 
.·H H 
.. /3.os3 A 
N~o~ 
H 0 
Figure 88. Schematic representation of hydrogen-bonding interactions between 
compound 263 (conformer 20) and the HIV -1 protease receptor cavity in the 
presence of a structural water molecule. 
The hydrogen-bonding interactions observed on docking compound 272 into the HIV -1 
protease receptor cavity are illustrated in Figures 89-92. This compound 272 appears to 
interact with the St, 84 and S3'enzyme binding pockets with van der Waals energy of 
-27.5 kcal mor1 and an overall binding energy of 139.9 kcal mor1 and was found to 
occupy ca. 0.331 .A? of the receptor cavity. In this case, the substrate hydrogen bonds 
directly to Asp 25AC02- via the threonine hydroxyl hydrogen and via a structural water 
molecule as illustrated in Figures 89,90. In the case of conformer 20, however, the 
separations are all so large (ca. 8-10 .A.) as to preclude hydrogen-bonding interactions 
(Figures 91, 92). Attempts to dock compound 272 into the receptor cavity in the absence 
of a structural water molecule again revealed no interactions with the amino acid 
residues in the enzyme binding pockets. 
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Figure 89. Complex of compound 272 (conformer 1) with the HIV -1 protease receptor 
cavity showing interactions with a structural water molecule. (Asterisk 
indicates structural water molecule.) 
CN 
C02 Me 
0 N~0'H 
_, ,' 1 ',,2.192 A Ii 2.1ssA / H ----
2·042 A I ,'/ As 25A-COO-Ile50A-NH ............ -0 ,' 2.831 A p 
:'It' 
;2.090 A 
HN-IIe50B 
Figure 90. Schematic representation of hydrogen-bonding interactions between 
compound 272 (conformer 1) and the HIV -1 protease receptor cavity in the 
presence of a structural water molecule. 
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Figure 91. Complex of compound 272 (conformer 20) with the HIV -1 protease receptor 
cavity showing distances between the substrate and potential hydrogen-
bonding moieties. (Asterisk indicates structural water molecule.) 
0 OH 
CN 
C02Me 0 NA(0'H ,' A ,' 1 --,9.806 A H 4.478 ,/ H '--, 
2.042 A I , -ooC-Asp 25A 
Ile50A-NH ............. 0 / 7.997 A 
:'H-' 
12.090 A 
HN-Ile50B 
Figure 92. Schematic representation of distances between compound 272 (conformer 
20) and potential hydrogen-bonding moieties in the HIV -1 protease receptor 
cavity. 
Docking of the compounds 222, 241, 266, 269 and 274 into the HIV-1 protease receptor 
cavity, has revealed some hydrogen-bonding interactions which are illustrated 
schematically in Figure 93. In each case, conformer 1 shows appropriate atomic 
separations consistent with effective hydrogen-bonding interaction, whereas conformer 
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20 exhibits separations so large as to preclude hydrogen-bonding interaction. Table 18 
details the enzyme binding pockets which interact with these compounds; their van der 
Waal energies and overall binding energies and also the space they appear to occupy in 
the receptor cavity. Attempts to dock these compounds into the receptor cavity in the 
absence of structural water molecule, reveals that none of them were sufficiently close to 
the amino acid residues in the enzyme binding pockets to experience receptor-substrate 
hydrogen bonding. 
CN :("O'H 
: 0 
1.587.*0 ~~ ............... 
/ 2.366 fo./ a 0 H ... /·:---- A I ___ .. , - 2.792 
Ile50A-NH -----<:>--- ,/ 
2.042 A I 'It" 
I 
HN-Ile50B HN-Ile50B 
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. / 2.090A 
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H . H 
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I 
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I 2.090 A'HN-IIe50B 
0 
Figure 93. Schematic representation of hydrogen-bonding interactions between 
"conformer 1" of compounds 222, 241, 266, 269 and 27 4 and the HIV -1 
protease receptor cavity in the presence of structural water molecules. 
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Table 18. Results obtained when compounds 2, 222, 222, 241, 258, 260, 266, 269, 272 
and 274 were docked in the HIV-1 Protease receptor cavity. 
Compound Binding Energy I kcal.mor' Space occupied Enzyme binding 
Van der Waals Overall A? pockets nteracting 
Ritanovir 903.5 15171.7 0.612 S3',S2',SI', S1,S2, 
222 241.8 252.2 0.408 s4 
241 65.46 204.7 0.394 s 3' and s4 
258 -45.29 164.2 0.336 S1·, S3· and S4 
263 -16.73 156.4 0.321 s3' and s4 
266 -27.50 155.2 0.319 s 3' and s4 
269 -24.04 160.3 0.308 s 3' and s4 
272 -17.19 139.9 0.331 sl ·, s3' and s4 
274 -38.26 156.1 0.287 s 3' and s 4 
These in silico studies certainly indicate the capacity of the chromone containing-
analogues 2, 222, 222, 241, 258, 260, 266, 269, 272 and 274 to interact with the receptor 
cavity, but further modification of these compounds may well be necessary to increase 
the number of efficient hydrogen-bonding interactions with critical enzyme binding 
pockets. Careful consideration of their potential for binding via hydrophobic interactions 
will also be critical. The observation that there were, in general, no hydrogen-bonding 
interactions in the absence of structural water molecules in the receptor cavity, suggest 
the possibility of introducing a group on the inhibitor which will replace the need for 
structural water. It is perhaps significant that compound 263, which showed no activity 
at all in the enzyme inhibition studies (Section 2.4.3), exhibits a much higher in silico 
van der Waals binding energy (-16.73 kcal.mor1) than the competitive inhibition 266 (-
27.50 kcal.mor1) and the non-competitive inhibition 258 (-45.29 kcal .mor1). In all cases, 
the favoured bound conformation was found to have a similar conformation to that of the 
' isolated' global minimum conformation. 
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2.6 KINETIC MECHANISTIC STUDY of the BAYLIS-HILLMAN 
REACTION OF 2-NITROBENZALDEHYDES 
Shi et al, 199-20 1 have recently reported the formation of the bis-MVK Baylis-Hillman 
adducts 278a-d and 279a-d, together with the normal Baylis-Hillman products 277a-d, 
when certain arylaldehydes 275a-d are reacted with the Michael acceptor MVK 276, 
(Scheme 65). They observed that an excess of MVK 276 was found to promote formation 
of the his-MVK products and the MVK dimer 246. 199• 202-203 
275a-e 276 
R 
a 3-N02 
b 4-N02 
c 4-Br 
d 4-Cl 
e 2-N02 
Scheme 65 
DABCO, 20-160hrs • 
-30°C or 20°C or 70°C 
DMForDMSO 
or CH2Cl2 
~ 
R 
277a-e 
+ 
246 
OH 0 
278a-d = syn 
279a-d = anti 
When 2-nitrobenzaldeyde 275e was reacted with MVK 276, Shi et al199 did not obtain the 
diastereomeric adducts 278e and 279e but only the normal Baylis-Hillman product 277e. 
However, Pakade working on a project in our group on the application of Baylis-Hillman 
methodology in the construction quinoline derivatives, 193•194 was able to isolate both the 
normal Baylis-Hillman product 277f and the corresponding diastereomeric adducts 278f 
and 279f from the reaction of 3-methoxy-2-nitrobenzaldehyde 275f with MVK 276 
(Scheme 66). This observation has prompted us to explore the mechanism of these 
Baylis-Hillman reactions, focusing, initially, on the reaction of 3-methoxy-2-
nitrobenzaldehyde 275f with MVK 276 in the presence of diazabicyclo(5.5.5.]octane 
(DABCO) in CHCh or CDC13. 
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The formation of adducts of type 278 and 279 from 3-methoxy-2-nitrobenzaldehyde 
275f but not 2-nitrobenzaldehyde 275e raises interesting mechanistic questions. While 
Shi et a/?00 had proposed the possibility of two possible mechanistic pathways, which 
are outlined for the reaction of 3-nitrobenzaldehyde 275a in Scheme 67, they favoured 
the Path I since there was no reaction when Path TI was explored by treating 3-
nitrobenzaldehyde 275a with MVK dimer 246 in the presence of DABCO. Shi et a/.200 
indicated that Paths I and II would be expected to involve the steps detailed in Scheme 
67, which has also provided the framework for a parallel theoretical study in our group. 
Path I involves the nucleophilic addition of DABCO (C) to the activated alkene, MVK 
276, to form a zwitterionic enolate (D), followed by addition of this intermediate D to 
the aldehyde 275a; proton transfer and release of the catalyst, DAB CO (C), then affords 
the normal Baylis-Hillman product 277a. This product (277a) then reacts with a second 
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zwitterionic enolate species (D) to yield the syn- and anti-adducts 278a and 279a. Path 
II, on the other hand, involves the reaction of MVK 276 with DABCO (C) to form the 
zwitterionic enolate (D), which then attacks another MVK molecule 276, to form the bis-
MVK zwitterionic enolate (G). Instead of releasing DABCO to afford the MVK dimer 
246 the enolate G can now attack the aldehyde 27Sa resulting in the formation of the syn 
and anti adducts 278a and 279a after release of DABCO (C). It should be noted that in 
Path I, the diastereomers 278a and 279a are produced via the formation of the normal 
Baylis-Hillman product 277a, whereas in Path II, they are produced directly from the 
reaction of 3 -nitrobenzaldehyde 275a. 
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It was decided to investigate the use of NMR methods to monitor the progress of the 
reaction. This required:- i) separation and characterization of each of the components in 
the reaction mixture; and ii) sufficient resolution of significant signals in the spectrum of 
the mixture to permit identification and integration of structure-specific signals. 
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2.6.1 Isolation of the reaction products 
The reaction between 3-methoxy-2-nitrobenzaldehyde 275f and MVK 276 (Scheme 66) 
was repeated. Flash chromatography of the crude product formed after 24h yielded the 
pure MVK dimer 246 and a mixture of the syn-and anti-diastereomers 278f and 279f, 
respectively. Since flash and radial chromatography failed to separate the diastereomeric 
adducts 278f and 279f, HPLC was used to obtain the pure diastereomers. The normal 
Baylis-Hillman product 277f could not be observed when the reaction was stopped after 
24 hours and, consequently, was isolated by stopping the reaction after 2 hours. The 1 H 
NMR spectra of the Baylis-Hillman product 277f, the syn-and anti-diastereomers, 278f 
and 279f, respectively, and the MVK dimer 246 are illustrated in Figures 94-97. The 1H 
NMR spectrum (Figure 94) for the Baylis-Hillman product 271f reveals:- singlets at 2.33 
and 3.88 ppm which correspond to the 5'-acetyl and 3-methoxy protons, respectively; a 
broad signal at 3.45 ppm corresponding to the hydroxyl proton; a singlet at 5.67 ppm 
corresponding to the 3'-methine proton; two singlets at 5.95 and 6.22 ppm corresponding 
to the diastereotopic 1 ' -methylene protons; and the three aromatic signals further 
downfield. The 1H NMR spectrum (Figure 95) of the syn-diastereomer 278f reveals an 
additional singlet at 2.3 5 ppm, which corresponds to the 9' -methyl protons, multiplets at 
2.35 and 2.61 ppm, which correspond to the diastereotopic 3'-methylene protons, and a 
multiplet at 3.21 ppm corresponding to the 4'-methine proton. The 1H NMR spectrum 
(Figure 96) of the anti-diastereomer 279f, exhibits the same spectroscopic pattern as the 
syn-diastereomer but with obvious differences in the chemical shift values. For 
comparative purposes, the 1H NMR spectrum of the MVK dimer 246 is illustrated in 
Figure 97. Examination of the spectra of the reactants and all three products permitted 
identification of the signals to be used as NMR probes in the kinetic studies. 
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Figure 94. 400 MHz 1H NMR spectrum of the Baylis-Hillman product 277f in CDCI3• 
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Figure 95. 400 MHz 1H NMR spectrum of the syn-diastereomer 278f in CDCI3• 
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2.6.2 Optimization of the spectroscopic analysis methodology 
Figure 98 illustrates the 1H NMR spectrum for the reaction after I minute, with the arrow 
indicating the region where the vinylic protons normally resonate. Initially, it was hoped 
that the vinylic methylene proton signals for each species (between 5.6 and 6.9 ppm) 
could be used to monitor the progress of the reaction. However, signal overlap made it 
difficult to integrate the signals for the individual products (Figure 99). An attempt was 
made to address this problem by employing a deconvolution method.205 This method 
permits multipoint baseline correction and curve fitting (Figure 1 00), which enhances 
peak resolution and peak visibility (Figure 101 ). Unfortunately, this method could not be 
used since careful analysis of the results revealed some obvious errors, and attention was 
turned to the use of 13C NMR spectroscopy. However, since different carbon nuclei 
typically exhibit different relaxation times, signal integration cannot normally be used 
for quantitative purposes. 
I 
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Figure 98. 400 MHz 1H NMR spectrum reflecting the DABCO-catalysed reaction of 3-
methoxy-2-nitrobenzaldehyde 275f with MVK 276 in CDCh after lmin. 
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the DABCO-catalysed reaction of 3-methoxy-2-nitrobenzaldehyde 275f with 
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Figure 100. Expansion of a region of the 400MHz 1H NMR spectrum (Fig. 98) 
reflecting the DABCO-catalysed reaction of 3-methoxy-2-
nitrobenzaldehyde 275f with MVK 276 in CDCl3 after 1 min, with the curve 
fitted spectrum, after multipoint baseline correction, in blue. 
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Figure 101. Expansion of a region of the 400MHz 1 H NMR spectrum (Fig. 98) 
reflecting the DABCO-catalysed reaction of 3-methoxy-2-nitrobenzaldeyde 
275f with MVK 276 in CDCh after I min, following multipoint baseline 
correction and curve fitting. 
This problem can be obviated by introducing a pulse delay long enough to ensure 
complete relaxation of the nuclei of interest. In order to establish the relevant spin-lattice 
relaxation times (T1), an inversion recovery sequence was employed (Figure 1 02). Since 
the vinylic methylene carbon signals for the reactants and products were expected to be 
used to monitor the reaction, particular attention was given to the spectral region 
between 126 and 129 ppm. In this approach, the magnetization of the carbon nuclei is 
inverted towards the - z axis with a 1t pulse, the nuclei are allowed to relax back towards 
the +z axis and then subjected to a n/2 pulse before the signal intensity is measured. It 
can be observed (Figure 102) that all the signals are negative up to lOs. As the pulse 
delay is increased some of the signals remain negative while others become positive. The 
relaxation time for a given nucleus can be determined using the following equation:206 
T 1 = 'tnull/ ln2 = 1.443 X 'tnull 
168 
Results and Discussion 
Unfortunately, even after 50s (T1 = 72.2s) the vinylic methylene carbon signals (marked 
by the bracket) are still negative. Given the need for multiple acquisitions and the 
observed rate of the reaction, it was evident that it would be impractical to use 13C NMR 
spectroscopy to monitor the reaction since it would take too long. 
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Figure 102. Stack-plot of inversion recovery spectra of the mixture obtained in the 
DABCO-catalysed reaction of 3-methoxy-2-nitrobenzaldehyde 275f with 
MVK 276 in CDCh, recorded after specified pulse delays. 
An alternative approach, which was finally used and which worked effectively, was to 
select other signals in the 1H NMR spectra which correspond uniquely to the reactants 
275f and 276 and the products 277f, 278f and 279f, and 246. Thus, formation of the 
MVK dimer 246 was monitored using the multiplet at 2.15 ppm (corresponding to the 3-
and 4-methylene protons), the diastereomers 278f and 279f, using the singlets at 5.34 
169 
Results and Discussion 
using the singlet at 5.74 ppm (corresponding to one of the 1 '-methylene protons). For 
monitoring consumption of starting materials, use was made of the doublet at 5.54 ppm 
(due to the vinylic protons in MVK 276) and the singlet at 9.51 ppm (due to the 
aldehydic proton in the substrate 275f). 
2.6.3. Analysis of the kinetic data 
The kinetic studies were conducted on an NMR-tube scale, as described in the 
experimental section. 1,3,5-Trimethoxybenzene (TMB) was used as an internal standard 
and Figure 103 illustrates the 1H NMR spectra recorded : a) after 1 minute and b) after 
14 hours, as well as the signals used to monitor each species. In the spectrum recorded 
after 1 minute (Fig. 103a), the substrate 275f aldehyde signal is evident at 9.50 ppm, but 
is clearly absent in the spectrum recorded after 14 h (Fig. 1 03b ), indicating that after 14 
h all of the aldehyde starting material had been consumed. The integrals were corrected 
using TMB - an internal standard which gives rise to a singlet at 3.30 ppm, 
corresponding to three methoxy groups. The changes in the spectra with time are clearly 
illustrated in the stack-plot reproduced in Figure 104. Although spectra were run at 10 
minute intervals, the stack-plot reflects the change at 1 hourly intervals. 
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Figure 103. 400 MHz 1H NMR spectra ofthe DABCO-catalysed reaction of3-methoxy-
2-nitrobenzaldehyde 275f with MVK 276 in CDC13: (a) at the beginning of 
the reaction and (b) when the reaction was stopped after 14 b. 
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Figure 104. Stack-plot of 400 MHz 1H-NMR spectra for the DABCO-catalysed reaction 
of 3-methoxy-2-nitrobenzaldehyde 275f with MVK 276 in CDCI3, recorded 
at 1 hour intervals. 
In order to simplify analysis ofthe kinetic data, the structures detailed in Scheme 67 are 
represented in Scheme 68 by the letters A-H where A = 269f; B = 270; C = DABCO; D 
= zwitterionic intermediate; E = 271f; Fsyn = 272f; Fanti = 273f; G = MVK dimer enolate; 
and H = 246. The simplified sequence is illustrated in Figure I 05. 
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Figure 105. Simplified schematic diagram illustrating possible reaction pathways 
(cf Schemes 67 and 68). 
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Figure 111. Time-corrected plot of the sum of the concentrations of the aldehyde 275f 
[A] and the substrate-derived products 277f [E), 278f [Fsyn] and 279f [Fanti] 
with time. 
F anti and Fsyn are presumed to be formed initially via two routes, viz., Path I , in which 3-
methoxy-2-nitrobenzaldehyde 275f (A) is converted to the diastereomeric adducts 278f 
(Fsyn) and 279f (Fanti) via the formation of the normal Baylis-Hillman product 277f (E) 
and path II, in which the diastereomeric adducts 278f (Fsyn) and 279f (Fanti) are formed 
without the intermediate 277f (E) (refer to Scheme 68 and Figure 1 05). After 9910 s, 
(Figure 112). 
[A]~ 0 moLL-1 
[E) ~ 0.24 moLL-' 
[Fanti] ~ 0.16 moLL- ' 
[Fsyn] ~ 0.26 moLL-' 
Since [E) + [Fanti] + [Fsyn] = 0.66 moLL-'~ [A)o 
then, at any time t, 
[F] final- [E) is the amount ofFtotal = (Fanti and Fsyn) formed via path II. 
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Figure 112. Time-corrected plots of the changes in concentrations of 3-methoxy-2-
nitrobenzaldehyde 275f (A), the Baylis-Hillman product 277f (E), the 
Baylis-Hillman diadducts 278f (Fsyn) and 279f (Fanti), the MVK dimer 246 
(H) and [F10 1a1] with time, during the initial stage of the reaction. 
Initially, Fsyn is formed more rapidly than Fanti but, after reaching a max1mum 
concentration of about 0.26 mol L-1 at about 10 000 s, Fsyn begins to decrease linearly 
(Figure 113). On the other hand, [Fami] increases almost linearly after rapidly reaching 
about 0.16 mol L-1• [Fsyn] and [E] reach a maximum at about the same time that the 
aldehyde [A] has been consumed (Figure 113). Clearly, once [A] has reached zero, the 
formation of [F ami] and [Fsyn] via path II will cease. After about 10 000 s [F101] increases 
approximately linearly and after 50 000 s approaches the value of [A]0 . 
Thus, after about 10 000 s, [Ftod = kFt + [Ftod 10000 
Where kF = 2.79 x 10-6 mol L-1 s·1and [Ftot]o = 0.405 mol L-1 
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Figure 113. Plots ofthe changes in [Ft0 t], [Fanti] and [Fsyn], [E] and [Ftod- [E] against 
corrected time. 
The plots in the approximately linear region (Figure 113) afford slopes and intercepts 
and, hence, rate constants for the formation of Fanti and the consumption of Fsyn and E 
and their concentrations at t = 10 000 s (Table 17). 
Table 17. Kinetic data for the approximately linear region after ca. 10 OOOs in (Figure 
I 05). 
Component Rate constant I mol L-1 s·1 Concentration at t =1 0 000 s I 
moiL-1 
Ftot - E (path I) 5.52 X 10'6 0.147 
Ftot 2.79 X 10'6 0.405 
Fanti 3.45 X 10'6 0.105 
Fsyn -2.07 X 10'6 0.042 
E -2.66 X 10'6 0.256 
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Figure 114. Time-corrected plots of change in [FtotL [Fantd and [Fsyn], [E] and [F101]- [E] 
against time for the initial stage of the reaction. 
In the initial stage of the reaction the product distribution is essentially kinetically 
controlled and [Fsyn]> [E] > [Fanti] (Figure 114). After 10 000 s, however, the substrate 
concentration [A) = 0 and the formation of Fsyn and/or Fanti is assumed to proceed via 
Path I alone and require the equilibration: 
F syn ~ E ::;;;:::=::::=: F anti 
The final product distribution is thus thermodynamically controlled, with Fanti being the 
most stable product, produced by concomitant consumption of both the normal Baylis-
Hillman product E and the diadduct Fsyn· From the product distribution after about 50 
000 s, it is apparent that the equilibrium constant at 298 K is approaching a value of 1.3), 
(i.e. K = 0.31 /0.24 = 1.3). 
The reaction using the aldehyde 275f (A) was repeated at various temperatures (295-315 
K) with the intention of accessing activation energy data. However, no consistent trends 
were observed. This is, perhaps, not surprising given the complexity of the 
transformation and the reversibility of the various steps. 
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The formation of the MVK dimer 246 (H) should be third-order, i.e. Rate = k [B]2[D] 
but, since the catalyst concentration [D] is constant, it may be expected to be pseudo 
second-order, as reflected in the linear second-order plot (after about 10 000 s) shown in 
Figure 115, the slope affording a pseudo-second-order rate constant of 3.97 x 1 o-6 mol L-
1 s·1 with r2 = 0.975. 
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Figure 115. Pseudo-second-order plot reflecting the formation of the MVK dimer (H) 
from MVK (B) with respect to MVK [B] (r2 = 0.975). 
Kinetic studies were also undertaken using MVK 276 and the arylaldehydes 275a, 280 
and 281 with the aim of exploring the effect of different substituents on reactivity. These 
compounds all follow the same trend as 3-methoxy-2-nitrobenzaldehyde 275f affording 
the corresponding Baylis-Hillman products and syn-and anti-diadducts. Table 18 
summarizes the rate constants for the disappearance of the substrates 275f, 275a, 280 
and 281 and ofMVK 276 in each case. 
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Table 18. Comparison of the rate constants (ka) for the consumption of the aldehyde 
substrates during Baylis-Hillman reactions. 
Entry Benzaldehyde Compound ka I (s-1) 
substituents 
I 3-MeO, 2-N0 2 275f 4.74 X 104 
2 4-N02 275a 4.02 X 10"4 
3 5-Cl, 6-N02 280 3.78 X 10-4 
4 2-Cl, 6-N02 281 3.85 X 10"5 
It seems that 3-methoxy-2-nitrobenzaldehyde 275f (entry 1) is the most reactive of the 
set of four benzaldehyde derivatives examined. The 4-nitro- and 5-chloro-6-
nitrobenzaldehydes exhibit similar rates of consumption (entries 2 and 3), but the 2-
chloro-6-nitro analogue 281 reacts an order of magnitude more slowly (entry 4). The 
pair of substituents ortho to the aldehyde group in compound 281 may force the 
aldehyde moiety to adopt an arrangement perpendicular to the aromatic ring and thus 
sterically inhibiting attack by nucleophilic species. 
These kinetic studies have revealed that both mechanistic pathways (Scheme 67) operate 
during the formation of the syn-and anti-diadducts 272f (F5yn) and 273f (Fanti), and that 
product selectivity is kinetically controlled in the early stage of the reaction, but that the 
final product distribution is thermodynamically controlled. The rejection, by Shi et a!. 200 
of Path II, was based on the fact that treatment of 3-methoxy-2-nitrobenzaldehyde 269a 
with the MVK dimer 246 in the presence of DABCO failed to afford the bis-MVK 
adducts 278a and 279a. However, Path II requires the zwitterionic enolate G (Scheme 
67) whereas, once formed, the MVK dimer 246 may be expected to form the isomeric 
intermediate I (Scheme 69) not G. 
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2.7 CONCLUSION 
Many chromone derivatives are known to exhibit pharmacological activity,88•89 and in 
this study, chromone derivatives have been explored as scaffolds for the construction of 
HIV -1 protease inhibitors. Chromone-3-carbaldehydes have been successfully 
synthesized using Vilsmeier-Haack methodology in yields ranging from 43 to 85%, 
while chromone-2-carbaldehydes have been obtained via the Kostanecki- Robinson 
reactions in yields ranging from 46 to 65%. The chromone-2-carbaldehyde yields were 
increased from 50 to 70% when the reaction time was extended from 12 hours to 20 
hours; use of 1-chloronaphthalene or dioxane instead of xylene as solvent was also 
investigated but the results confirmed that xylene was the best solvent for these 
reactions. 
Application of the Baylis-Hillman reaction to the chromone-3-carbaldehydes and 
chromone-2-carbaldebydes has been studied using three different catalysts, viz. , 1,4-
diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]-undec-7-ene (DBU) and 3-
hydroxyquinuclidine (3HQ), and three different activated alkenes, viz., acrylonitrile, 
methyl acrylate and methyl vinyl ketone. These reactions generally afforded both normal 
Baylis-Hillman and dimeric Baylis-Hillman products in high yields when chromone-3-
carbaldehydes were used as substrates. Both the yields and the reaction rates were 
increased when DABCO was employed in the presence of the ionic liquid, 1-methyl-2-
pyrrolidine (1-NMP). 167 However, only dimeric products were isolated when this 
reaction was performed at 0°C in the presence of organic solvents. DBU was found to be 
a more efficient catalyst than 3HQ since it afforded the Baylis-Hillman products in good 
yields over shorter reaction periods. Interestingly, when the chromone-3-carbaldehydes 
were reacted with methyl vinyl ketone, dimeric Baylis-Hillman products were obtained 
together with novel tricyclic adducts, but none of normal Baylis-Hillman products were 
isolated. The tricyclic adducts appear to be formed via an unprecedented transformation 
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involving attack of the zwitterionic enolate at C(2) of the chromone-3-carbaldehyde 
which then undergoes proton transfer and, finally, elimination of the catalyst. 
When chromone-2-carbaldehydes were used as substrates in the presence of methyl 
vinyl ketone, the MVK dimer together with syn- and anti-diastereomeric adducts were 
obtained. Furthermore, unprecedented reactions were also observed when these 
substrates were reacted with methyl acrylate and acrylonitrile, as activated alkenes, 
which afforded interesting novel products in low yields. These reactions indicate that the 
electrophilicity of C(2) renders it more susceptible to nucleophilic attack than carbonyl 
carbon of the aldehyde group. This is illustrated by the attack of the zwitterionic enolate 
at C(2) followed by displacement of the 2-aldehyde group. When DBU was used as the 
catalyst in the presence of MVK, neither chromone-2-carbaldehydes nor chromone-3-
carbaldehydes appeared to react, confirming that DBU is not a good catalyst for 
reactions with MVK.186 
Reactions between the normal Baylis-Hillman adducts derived from the chromone-3-
carbaldehydes and acrylonitrile, on one hand, and various amino derivatives, on the 
other, afforded aza-Michael products. Tetrabutylammonium bromide (TBAB) and the 
ionic liquid, 3-butyl-1-methylimidazoleboranetetrafluoride (BmirnBF4), were used as 
catalysts and the products were typically obtained in yields of 20-68%. These aza-
Michael products (or compounds derived therefrom) had been targeted as truncated 
ritonavir analogues for investigation as potential HIV -1 protease inhibitors, designed to 
partially resemble the clinically useful hydroxyethylene dipeptide drug. This design 
strategy involved elongation of the Baylis-Hillman products with amino derivatives to 
form aza-Michael products containing a hetero-aromatic system at one end attached to a 
chain containing hydroxyl and other ftmctional groups capable of hydrogen-bonding 
interactions with the protease receptor. In the absence of catalyst, the aza-Michael 
products were obtained after 6 weeks, whereas in the presence of catalyst, they were 
obtained in 5 days! Although use ofBmimBF4 resulted in products in higher yields, this 
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catalyst was not miscible with all the organic solvents examined. Consequently, TBAB, 
which proved to dissolve more readily, was used in all reactions. 
Analysis of the HIV -1 protease enzyme-inhibition activity of selected aza-Michael 
products revealed that one compound exhibited non-competitive inhibition [with an 
inhibition constant (Ki) of ca. 0.0032 nM], while another exhibited competitive 
inhibition (with a Ki value of ca. 0.0064 nM). However, one of the three compounds 
examined did not show any activity. 
Computer modelling studies were conducted on a range of the synthesized chromone-
containing derivatives using the Cerius2 LigandFit module. These in silica studies 
clearly indicated the capacity of the chromones-containing analogues to interact with the 
receptor cavity through hydrogen-bonding interactions. However, these interactions did 
not involve all of the significant binding pockets in the receptor and, moreover, 
depended on the presence of a structural water molecule in the receptor cavity. In all 
cases, the favoured bound conformation was found to have a similar conformation to 
that of the ' isolated' global minimum. 
Finally, attention was given to the mechanism of the Baylis-Hillman reaction of selected 
2-nitrobenzaldehydes with MVK in the presence of DABCO - a reaction which affords 
the normal Baylis-Hillman product, the MVK dimer as well as syn- and anti-bis-MVK 
Baylis-Hillman adducts. Kinetic studies were perfomed using NMR spectroscopy and 
confirmed the simultaneous operation of two mechanistic pathways during the formation 
of the syn- and anti-diadducts during the early stage of the reaction. These diadducts 
were successfully separated using HPLC. The anti-diadduct was found to be the more 
stable and, hence, thermodynamically favored product. The syn-diadduct, on the other 
hand, is kinetically favoured (being formed during the initial stage of the reaction) and is 
converted to the anti-diadduct at a later stage. The kinetic study afforded rate constants 
for the formation of the various products as well as the consumption of the reactants, and 
provided useful insights into the complex mechanism. 
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Future research in this area is expected to involve the following. 
(i) Confirmation of the structures of the products of unexpected reactions using 
single crystal X-ray analysis. 
(ii) Elaboration of the aza-Michael products to increase the number of efficient 
hydrogen-bonding interactions with critical enzyme binding pockets and to 
replace the need for structural water. 
(iii) Hydrolysis of nitriles obtained in the aza-Michael reaction to affords amides and 
acids as potential HIV -1 protease inhibitors. 
(iv) Application of the aza-Michael reaction to Baylis-Hillman products derived from 
a.,~-unsaturated carbonyl compounds. 
(v) Modification of the Baylis-Hillman dimers by incorporating functional 
groups which will enhance hydrogen-bonding interaction with critical enzyme 
binding pockets and also replace the need for structural water. 
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3. EXPERIMENTAL 
3.1 General Directions 
1H and 13C-NMR spectra were recorded on a Bruker Avance 400MHz spectrometer at 
303K, and were calibrated using the solvent signals; coupling constants are given in 
Hertz (Hz). Melting points were determined using a Kofler hot-stage apparatus, and are 
uncorrected. IR spectra were recorded on a Perkin Elmer Spectrum 2000 FT-IR 
spectrometer. Low-resolution mass spectra were obtained on a Finnegan-Mat GCQ mass 
spectrometer, and high-resolution mass spectra were recorded on a VG70-SEQ double-
focusing magnetic sector instrument (University of the Witwatersrand Mass 
Spectrometry Unit) and on a Micromass 70-70E spectrometer (Universiteit vir Hoer 
Christelike Onderwys in Potchefstroom Mass Spectrometry Unit). 
Flash chromatography was carried out using Merck silica gel 60 [230 - 400 mesh 
(particle size 0.040 - 0.063mm)] and preparative layer chromatography was conducted 
using silica gel 60 PF254. Chromatotron plates were prepared using silica gel 60 PF254 
containing CaS04. Thin layer chromatography (TLC) was carried out on pre-coated 
Merck silica gel F2s4 plates, visualization being achieved by inspection under UV light 
(254nm) or following exposure to iodine. 
Solvents were dried using the procedures prescribed by Perrin and Armarego.49 N,N-
Dimethylformamide (DMF) was pre-dried and distilled from 3A molecular sieves under 
reduced pressure. Ethanol and methanol were dried by reaction with Mg turnings and 
iodine and then distilled from the resulting magnesium alkoxide under nitrogen. THF 
and diethyl ether were pre-dried over CaH2 and then distilled from Na wire in the 
presence ofbenzophenone under nitrogen. 
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3.2 Preparation of chromone derivatives 
3.2.1 Synthesis of chromone-3-carbaldehydes 
0 
CHO 
8 
Chromone-3-carbaldehyde 83 127 
POCh (9.4 mL, O.IOmol) was added dropwise, during a period of 0.5h. , to a stirred 
solution of o-hydroxyacetophenone 84 (3.0 mL, 25 mrnol) in dry DMF (25 mL) under 
N2, while maintaining the temperature at - 23°C using a liquid N2-carbon tetrachloride 
bath. The resulting mixture was stirred overnight at room temperature and then poured 
into ice-water (50 mL). The resulting precipitate was filtered off, and washed 
successively with water and EtOH. Recrystallisation from acetone afforded chromone-3-
carbaldehyde 83 as a colourless crystalline solid (3 .09g, 71 %), m.p. 153-154°C (lit., 127 
152- 153°C); Vmax (KBr)/cm-1 1649 and 1690 (2x C=O); OH (400 MHz; CDCh) 7.49 
(lH, t, J=7.1 Hz, 6-H), 7.53 (lH, d, J= 8.8 Hz, 8-H), 7.74 (1H, t, J= 7.8 Hz, 7-H), 8.23 
(lH, d, J= 8.0 Hz, 5-H), 8.54 (lH, s, 2-H) and 10.38 (lH, s, CHO); oc (100MHz; 
CDCh) 118.6 (C-8), 120.4 (C-3), 125.3 (C-4a), 126.2 (C-5), 126.6 ( C-6), 134.8 (C-7), 
156.2 (C-8a), 160.6 (C-2), 176.0 (C=O) and 188.6 (CHO); mlz 174 (M+, 6%) and 146 
(100). 
6-Chlorochromone-3-carbaldehyde 184127 
The experimental procedure employed for the synthesis of chromone-3-carbaldehyde 83 
was followed, using POCh (18.7 mL, 200 mmol), 5-chloro-2-hydroxyacetophenone 180 
(8.53 g, 50.0 mmol) and dry DMF (50 mL). Work-up afforded 6-chlorochromone-3-
carbaldehydes 184 as a yellow crystalline solid (8.45 g, 81%), m.p. 165-167 °C (lit.,207 
166-168°C); Vmax (KBr)/cm-1 1655 and 1695 (2x C=O); OH (400 MHz; CDCh) 7.49 (lH, 
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d, 1=8.9 Hz, 8-H), 7.68 (1H, dd, 1=2.6 and 8.9 Hz, 7-H), 8.25 (1H, d, 1=2.5 Hz, 5-H), 
8.52 (1H, s, 2-H) and 10.36 (1H, s, CHO); oc (lOOMHz; CDCb) 120.3 (C-8), 125.6 (C-
5), 126.3 (C-4a), 132.8 (C-6 and C-3), 135.0 (C-7), 154.5 (C-8a), 160.6 (C-2), 174.8 
(C=O) and 188.1 (CHO); m/z 208 (M\ 4%) and 180 (100). 
6-Bromochromone-3-carbaldehyde 185 127 
The experimental procedure employed for the synthesis of chromone-3-carbaldehyde 83 
was followed, using POCl3 (8.4 mL, 90 mmol), 5-bromo-2-hydroxyacetophenone 181 
(5.0 g, 23 mmol) and DMF (25 mL). Work-up afforded 6-bromochromone-3-
carbaldehyde 185 as a yellow crystalline solid (4.92 g, 85%), m.p. 187-189 °C (lit., 127 
186-188°C); Vmax (KBr)/cm·1 1655 and 1699 (2x C=O); OH (400 MHz; CDCb) 7.42 (IH, 
d, 1=8.9 Hz, 8-H), 7.83 (lH, dd, 1=8.9 and 2.3 Hz, 7-H), 8.41 ( 1H, d, 1=2.4 Hz, 5-H), 
8.53 (lH, s, 2-H) and 10.35 (lH, s, CHO); oc (lOOMHz; CDCb) 120.3 (C-3), 120.4 (C-
6), 120.5 (C-8), 126.6 (C-4a), 128.8 (C-5), 137.8 (C-7), 155.0 (C-8a), 160.6 (C-2), 174.7 
(C=O) and 188.1 (CHO); CwHs03Br, m/z 252 (M\ 4%) and 226 (100). 
6-Fluorochromone-3-carbaldehyde 186 127 
The experimental procedure employed for the synthesis of chromone-3-carbaldehyde 83 
was followed, using POCl3 (4.2 mL, 45 mmol), 5-fluoro-2-hydroxyacetophenone 182 
(2.5 g, 16 mmol) and dry DMF (13 mL). Work-up afforded 6-fluorochromone-3-
carbaldehyde 186 as a yellow crystalline solid (2.5 g, 83%), m.p. 157-159 °C (lit.,198 
158°C); Vmax (KBr)/cm·1 1657 and 1701(2x C=O); oH (400 MHz; CDC13) 7.46 (lH, m, 8-
H), 7.55 (1H, dd, 1= 4.1 and 9.1 Hz, 7-H), 7.93 (1H, d, 1= 3.0 and 7.9 Hz, 5-H), 8.53 
(lH, s, 2-H) and 10.34 (lH, s, CHO); oc (100MHz; CDCb) 111.2 (1cF=24.0 Hz, C-5), 
119.7 (C-4a), 120.8 (1cF= 8.1 Hz, C-8), 123.0 (1cF = 25Hz, C-7), 126.8 (C-3 and C-6), 
152.4 (C-8a), 160.6 (C-2), 175.2 (C=O) and 188.2 (CHO); mlz 192 (M+, 4%) and 164 
(100). 
6-Methoxychromone-3-carbaldehyde 187 127 
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The experimental procedure employed for the synthesis of chromone-3-carbaldehyde 83 
was followed, using POCh (13.5 mL, 144 mmol), 2-hydroxy-6-methoxyacetophenone 
183 (6.0 g, 36 mmol) and dry DMF (25 mL). Work-up afforded 6-methoxychromone-3-
carbaldehyde 187 as a yellow crystalline solid (4.3 g, 59%), m.p. 164-165 °C (lit.,127 
164-166°C); Vmax (KBr)/cm·1 1657 and 1701 (2x C=O); OH (400 MHz; CDCh) 3.92 (3H, 
s, OCH3), 7.31 (IH, dd, J=9.2 and 3.1 Hz, 7-H), 7.46 (IH, d, J=9.1 Hz, 8-H), 7.64 (1H, 
d, J=3.1 Hz, 5-H), 8.51 (lH, s, 2-H) and 10.39 (lH, s, CHO); oc (IOOMHz; CDCh) 56.1 
(OCH3), 105.5 (C-5), 119.6 (C-3), 120.0 (C-8), 124.4 (C-7), 126.1 ( C-4a), 151.0 (C-6), 
158.0 (C-8a), 160.2 (C-2), 175.9 (C=O) and 188.7 (CHO); m/z 204 (M\ 1%) and 176 
(100). 
3.2.2 Synthesis of chromone-2-carbaldehydes 
0 OH 
R 
1-(2-Hydroxyphenyl)-1,3-butanedione 19286· 208 
Me 
A solution of o-hydroxyacetophenone 84 (1 0 mL, 83 mmol) in dry EtOAc (35 mL, 0.36 
mol) was added dropwise to a stirred suspension of NaOEt [generated in situ by adding 
Na metal lumps (8.0 g, 0.35 mol) to dry EtOH (40 mL)]. The resulting yellow mixture 
was boiled gently under reflux for ca 8h, until a thick yellow slurry was formed. After 
cooling, the mixture was poured into Et20 (200 mL) and allowed to stand for 1h. The 
resulting precipitate was filtered off, washed with EhO and dissolved in ice-cold water 
(100 mL). The resulting solution was acidified with acetic acid and the resulting 
precipitate was filtered off and recrystallized from petroleum ether (b.p. 60-80°C) to 
afford 1-(2-hydroxyphenyl)-1 ,3-butanedione 192 as a yellow solid (8.2g, 57%), which 
was used immediately without further purifications. 
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1-(5-Chloro-2-hydroxyphenyl)-1, 3-butanedione 19386· 208 
The experimental procedure employed in the synthesis of 1-(2-hydroxyphenyl)-1 ,3-
butanedione 192 was followed, using 5-chloro-2-hydroxyacetophenone 188 (3.0 g, 18 
mmol), dry EtOAc (7.0 mL, 70 mmol) and NaOEt [generated in situ by adding Na metal 
(1.6 g, 70 mmol) to dry EtOH (9.0 mL)] . Work-up afforded 1-(5-chloro-2-
hydroxychlorophenyl)-1,3-butanedione 182 as yellow solid (2.8g, 74%), which was used 
immediately without further purification. 
1-(5-Bromo-2-hydroxy-phenyl)-1, 3-butanedione 19486· 208 
The experimental procedure employed in the synthesis of 1-(2-hydroxyphenyl)-1 ,3-
butanedione 192 was followed, using 5-bromo-2-hydroxyacetopheone 189 (10.0 g, 47 
mmol), dry EtOAc (18.2 mL, 186 mmol) and NaOEt [generated in situ by adding Na 
metal (4.28 g, 186 mmol) to dry EtOH (45 mL)]. Work-up afforded 1-(5-bromo-2-
hydroxy-phenyl)-1,3-butanedione 194 as yellow solid (4.7g, 39%), which was used 
immediately without further purification. 
1-(5-Fluoro-2-hydroxyphenyl)-1, 3-butanedione 19586· 208 
The experimental procedure employed in the synthesis of 1-(2-hydroxyphenyl)-1,3-
butanedione 192 was followed, using 5-fluoro-2-hydroxyacetopheone 190 (3.0 g, 19.4 
mmol), dry EtOAc (7.6 mL, 78 mmol) and NaOEt [generated in situ by adding Na metal 
(1.79 g, 78 mmol) to dry EtOH (29 mL)]. Work-up afforded 1-(5-fluoro-2-
hyclroxyphenyl]-1 ,3-butanedione 195 as yellow solid (1.6 g, 47%), which was used 
immediately without further purification. 
1-(2-Hydroxy-5-methoxyphenyl)-1, 3-butanedione 18586• 208 
The experimental procedure employed in the synthesis of 1-(2-hydroxyphenyl)-1 ,3-
butanedione 192 was followed, using 2-hydroxy-5-methoxyacetopheone 191 (10 g, 60 
mmol), dry EtOAc (26 mL, 0.3 mol) and NaOEt [generated in situ by adding Na metal 
(5.80 g, 252 mmol) to dry EtOH (29 mL)]. Work-up afforded 1-(2-hydroxy-5-
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rnethoxyphenyl)-1,3-butanedione 196 as yellow solid (7.1 g, 73%), which was used 
immediately without further purification. 
0 
2-Methylchromone 9086' 208 
A stirred solution of 1-(2-hydroxyphenyl)-1 ,3-butanedione 192 (2.0 g, 11 mmol), glacial 
acetic acid (10 mL) and H2S04 (98%, 0.4 mL) was boiled gently under reflux for 4h. 
The resulting, hot, brick-red solution was poured into ice-cold water (50 rnL) and 
basified with 10% aq. NaHC03. The resulting precipitate was filtered, washed with ice-
cold water, and recrystallized from hexane to afford 2-rnethylchromone 90 as a yellow 
solid (1.2 g, 68%), m.p. 68-70°C (lit209 69-70°C), Vmax (KBr)/cm·1, 1654 (C=O); OH ( 400 
MHz; CDCl3) 2.36 (3H, s, CH3), 6.15 (1H, s, 3-H), 7.38 (IH, m, 8-H), 7.62 (1H, m, 7-
H), and 8.16 ( 1H, dd, 1=8.0 and 1.6 Hz, 5-H); oc(100 MHz; CDCb) 20.5 (CH3), 110.5 
(C-3), 117.7 (C-8), 123.5 (C-4a), 124.9 (C-6), 125.6 (C-5), 133.4 (C-7), 156.5 (C-8a), 
166.2 (C-2) and 178.2 (C=O); mlz 160 (M+, 100%). 
6-Chloro-2-methylchromone 197 
The experimental procedure employed in the synthesis of 2-methylchrornone 90 was 
followed, using 1-(5-chloro-2-hydroxyphenyl)-1 ,3-butanedione 193 (2.0 g, 9.4 mmol), 
glacial acetic acid (11 mL) and H2S04 (98%, 0.4 rnL). Work-up afforded 6-chloro-2-
methylchromone 197 as a yellow solid (1.6 g, 86%). m.p. 112-l14°C; Vmax (KBr)/crn·1, 
1674 (C=O), (Found: M+194.0139. Calc. for CwH7Cl02, M: 194.9904); OH (400 MHz; 
CDCh) 2.38 (3H, s, CH3), 6.16 (1H, s, 3-H), 7.36 (1H, d, 1=8.9 Hz, 8-H), 7.57 (1H, dd, 
1=8.9 and 2.6 Hz, 7-H), and 8.12 (1H, d, 1=2.6 Hz, 5-H); oc (100 MHz; CDCh) 20.9 
(CH3), 110.5 (C-3), 119.5 (C-5), 124.5 (C-7), 125.1 (C-6), 130.9 (C-8), 133.6 (C-4a), 
154.8 (C-8a), 166.5 (C-2) and 177.0 (C=O); mlz 194(~, 100%). 
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6-Bromo-2-methylchromone 19886• 208 
The experimental procedure employed in the synthesis of 2-methylchromone 90 was 
followed, using 1-(5-bromo-2-hydroxyphenyl)-1 ,3-butanedione 194 (3.0 g, 12 mmol), 
glacial acetic acid (13 mL) and H2S04 (98%, 0.4 mL). Work-up afforded 6-bromo-2-
methylchromone 198 as a yellow solid (1.9 g, 69%). m.p.l18-120°C; Vmax (KBr)/cm-1, 
1676 (C=O), (Found: M + 239.9607. Calc. for C10H7Br02, M: 239.8622); <h-1 (400 MHz; 
CDCh) 2.38 (3H,s, CH3), 6.17 (1H, s, 3-H), 7.31 (lH, d, J= 8.9 Hz, 8-H), 7.71 (1H, dd, 
J=8.9 and 2.5 Hz, 7-H), and 8.30 (1H, d, J=2.5 Hz, 5-H); De (100 MHz; CDCh) 20.6 
(CH3), 110.6 (C-3), 118.3 (C-5), 119.8 (C-7), 124.9 (C-6), 128.3 (C-8), 136.4 (C-4a), 
155.2 (C-8a), 166.5 (C-2) and 176.8 (C=O); mlz 239 (M+, 100%). 
6-Fluoro-2-methylchromone 19986· 208 
The experimental procedure employed in the synthesis of 2-methylchromone 90 was 
followed, using 1-(5-fluoro-2-hydroxyphenyl)-1 ,3-butanedione 195 (0.5 g, 2.6 mmol), 
glacial acetic acid (6.0 mL) and H2S04 (98%, 0.4 mL). Work-up afforded 6-fluoro-2-
methylchromone 199 as a yellow solid (0.4 g, 88 %), m.p. 102-103°C (lit210 101-102°C), 
V111ax (KBr)/cm-, 1685 (C=O); DH (400 MHz; CDCh) 2.37 (3H,s, CH3), 6.14 (1H, s, 3-H), 
7.35-7.42 (2H, m, 7-H and 8-H), 7.78 (1H, dd, J =8.4 and 3.3Hz, 5-H); De (100 MHz; 
CDCh) 20.5 (CH3), 109.9 (C-3), 110.6 (C-5), 119.8 (C-7), 119.9 (C-6), 121.4 (C-8), 
121.6 (C-4a), 160.6 (C-8a), 166.4 (C-2) and 177.3 (C=O); mlz 178 (M+, 100%). 
6-Methoxy-2-methylchromone 20086• 208 
The experimental procedure employed in the synthesis of 2-methylchromone 90 was 
followed, using 1-[2-hydroxy-5-methoxyphenyl]-1 ,3-butanedione 196 ( 4.0 g, 20 mmol), 
glacial acetic acid (21.5 mL) and H2S04 (98%, 0.9 mL). Work-up afforded 6-methoxy-
2-methylchromone 200 as a yellow solid (2.64 g, 69%). m.p. 107-108°C (lit211 107-
l080C), Vmax (KBr)/cm-, 1675 (C=O); DH (400 MHz; CDCh) 2.35 (3H, s, CH3), 3.86 (3H, 
s, OCH3), 6.14 (lH, s, 3-H), 7.20 (2H, m, 6-H and 8-H), 7.72 (1H, d, J= 9.1 Hz, 7-H) 
and 7.53 (IH, d, J=3.0 Hz, 5-H); De (100MHz; CDCl3) 20.5 (CH3), 55.9 (OCH3), 104.9 
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(C-5), 109.8 (C-3), 119.1 (C-7), 123.4 (C-8), 124.1 (C-4a), 151.3 (C-6), 156.8 (C-8a), 
165.9 (C-2), and 178.0 (C=O); m/z 190 (W, 100%). 
Chromone-2-carbaldeyde 91 130-131 
A stirred mixture of 2-methylchromone 90 (2.0 g, 11 rnmol), Se02 (6.1 g, 31 mmol) and 
xylene (50 mL) was boiled under reflux at for 12 h. The resulting mixture was filtered 
while hot to remove the black selenium, and the filtrate concentrated in vacuo. Flash 
chromatography of the residue on silica (elution with CHCh) afforded chromone-2-
carbaldeyde 91 as a brown solid (1.2 g, 65%). Repeating this reaction for 20 h afforded 
chromone-2-carbaldeyde 91 as a brown solid (1.3 g, 70%), m.p. 161-162°C (lit58160-
1630C), Vmax (KBr)/cm-1, 1664 and 1700 (2xC=O); 0H(400 MHz; CDCh) 6.18 (1H, s, 3-
H), 7.38 (IH, m, 6-H), 7.62 (1H, m, 8-H), 7.77 (1H, m, 7-H), 8.20 (1H, m, 5-H) and 9.79 
( 1H, s, CHO); oc(lOO MHz; CDCh) 117.0 (C-3), 118.8 (C-8), 124.9 (C-4a), 125.9 (C-
6), 126.2 (C-5), 135.2 (C-7), 155.6 (C-8a), 156.0 (C-2), 178.3 (C=O) and 185.5 (CHO); 
mlz 174 (W, 100%). 
6-Chlorochromone-2-carbaldeyde 201 
The experimental procedure employed in the synthesis of chromone-2-carbaldeyde 91 
was followed, using 6-chloro-2-methylchromone 197 (2.00 g, 10.3 mmol), Se02 (5.70 g, 
51.4 mmol) and xylene (25 mL). Work-up afforded 6-chlorochromone-2-carbaldehyde 
201 as a yellow solid (g, 46%). m.p. 162-164°C, Vmax (KBr)/cm-1, 1674 and 1717 
(2xC=O), (Found: M+:207.9911. Calc. for C10HsCI03, M: 208.9353); oH (400 MHz; 
CDCb) 6.90 (IH, s, 3-H), 7.57 (IH, d, J=9.0 Hz, 8-H), 7.71 (1H, dd, J=9.0 and 2.6 Hz, 
7-H), 8.17 (lH, d, J=2.6 Hz, 5-H) and 9.79 (1H, s, CHO); oc (1 00 MHz; CDCh) 116.6 
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(C-3), 120.5 (C-5), 125.3 (C-7), 125.7 (C-6), 132.3 (C-8), 135.4 (C-4a), 153.9 (C-8a), 
156.0 (C-2), 177.1 (C=O) and 185.0 (CHO); m/z 208 (M+, 100%). 
6-Bromochromone-2-carbaldeyde 202 
The experimental procedure employed in the synthesis of chromone-2-carbaldeyde 91 
was followed, using 6-bromo-2-methylchromone 198 (2.0 g, 8.4 mmol), Se02 (4.6 g, 42 
mmol) and xylene (30 mL). Work-up afforded 6-bromochromone-2-carbaldehyde 202 as 
a yellow solid (1.0 g, 47%). m.p.l70-172°C, Vmax(KBr)/cm-1, 1675 and 1717 (2xC=O); 
(Found: W: 254.9506. Calc. for C10HsBr03, M: 254.8571); OH (400 MHz; CDCh) 6.91 
(1H, s, 3-H), 7.50 (1H, d, J=8.9 Hz, 8-H), 7.84 (1H, dd, J=8.9 and 2.5 Hz, 7-H), 8.31 
(IH, d, J=2.4 Hz, 5-H) and 9.78 (lH, s, CHO); 8c (100 MHz; CDCh) 116.8 (C-3), 119.8 
(C-5), 120.7 (C-7), 126.0 (C-6), 128.6 (C-8), 138.2 (C-4a), 154.4 (C-8a), 156.0(C-2), 
176.9 (C=O) and 185.0 (CHO); mlz 254(W, 100%). 
6-Fluorochromone-2-carbaldeyde 203212 
The experimental procedure employed in the synthesis of chromone-2-carbaldeyde 91 
was followed, using 6-fluoro-2-methylchromone 199 (2.0 g, 11 mmol), Se02 (6.2 g, 56 
mmol) and xylene (30 rnL). Work-up afforded 6-fluorochromone-2-carbaldehyde 203 as 
a yellow solid (1.1 g, 52%). m.p. 155-157 °C (lit212 156-158°C), Vmax(KBr)/cm-1, 1675 
and 1719 (2xC=O); 8H (400 MHz; CDCh) 6.89 (1H, s, 3-H), 7.49 (1H, m, 7-H), 7.63 
(lH, m, 8-H), 7.84 (lH, m, 5-H) and 9.79 (lH, s, CHO); 8c (lOOMHz; CDCh) 110.8 (C-
3), 111 (C-5), 115.7 (C-7), 121.0 (C-6), 121.1 (C-8), 123.6 (C-4a), 156.1 (C-8a), 160.8 
(C-2), 177.5 (C=O) and 185.1 (CHO); mlz 192 (W, 100%). 
6-Methoxychromone-2-carbaldeyde 204212 
The experimental procedure employed in the synthesis of chromone-2-carbaldeyde 91 
was followed, using 6-methoxy-2-methylchromone 200 (2.0 g, 11 mmol), Se02 (5.8 g, 
53 mmol) and xylene (30 mL). Work-up afforded 6-methoxychromone-2-carbaldehyde 
204 as a yellow solid (1.37 g, 64%), m.p.174-176 °C (lit212 174-176 °C), Vmax (KBr)/cm·1, 
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1678 and 1719 (2xC=O); 0H(400 MHz; CDCh) 3.91 (3H, s, OCH3), 6.88 (1H, s, 3-H), 
7.34 (1H, m, 8-H), 7.53-7.56 (2H, m, 5-H and 7-H) and 9.80 (1H, s, CHO); Oc (100 
MHz; CDCb) 56.0 (OCH3), 104.9 (C-5), 115.8 (C-3), 120.2 (C-7), 124.5 (C-8), 125.7 
(C-4a), 152.0 (C-6), 156.0 (C-8a), 157.8 (C-2), 178.1 (C=O) and 185.5 (CHO); m/z 204 
(W, 100%) 
3.3 Baylis-Hillman reactions of cbromone-3-carbaldehydes 
3.3.1 Reactions of chromone-3-carbaldehydes with acrylonitrile 
3-(2-cyano-3-hydroxypropen-3 -yl)-4H-J-benzopyran-4-one 212 
Acrylonitrile (0.56mL, 8.6 mmol) was added to a stirred solution of chromone-3-
carbaldehyde 83 (l.Og, 5.8 mmol) and 3-hydroxyquinuclidine (3.7 g, 29 mmol) in CHCh 
(7.0 mL). The resulting mixture was stirred vigorously at room temperature for 25h. 
Evaporation of solvent in vacuo gave a brown oily residue which was purified by flash 
chromatography [on silica; elution with hexane-EtOAc (2:3)] to afford 3-(2-cyano3-
hydroxypropen-3-yl)-4H-1-benzopyran-4-one 212 as a yellow crystalline solid (0.24 g, 
98%). m.p. 68-70 °C, (lit.,212 68-70°C), (Found M +: 227.0570. Calc. for C13H9N03, M: 
227.0582), Vmax (K.Br)/cm"1 3430 (br, OH), 2225 (CN) and 1630 (C=O); OH (400 MHz; 
CDCh) 4.22 (lH, br s, 3'-0H), 5.29 (1H, s, 3'-H), 6.13 and 6.32 ( 2H, 2xs, 1'-CH2) , 
7.44 (1H, t, J=7.6 Hz, 6-H), 7.50 (IH, d, J= 8.5 Hz, 8-H), 7.72 (lH, t, J= 7.8 Hz, 7-H), 
8.05 (IH, s, 2-H) and 8.18 (lH, d, J= 8.0 Hz, 5-H); oc (lOOMHz; CDCh) 69.3 (C-3'), 
116.7 and 124.3 (C-2' and CN), 118.3 (C-8), 121,3 (C-3), 123,8 (C-4a), 125.5 (C-5), 
125.6 ( C-6), 131.0 (C-1 '), 134.4 (C-7), 153.8 (C-2), 156.4 (C-8a) and 177.6 (C=O); m/z 
227 (M+, 46%) and 210 (100). 
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Note: 
i) This reaction was repeated using DBU (2.2 mL, 15 rnrnol) as catalyst for 6 and 24 
hours. The reaction was then quenched, in each case, by diluting with diethyl ether (20 
mL), and the resulting mixture was washed with aq. HCl (2-M, 20 mL) and then 
withwater (20 mL) and dried over NaS04. Evaporation of the solvent in vacuo gave a 
brown oily residue which was purified by flash chromatography [on silica; elution with 
hexane-EtOAc (2:3)] to afford 3-(2-cyano-3-hydroxypropen-3-yl)-4H-1-benzopyran-4-
one 212 as a yellow crystalline solid (0.15 g, 60%) and (0.20 g, 80%), respectively. 
ii) The reaction was repeated for 24 hours using DABCO (0.27g, 2.4 rnrnol) as catalyst 
and an ionic liquid, 1-methyl-2-pyrollidine (1-NMP), ( 4 mL) as solvent. The reaction 
was quenched by dilution with water (15 mL) followed by extraction with EtOAc (3 x 
10 mL). Evaporation of the organic solvent in vacuo gave a brown oily residue which 
was purified by flash chromatography (on silica; elution with hexane-EtOAc (1:2)] to 
afford 3-(2-cyano-3-hydroxypropen-3-yl)-4H-1-benzopyran-4-one 212 as a yellow 
crystalline solid (0 .15 g, 60% ). 
6-Chloro-3-(2 -cyano-3 -hydroxypropen-3 -yl)-4H-1-benzopyran-4-one 213 
The experimental procedure employed for the synthesis of 3-(2-cyano-3-hydroxypropen-
3-yl)-4H-1-benzopyran-4-one 212 was followed, using 6-chlorochromone-3-
carbaldehyde 184 (0.50 g, 2.4 rnrnol), acrylonitrile (0.24 mL, 3.6 mmol), 3-
hydroxyquinuclidine (1.53 g, 12.0 mmol) and CHCh (7.0mL). Work-up afforded 6-
chloro-3-(2-cyano-3-hydroxypropen-3-yl)-4H-1-benzopyran-4-one 213 as a yellow 
crystalline solid (0.42g, 66%), m.p. 132-133°C (lit.,212 131-133°C); (Found W: 
261.01 96. Calc. for C13Hs03N35Cl, M: 261.0193); Vmax(KBr)lcm·1 3440 (br, OH), 2300 
(CN) and 1653 (C=O); 8H (400 MHz; CDCh) 4.04 (1H, br s, 3'-0H), 5.34 (lH, s, 3'-H), 
6.12 and 6.30 (2H, 2xs, l'-CH2), 7.45 (lH, dd, J=8.9 and 2.1 Hz, 7-H), 7.64 (lH, d, 
J=8.9 Hz, 8-H), 8.08 (1H, s, 2-H) and 8.12 (1H, d, J= 2.1 Hz, 5-H); 8c (100 MHz; 
CDCh) 69.5 (C-3'), 104.3 (C-5), 116.8 (C-3), 119.8 (C-8), 120.2 (C-4a), 124.2 and 
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124.3 (C-2' and CN), 124.7 (C-7), 131.0 (C-1 ' ), 151.2 (C-8a), 153.4 (C-2), 157.4 (C-6) 
and 177.6 (C=O); mlz 261 (M+, 52%) and 209 (100). 
Note: 
i) When DBU (0.91g, 6.2 mmol) was used as catalyst, work-up after 6 hours and 24 
hours afforded 6-chloro-3-(2-cyano-3-hydroxypropen-3-yl)-4H-1-benzopyran-4-one 213 
as a yellow crystalline solid (0.36 g, 56%) and (0.45 g, 71 %), respectively. 
ii) When DABCO ( 0.14 g, 1.2 mmol) and 1-NMP (2 mL) were used as catalyst and 
solvent, respectively, work-up afforded 6-chloro-3-(2-cyano-3-hydroxypropen-3-yl)-4H-
l -benzopyran-4-one 213 as a yellow crystalline solid (0.32g, 50%). 
6-Bromo-3-(2-cyano-3-hydroxypropen-3-yl)-4H-l-benzopyran-4-one 214 
The experimental procedure employed for the synthesis of 3-(2-cyano3-hydroxypropen-
3-yl)-4H-1-benzopyran-4-one 212 was followed, usmg 6-bromochromone-3-
carbaldehyde 185 (1.00 g, 3.95 mmol), acrylonitrile (0.39 mL, 5.9 mmol), 3-
hydroxyquinuclidine (2.5 g, 20 mmol) and CHCh (7.0 mL). Work-up afforded 6-bromo-
3-(2-cyano-3-hydroxypropen-3-yl)-4H-1-benzopyran-4-one 214 as an orange-yellow 
crystalline solid (0.88 g, 73%), m.p.l24-125 °C (lit.52, 122-125°C); (Found M +: 
304.9724. Calc. for C13Hs0 3N79Br, M: 304.9688), Vmax (KBr)/cm-1 3420 (br, OH), 2225 
(CN) and 1648 (C=O); 8H (400 MHz; CDCh) 4.18 (lH, br s, 3'-0H), 5.33 (1H, s, 3' -H), 
6.12 and 6.31 (2H, 2xs, 1 ' -CH2), 7.40 (IH, d, J=8.9 Hz, 8-H), 7.79 (lH, dd, J= 8.9 and 
2.40 Hz, 7-H), 8.09 (1H, s, 2-H) and 8.28 (1H, d, J= 2.4 Hz, 5-H); 8c (lOOMHz; CDCh) 
69.0 (C-3 ' ), 116.5 (CN), 119.3 (C-6), 120.3 (C-8), 121.6 (C-2'), 123.9 ( C-3), 124.9 (C-
4a), 128.2 (C-5), 131.5 (C-1 ' ), 137.5 (C-7), 154.0 (C-2), 155.1 (C-8a) and 176.1 (C=O); 
mlz 305 (M+, 44%) and 253 (100). 
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Note: 
i) When DBU (2.2 g, 15 mmol) was used as catalyst, work-up after 6 hours and 24 hours 
afforded 6-bromo-3-(2-cyano-3-hydroxypropen-3-yl)-4H-1-benzopyran-4-one 214 as a 
yellow crystalline solid (0.63 g, 52%) and (0.78 g, 63%), respectively. 
ii) When DABCO (0.14 g, 1.2 mmol) and 1-NMP (2 mL) were used as catalyst and 
solvent, respective! y, work-up afforded 6-bromo-3 -(2 -cyano-3 -hydroxypropen-3-yl)-4 H-
1-benzopyran-4-one 214 as a yellow crystalline solid (0.60 g, 50%). 
6-Fluoro-3-(2-cyano-3-hydroxy propen-3-yl)-4H-1-benzopyran-4-one 215 
The experimental procedure employed for the synthesis of 3-(2-cyano-3-hydroxy 
propen-3-yl)-4H-1-benzopyran-4-one 212 was followed, using 6-fluorochromone-3-
carbaldehyde 186 (0.50 g, 2.6 rnmol), acrylonitrile (0.26 mL, 3.9 mmol), 3-
hydroxyquinuclidine (1.6 g, 13 mmol) and CHCh (7.0 mL). Work-up afforded 6-fluoro-
3-(2-cyano-3-hydroxy propen-3-yl)-4H-l-benzopyran-4-one 215 as a yellow crystalline 
solid (0.38 g, 60%), m.p. 59-60 °C (lit., 212 58-60°C), (Found: M +, 245.0490, C13H80 3NF 
requires M, 245.0488), Vmax (KBr)/cm-1 3200 (br, OH), 2235 (CN) and 1640 (C=O); OH 
(400 MHz; CDCb) 4.08 (lH, br s, 3'-0H), 5.31 (lH, s, 3'-H), 6.15 and 6.33 (2H, 2xs, 
1 '-CH2), 7.45 (1H, m, 7-H), 7.53 (lH, m, 8-H), 7.81 (IH, dd, J =8.1 and 3.1 Hz, 5-H) and 
8.08 (1H, s, 2-H); oc (lOOMHz; CDCb) 69.1 (C-3 '), 110.3 (JcF = 23Hz, C-5), 116.6 and 
124.0 (C-2' or CN), 120.5 (JcF = 8.1 Hz, C-8), 120.7 (C-3), 122.9 (JcF = 25 Hz, C-7), 
124.9 (JcF = 7.6 Hz, C-4a), 131.4 (C-1 '), 152.5 (C-8a), 154.0 (C-2), 160.0 (C-6) and 
176.5 (C=O); mlz 245 (M+, 57%) and 193 (100). 
Note: 
i) When DBU (1.0 g, 6. 7 mmol) was used as catalyst, work-up after 6 hours and 24 
hours afforded 6-fluoro-3-(2-cyano-3-hydroxy propen-3-yl)-4H-1-benzopyran-4-one 215 
as a yellow crystalline solid (0.32 g, 50%) and (0.38 g, 60%), respectively. 
202 
Experimental 
ii) When DABCO ( 0.14 g, 1.2 mmol) and 1-NMP (2mL) were used as catalyst and 
solvent, respectively, work-up afforded 6-fluoro-3-(2-cyano-3-hydroxy propen-3-yl)-4H-
1-benzopyran-4-one 215 as a yellow crystalline solid (0.31 g, 48%). 
3 -(2-cyano-3-hydroxypropen-3-yl)-6-methoxy-4H-1-benzopyran-4-one 216 
The experimental procedure employed for the synthesis of 3-(2-cyano-3-hydroxy 
propen-3-yl)-4H-1-benzopyran-4-one 212 was followed, using 6-methoxychromone-3-
carbaldehyde 187 (1.0 g, 4.9 mmol), acrylonitrile (0.48 mL, 7.3 mmol), 3-
hydroxyquinuclidine (3.1 g, 25 mmol) and CHCh (10 mL). Work-up afforded 3-(2-
cyano-3-hydroxypropen-3-yl)-6-methoxy-4H-l-benzopyran-4-one 216 as a yellow 
crystalline solid (0.89 g, 71 %), m.p. 114-115 °C (lit., 212 114-117°C), (Found: M +: 
257.0686. Calc. for Ct4Hll04N, M: 257.0688), Vmax (KBr)/cm-1 3400 (br, OH), 2225 
(CN) and 1650 (C=O); 8H (400 MHz; CDCh) 3.89 (3H, s, OCH3), 4.41 (lH, br s, 3' -
0H), 5.28 (1H, s, 3'-H), 6.14 and 6.34 (2H, 2xs, 1'-CH2), 7.32 (1H, dd, J=9.2 and 3.1 
Hz, 7-H), 7.45 (lH, d, J= 9.2 Hz, 8-H), 7.52 (1H, d, J= 3.1 Hz, 5-H) and 8.08 (1H, s, 2-
H); 8c (100 MHz; CDCh) 55.9 (OCH3), 69.1 (C-3 '), 104.4 (C-5), 116.8 and 124.2 (C-2' 
orCN), 119.8 (C-8), 120.3 (C-3), 124.3 (C-7), 124.8 (C-4a), 131.0 (C-1 ' ), 151.3 (C-8a), 
154.0 (C-2), 160.0 (C-6) and 176.5 (C=O); mlz 257 (M+, 46%) and 205 (100). 
Note: 
i) When DBU (1.85 g, 12.6 mmol) was used as catalyst, work-up after 6 hours and 24 
hours the work-up afforded 3-(2-cyano-3-hydroxypropen-3-yl)-6-methoxy-4H-1-
benzopyran-4-one 216 as a yellow crystalline solid (0.69 g, 55%) and (0.97 g, 77%), 
respectively. 
ii) When DABCO (0.14 g, 1.2 mmol) and 1-NMP (2mL) were used as catalyst and 
solvent, respectively, the work-up afforded 3-(2-cyano-3-hydroxypropen-3-yl)-6-
methoxy-4H-1-benzopyran-4-one 216 as a yellow crystalline solid (0.56 g, 45%). 
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3.3.2 Reactions of chromone-3-carbaldehydes with methyl acrylate 
I ' 8' 
0 Sa' ~7' 
OMe 
8 
(i) 
3-[3-Hydroxy-2-(methoxycarbonyl)-l-propen-3-yl]-4H-l-benzopyran-4-one 217 and the 
corresponding dimer 222 
Methyl acrylate (0.56mL, 8.6 mmol) was added to a stirred solution of chromone-3-
carbaldehyde 83 (1.0 g, 5.8 mmol) and 3-hydroxyquinuclidine (3.7 g, 29 mmol) in 
CHCb (7.0 mL). The resulting mixture was stirred vigorously at room temperature for 
24h. Evaporation of the solvent in vacuo gave a brown oily residue, which was purified 
by flash chromatography [on silica; elution with hexane-EtOAc (1 :2)] afforded two 
fractions. 
i) 3-[3-Hydroxy-2-(methoxycarbonyl)-1-propen-3-yl]-4H-1-benzopyran-4-one 217 as a 
yellow solid (1.21 g, 80%), m.p. 109-110 °C (lit., 212 109-112 °C); (Found M+: 260.0690. 
Calc. for C14H120s, M: 260.0685); Vmax (K.Br)/cm-13423 (br, OH), 1723 and 1655 (2 x 
C=O); 8H (400 MHz; CDCI3) 3.74 (3H, s, OCH3), 4.57 (lH, br s, 3'-0H), 5.59 (lH, s, 
3'-H), 6.14 and 6.43 (2H, 2xs, 1' -CH2), 7.41 (1H, m, 6-H), 7.45 (1H, d, J=8.0 Hz, 8-H), 
7.68 (lH, m, 7-H), 8.02 (1H, s, 2-H) and 8.18 (1H, dd, J=8.0 and 1.4 Hz, 5-H); 8c (100 
MHz; CDCh) 52.0 (OCH3), 67.6 (C-3'), 118.3 (C-8), 123.0 (C-3), 124.0 (C-4a), 125.4 
(C-6), 125.6 (C-5), 126.8 (C-1'), 134.0 (C-7), 139.5 (C-2'), 154.3 (C-2), 156.3 (C-8a), 
166.5 (CO.O) and 177.9 (C=O); mlz 260 (M+, 7%) and 200 (1 00) 
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ii) The chromone dimer 222 as a pale yellow solid (0.73 g, 25%), m.p. 193-195 °C (lit., 52 
193-194°C), (Found: ~. 502.1250. Calc. for C2sH2209, M: 502.1257); Vmax (KBr)/cm-1 
1712, 1707, 1653 and 1631 (4 x C=O); 8H (400 MHz; CDCb) 3.12 and 3.37 (2H, 2x d, 
J=14.7 Hz, 13-CH2), 3.61 and 3.65 (6H, 2xs, 12-and 16-CHJ), 4.50 (2H, dd, J=1 7 and 
1.6 Hz, 2-CH2 ), 5.05 (1H, s, 9a-H), 6.90 (lH, t, J=7.8 Hz, 6-H), 6.97 (1H, d, J=8.4 Hz, 
5-H), 7.30 (lH, s, 4-H), 7.35 (1H, t, J=8.4 Hz, 7-H) 7.40 (2H, m, 7'-H and 8' -H), 7.50 
(IH, s, 17-H), 7.69 (1H, t, J=7.2 Hz, 6'-H), 7.72 (1H, dd, J=7.9 and 1.5 Hz, 8-H), 7.90 
(lH, s, 2'-H) and 8.16 (1H, d, J=7.2 Hz, 5'-H); 8c (lOOMHz; CDCh) 28.4 (C-13), 50.3 
(C-4a), 51.8 (C-12), 52.1 (C-1 6), 65.8 (C-2), 99.9 (C-9a), 117.7 (C-8), 117.9 (C-8'), 
119.9 (C-10a), 120.5 (C-4a'), 122.7 (C-6), I23.9 (C-3'), 125.5 (C-6'), 126.2 (C-5), 127.7 
(C-5 '), 129.1 (C-3), 130.8 (C-14), 133.1 (C-17), 133.8 (C-4), 136.0 (C-7), 136.1 (C-7'), 
154.9 (C-2'), 157.1 (C-8a), 155.8 (C-8a'), 163.8 (C-1 1), 167.3 (C-15), 174.9 (C-4') and 
191.4 (C-10); mlz 502 (~, 24%) and 243 (100) 
Note: 
i) The reaction was repeated using DBU (2. I 9 mL, I 5 mmol) as catalyst. After 24 hours, 
the reaction was quenched by diluting with diethyl ether (20 mL). The resulting solution 
was washed with aq. HCl (2-M, 20 mL), followed by water (20 mL) and then dried over 
NaS04. Evaporation of the solvent in vacuo gave a brown oily residue which was 
purified by flash chromatography [on silica; elution with hexane-EtOAc (2:3)] to afford 
3-[3-hydroxy-2-(methoxycarbonyl)-1-propen-3-yl]-4H-1-benzopyran-4-one 217 as a 
yellow solid (0.98 g, 65%). 
ii) The reaction was repeated using DABCO (0.27 g, 2.4 mmol) as catalyst and -NMP (4 
mL) as solvent. After 24h, the reaction was quenched by dilution with water (15 mL) 
and the resulting mixture was extracted with EtOAc (3 x 10 mL). Evaporation of the 
organic solvent in vacuo gave a brown oily residue, which was purified by flash 
chromatography [on silica gel and elution with hexane-EtOAc (1 :2)] to afford 3-[3-
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hydroxy-2-(methoxycarbonyl)-1-propen-3-yl]-4H-1-benzopyran-4-one 217 as a yellow 
crystalline solid (0.75 g, 50%). 
6-Chloro-3-{3-hydroxy-2-(methoxycarbonyl)-1-propen-3-yl]-4H-l-benzopyran-4-one 
218 and the corresponding dimer 223 
The experimental procedure employed for the synthesis of 3-[3-hydroxy-2-
(methoxycarbonyl)-1-propen-3-yl]-4H-1-benzopyran-4-one 217 and the corresponding 
dimer 222 was followed, using 6-chlorochromone-3-carbaldehyde 184 (1.0 g, 4.8 
mmol), methyl acrylate (0.48 mL, 7.2 mmol), 3-hydroxyquinuclidine (3.1 g, 24 mmol) 
and CHCh (7.0 mL). Work-up and flash chromatography afforded two fractions. 
i) 6-Chloro-3-[3-hydroxy-2-(methoxycarbonyl)-1-propen-3-yl]-4H-1-benzopyran-4-one 
218 as yellow solid (0.96 g, 68%), m.p. 108-110 °C (lit., 212 1 08-110°C), (Found MW: 
295 .0373. Calc. for c14Hu35Cl0s, M+l: 295.0373), Vmax (KBr)/cm-1 3423 (br, OH), 1718 
and 1650 (2 x C=O); oH (400 MHz; CDCh) 2.90 (1H, br s, 3'-0H), 3.74 (3H, s, OCH3), 
5.60 (1H, s, 3'-H), 6.14 and 6.44 (2H, 2xs, 1 ' -CH2), 7.42 (1H, d, J =8.9 Hz, 8-H), 7.61 
(1H, dd, J=8.9 and 2.5 Hz, 7-H), 8.04 (1H, s, 2-H) and 8.13 (1H, d, J=2.5 Hz, 5-H); Oc 
(100MHz; CDCh) 52.0 (OCH3), 67.4 (C-3 '), 120.0 (C-8), 123.2 (C-3), 124.8 (C-6), 
125.1 (C-4a), 125.6 (C-5), 127.0 (C-1 '), 131.4 (C-5), 134.2 (C-7), 154.5 (C-2), 154.6 (C-
8a), 166.5 (CO.O) and 176.6 (C=O); mlz 294 (~, 33%) and 234 (100). 
ii) The chromone dimer 223 as yellow solid (0.60 g, 22%), m.p. 210-212 °C (lit., 52 210-
2130C), (Found M+: 572.0636. Calc. for C2sH2oOl5Ch, M: 572.0641), Vmax (KBr)/cm-1, 
1715, 1710, 1650 and 1646 (4 x C=O); OH (400 MHz; CDCl3) 3.10 and 3.35 (2H, 2xd, 
J= 14.7 Hz, 13- CH2), 3.67 and 3.69 (6H, 2xs, 12 and 16-0CH3), 4.52 (2H, dd, J=17 and 
2.0 Hz, 2-CH2), 5.04 (1H, s, 9a-H), 6.93 (lH, d, J=8.9 Hz, 8-H), 7.27 (1H, m, 4-H), 7.29 
(1H, m, 7-H) 7.42 (lH, d, J=9 Hz, 8'-H), 7.48 (lH, s, 17-H), 7.61 (lH, m, 7'-H), 7.65 
( l H, d, J=2.4 Hz, 5-H), 8.00 (lH, s, 2'-H) and 8.10 (1H, d, J=2.5 Hz, 5' -H); oc 
(lOOMHz; CDCb) 28.4 (C-13), 50.3 (C-4a), 51.9 (C-1 2), 52.3 (C-16), 66.0 (C-2), 100.0 
(C-9a), 119.5 (C-8), 119.8 (C-8 '), 120.5 (C-4a), 120.8 (C-3'), 125.5 (C-5 '), 127.0 (C-5), 
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128.5 (C-10a), 129.4 (C-3), 131.2 (C-14), 131.7 (C-6'), 132.3 (C-17), 134.4 (C-7'), 
135.4 (C-7), 136.0 (C-4), 154.0 (C-8a), 155.1 (C-2' ), 155.5 (C-8a'), 163.8 (C-6), 167.8 
(C-11), 173.6 (C-15), 175.7 (C-4') and 190.3 (C-1 0); m/z 571 (M+, 38%) and 277 (100) 
Note: 
i) When DBU (1.8 g, 12 mmol) was used as the catalyst, work-up after 24 hours afforded 
6-chloro-3-[3-hydroxy-2-(methoxycarbonyl)-1-propen-3-yl]-4H- l -benzopyran-4-one 
218 as a yellow crystalline solid (0.89 g, 63%). 
ii) When DABCO (1.1 g, 9.6 mmol) was used as catalyst and 1-NMP (5 mL) as solvent, 
work-up after 24 hours afforded 6-chloro-3-[3-hydroxy-2-(methoxycarbonyl)-1-propen-
3-yl]-4H-1-benzopyran-4-one 218 as a yellow crystalline solid (0.66 g, 4 7% ). 
6-Bromo-3-[3-hydroxy-2 -(methoxycarbonyl)-1-propen-3 -yl) -4H -1-benzopyran-4-one 
219 and the corresponding dimer 224 
The experimental procedure employed for the synthesis of 3-[3-hydroxy-2-
(methoxycarbonyl)-1 -propen-3-yl]-4H-1-benzopyrao-4-one 217 and the corresponding 
dimer 222 was followed, using 6-bromochromone-3-carbaldehyde 185 (1. 1 g, 4.4 
mmol), methyl acrylate (0.44 mL, 6.6 mmol), 3-hydroxyquinuclidine (2.8 g, 22 mmol) 
and CHCb (7.0 mL). Work-up and flash chromatography afforded two fractions. 
i) 6-Bromo-3-[3-hydroxy-2-(methoxycarbonyl)-1-propen-3-yl]-4H-1-benzopyran-4-one 
219 as a yellow solid (1.1 g, 70%), m.p. 114-116 °C (lit., 212 114-116°C), (Found M+: 
337.9790. Calc. for Ct4Htr79Br0s, M: 337.9789), Vmax (KBr)/cm-1 3440 (br, OH), 1716 
and 1642 (2 x C=O); oH (400 MHz; CDCb) 3.75 (3H, s, OCH3), 4.38 (1H, d, J =8.0 Hz, 
3'-0H), 5.59 (IH, d, J=8.0 Hz, 3'-H), 6.11 and 6.42 (2H, 2 x s, 1 ' - CH2) , 7.37 (IH, d, 
J=8.9 Hz, 8-H), 7.75 (IH, dd, J= 9.0 and 2.5 Hz, 7-H), 8.02 (1H, s, 2-H) and 8.28 (1H, 
d, J=2.5 Hz, 5-H); 8c (100 MHz; CDCb) 52.0 (OCH3), 67.5 (C-3 '), 118.8 (C-8), 120.2 
(C-6), 123.3 (C-3), 125.2 (C-4a), 125.6 (C-5), 127.0 (C-1 ' ), 128.3 (C-5), 137.0 (C-7), 
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154.5 (C-2), 155.0 (C-8a), 166.5 (CO.O) and 176.5 (C=O); mlz 338 (W, 17%) and 280 
(100). 
ii) The corresponding dimer 224 (0.52 g, 18%), m.p. 223-225 °C (lit., 52 223-225 °C), 
(Found ~: 657.9471. Calc. for C2sH2o79Br20s, M: 657.9474), Vmax (KBr)/cm-11715, 
1705, 1650 and 1646 (4 x C=O); oH (400 MHz; CDCh) 3.11 and 3.33 (2H, 2x d, 1=14.7 
Hz, 13-CH2), 3.65 and 3.69 (3H, 2xs, 12 and 16-0CHJ), 4.51 (2H, dd, 1=17.0 and 2.0 
Hz, 2-CH2) , 5.02 (lH, s, 9a-H), 6.88 (1H, d, 1=8.8 Hz, 8-H), 7.27 (lH, m, 4-H), 7.35 
(1H, d, 1=8.9 Hz, 7'-H) 7.41 (IH, dd, 1=9.0 and 2.5 Hz, 7-H), 7.48 (1H, s, 17-H), 7.78 
(IH, dd, 1=9.0 and 2.5 Hz, 8'-H), 7.81 (1H, d, 1=2.5 Hz, 5-H), 7.88 (1H, s, 2' -H) and 
8.26 (1H, d, 1= 2.5 Hz, 5'-H); 8c (lOOMHz; CDCh) 28.4 (C-13), 50.3 (C-4a), 52.0 (C-
12), 52.3 (C-16), 66.0 (C-2), 100.0 (C-9a), 115.7 (C-8), 119.2 (C-4a'), 119.8 (C-8'), 
120.1 (C-10a), 120.6 (C-6), 121.3 (C-6 ' ), 125.0 (C-3 ' ), 128.8 (C-5'), 129.3 (C-3), 130.1 
(C-5), 131.2 (C-14), 132.8 (C-17), 135.4 (C-7'), 137.0 (C-7), 138.8 (C-4), 154.4 (C-2'), 
155.0 (C-8a'), 156.0 (C-8a), 163.8 (C-11), 167.1 (C-15), 173.5 (C-4' ) and 190.2 (C-10); 
mlz 658 (M+, 10%) and 323 (100). 
Note: 
i) When DBU (1.8 g, 12 mmol) was used as catalyst, work-up after 24 hours afforded 6-
bromo-3-[3-hydroxy-2-(methoxycarbonyl)-1-propen-3-yl]-4H-1-benzopyran-4-one 219 
as a yellow solid (0.86 g, 57%). 
ii) When DABCO (0.99 g, 8.8 mmol) was used as the catalyst and 1-NMP (5 mL) as 
solvent, work-up after 24 hours afforded 6-bromo-3-[3-hydroxy-2-(methoxycarbonyl)-
1-propen-3-yl]-4H-1-benzopyran-4-one 219 as a yellow solid (0.57 g, 38%). 
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6-Fluoro-3 -[3 -hydroxy-2-(methoxy carbonyl)-1-propen-3 -yl] -4H -1-benzopyran-4-one 
220 and the corresponding dimer 225 
The experimental procedure employed for the synthesis of 3-[3-hydroxy-2-
(methoxycarbonyl)-1-propen-3-yl]-4H-1-benzopyran-4-one 217 and the corresponding 
dimer 222 was followed, using 6-fluorochromone-3-carbaldehyde 186 (0.50 g, 2.6 
mmol), methyl acrylate (0.20 mL, 3.9 mmol), 3-hydroxyquinuclidine (1.7 g, 13 mmol) 
and CHCh (7.0 mL). Work-up and flash chromatography afforded two fractions. 
i) 6-Fluoro-3-[3-hydroxy-2-(methoxycarbonyl)-1-propen-3-yl]-4H-1-benzopyran-4-one 
220 as a yellow solid (0.46 g, 63%), m.p. 139-141 °C (lit., 212 140-142 °C), (Found M+: 
278.0596. Calc. for c14HliFOs, M: 278.0591); Vmax (KBr)/cm·1 3423 (br, OH), 1716 and 
1640 (2 x C=O); oH (400 MHz; CDCh) 3.75 (3H, s, OCH3), 4.43 (lH, d, 1=7.8 Hz, 3'-
0H), 5.60 (1H, d, 1=7.8 Hz, 3'-H), 6.12 and 6.46 (2H, 2xs, 1 ' - CH2), 7.40 (1H, m, 7-H), 
7.48 (1H, dd, J =9.1 and 4.2 Hz, 8-H), 7.81 (lH, dd, 1=8.3 and 3.0 Hz, 5-H) and 8.05 
(IH, s, 2-H); 8c (100 MHz; CDCb) 52.0 (OCH3), 67.6 (C-3'), 110.5 (C-5), 120.4 (C-8), 
122.3 (C-7), 122.5 (C-3), 125.8 (C-4a), 126.9 (C-1 ' ), 139.2 (C-2'), 152.5 (C-8a), 154.6 
(C-2), 159.6 (C-6), 166.5 (CO.O) and 177.1 (C=O); mlz 278 ~. 34%) and 193 (100). 
ii) The chromone dimer 225 as yellow solid (70 mg, 5%), m.p. 198-200 °C (lit., 212 198-
2000C), (Found: M+: 538.1074. Calc. for C2sH2oF20s, M: 538.1075), Vmax (KBr)/cm·1 
1727, 1713, 1650 and 1648 (4 x C=O); oH (400 MHz; CDCb) 3.10 and 3.35 (2H, 2xd, 
1=14.7 Hz, 13- CH2), 3.64 and 3.70 (3H, 2xs,12 and 16-0CH3), 4.51 (2H, dd, 1=17.0 
and 2.0 Hz, 2-CH2), 5.01 (IH, s, 9a-H), 6.97 (1H, dd, 1=9.0 and 4.0 Hz, 5-H), 7.05 (1H, 
m, 7-H), 7.24 (IH, s, 4-H), 7.33 (1H, dd, 1=8.3 and 2.8 Hz, 8-H), 7.38-7.48 (2H, m, 5'-
H and 7'-H), 7.50 (1H, s, 17-H), 7.78 (1H, dd, 1=8.3 and 2.8 Hz, 8' -H) and 7.90 (IH, s, 
2'-H); 8c (100 MHz; CDCb) 28.4 (C-13), 50.2 (C-4a), 51.9 (C-12), 52.2 (C-16), 65.9 
(C-2), 100.1 (C-9a), 111.0 (C-8'), 112.7 (C-8), 119.5 (C-5), 119.8 (C-3 '), 120.2 (C-5'), 
120.6 (C-10a), 122.3 (C-7'), 123.6 (C-7), 124.9 (C-4a' ), 129.4 (C-3), 131.1 (C-14), 
132.8 (C-17), 135.4 (C-4), 151.9 (C-8a'), 153.3 and 157.8 (C-8a and C-6' ), 155.1 (C-2'), 
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159.7 (C-6), 163.8 (C-11), 167.1 (C-15), 174.0 (C-14') and 190.6 (C-10); mlz 538 (M\ 
21 %) and 261 (100). 
Note: 
i) When DBU (0.99 g, 6.7 mmol) was used as the catalyst, work-up after 24 hours 
afforded 6-fluoro-3-[3-hydroxy-2-(methoxycarbonyl)-1 -propen-3-yl]-4H-1-benzopyran-
4-one 220 as a yellow solid (0.37 g, 50%). 
ii) When DABCO (0.585 g, 5.20 mmol) was used as the catalyst and 1-NMP (5 mL) as 
solvent, work-up after 24 hours afforded 6-fluoro-3-[3-hydroxy-2-(methoxycarbonyl)-1-
propen-3-yl]-4H-1-benzopyran-4-one 220 as a yellow solid (2.2 mg, 30%). 
3 -[3 -Hydroxy-2-(methoxycarbonyl)-1-propen-3 -y} -6-methoxy-4H -1-benzopyran-4-one 
221 and the corresponding dimer 226 
The experimental procedure employed for the synthesis of 3-[3-hydroxy-2-
(methoxycarbonyl)-1 -propen-3-yl]-4H-1 -benzopyran-4-one 217 and the corresponding 
dimer 222 was followed, using 6-methoxychromone-3-carbaldehyde 187 (1.0 g, 4.9 
mmol), methyl acrylate (0.49 mL, 7.3mmol), 3-hydroxyquinuclidine (3.1 g, 25 mmol) 
and CHCh (7.0 mL).Work-up and flash chromatography afforded two fractions. 
i) 3-[3-Hydroxy-2-(methoxycarbonyl)propen-3-y ]-6-methoxy-4H-1-benzopyran-4-one 
221 as yellow oil (1.1 g, 75%), (Found~: 290.0780. Calc for CisHI406, M: 290.0790); 
Vmax (KBr)/cm-1 3426 (br, OH), 1723 and 1643 (2 X C=O); OH (400 MHz; CDCh) 3.70 
(3H, s, CO.OCH3) , 3.81 (3H, s, 6-0CH3), 4.68 (1H, d, J=4.5 Hz, 3'-0H), 5.60 (1H, d, 
J=2.5 Hz, 3'-H), 6.1 0 and 6.39 (2H, 2 x s, 1 '-H), 7.18 (1H, dd, J=9.1 and 3.0 Hz, 7-H), 
7.30 (1H, d, J= 9.0 Hz, 8-H), 7.44 (1H, d, J= 3.0 Hz, 5-H) and 7.98 (lH, s, 2-H); 8c 
(lOOMHz; CDCh) 51.7 (CO.OCH3), 55.6 (6-0CH3), 67.1 (C-3 ' ), 104.3 (C-5), 119.4 (C-
8), 122.2 (C-3), 123.9 (C-7), 124.3 (C-4a), 126.3 (C-1'), 139.7 (C-2' ), 150.9 (C-8a), 
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154.0 (C-2), 156.8 (C-6), 166.3 (CO.O) and 177.4 (C=O); mfz 290 (M+, 26%) and 
151(100). 
ii) The corresponding dimer 226 (0.41 g, 15%) as a yellow viscous oil, (Found: M+, 
562.1467. Calc. for C3oH26011, M: 562.1475), Vmax (K.Br)/cm-1, and 1722, 1715, 1650 and 
1646 (4 x C=O); DH (400 MHz; CDCh) 3.10 and 3.35 (2H, 2xd, J =14.7 Hz, 13-CH2), 
3.60 (3H, s, 12-H), 3.70 (3H, s, 6-0CH3), 3.78 (3H, s, 16-H), 3.89 (3H, s, 6' -0CH3), 
4.39-4.53 (2H, dd, J=17 and 2.0 Hz, 2-CH2), 5.45 (1H, s, 9a-H), 6.70 (1H, s, 4-H), 6.73 
(1H, d, J=9.0 Hz, 9-H), 7.00 (lH, m, 7-H), 7. 10 (1H, d, J=3.0 Hz, 5-H), 7.26 (lH, dd, 
J=9.0 and 3.0 Hz, 7'-H), 7.38 (1H, d, J=9.1 Hz, 8'-H), 7.50 (1H, d, J=3.2 Hz, 5'-H), 
7.55 (1H, s, 17-H) and 7.91 (1H, s, 2'-H); 8c (100MHz; CDCh) 31.2 (C-13), 51.0 (C-
4a), 51.7 (C-12), 52.2 (C-16), 55.7 (6-0CH3), 55.9 (6' -0CH3), 62.9 (C-2), 99.2 (C-9a), 
105.3 (C-5'), 107.6 (C-5), 119.0 (C-l Oa), 119.2 (C-8), 119.4 (C-8'), 119.6 (C-3'), 123.9 
(C-7'), 124.5 (C-4a'), 125.6 (C-7), 129.9 (C-3), 130.6 (C-14), 133.3 (C-17), 135.0 (C-4), 
150.7 (C-8a'), 151.8 (C-8a), 154.3 (C-2'), 154.7 (C-6), 157.1 (C-6'), 163.9 (C-11), 167.8 
(C-15), 175.1 (C-4 ') and 192.4 (C-1 0); mlz 562 (~, 37%) and 289 (100). 
Note: 
i) When DBU (1.9 g, 13 mmol) was used as the catalyst, work-up after 24 hours afforded 
3-[3-hydroxy-2-( methoxycarbony I )-1-propen-3-y] -6-methoxy-4 H-1-benzopyran-4-one 
221 as a yellow solid (0.86 g, 61 %). 
ii) When DABCO ( 1.10 g, 9.78 mmol) was used as the catalyst and 1-NMP (5 mL) as 
the solvent, work-up after 24hours afforded 3-[3-hydroxy-2-(methoxycarbonyl)-1-
propen-3-y]-6-methoxy-4H-1 -benzopyran-4-one 221 as a yellow solid (0.62 g, 44%). 
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3.3.3 Reactions of chromone-3-carbaldehydes with methyl vinyl ketone 
I' 8' 
0 Sa' ~ 7' 
0 
8 
ii 
9-[11-acetyl-(15-oxo-butyl)-1 O-dihydro-3H-pyrano(9,2a)}chromen-3-one 231 and the 
corresponding dimer 241 
Methyl vinyl ketone (0.56mL, 8.6 mmol) was added to a stirred solution of chromone-3-
carbaldehyde 83 (1.0 g, 5.8 mmol) and 3-hydroxyquinuclidine (3.7 g, 29 mmol) in 
CHCh (7.0 mL). The resulting mixture was stirred vigorously at room temperature for 
24h. Evaporation of solvent in vacuo gave a brown oily residue which was purified by 
flash chromatography [on silica; elution with hexane-EtOAc (1 :2)] afforded two 
fractions. 
i) 9-[ll-Acetyl-(15-oxo-butyl)-1 O-dihydro-3H-pyrano(9,2a)}chromen-3-one 231 as a 
brown viscous oil (1.3 g, 69%), (Found W: 314.1131. Calc. for C1sH1s05, M: 314.1154) 
Vmax (KBr)/cm-11700, 1665 and 1650 (3 x C=O); 8H ( 400 MHz; CDCh) 1.98 and 2.25 
(2H, 2 x m, CH2CH2CO), 2.07 (3H, s, CH2CH2COCH3), 2.39 (3H, s, COCH3), 2.40 and 
2.60 (2H, 2xm, CH2CH2CO), 4.59 (lH, dd, J= 17.2 and 1.9 Hz, 10-Ha), 4.79 (lH, dd, J= 
17.2 and 1.5 Hz, 10-Hb), 5.13 (1H, s, 8a-H), 7.13 (2H, m, 5-H and 7-H), 7.30 (1H, br s, 
2-H), 7.57 (lH, t, 1=6.9 Hz, 6-H) and 7.90 (1H, d, 1=6.5 Hz, 4-H); 8c (100 MHz; CDCh) 
24.8 (CH2CH2CO), 25.5 (CH2CH2COCH3), 30.0 (COCH3), 37.8 (CH2CH2CO), 49.1 (C-
9), 65.9 (C-10), 99.9 (C-8a), 118.2 (C-7), 119.5 (C-2a), 123.0 (C-4), 127.9 (C-5), 135.4 
(C-6), 136.8 (C-2), 138.3 (C-3a), 157.6 (C-7a), 192.6 (3-C=O), 196.6 (15-C=O) and 
206.7 (11-C=O); mlz 314 (M+, 2%) and 193 (100). 
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ii) The chromone dimer 241 as a yellow solid (0.96 g, 35%), m.p. 193-195 °C (lit., 213 
193-194°C), (Found M+: 470.1364. Calc. for C2sH2207, M: 470.1366); Vmax (KBr)/cm-1, 
1698, 1669, 1642 and 1606 (4 x C=O); DH (400 MHz; CDCb) 2.29 and 2.42 (6H, 2xs, 
12- and 16-CH3) , 3.23 (2H, 2x d, J=14.7 Hz, 13-CH2), 4.52 (2H, dd, J=17 and 1.7 and 
Hz, 2-CH2 ), 5.00 (lH, s, 9a-H), 6.83-6.90 (2H, m, 6- and 5-H), 7.17 (1H, s, 4-H), 7.27 
(lH, m, 8-H), 7.40-7.47 (3H, m, 17-H, 7'-H and 8'-H), 7.69-7.75 (2H, m, 6' - and 7-H), 
7.90 (1H, s, 2'-H), and 8.13 (2H, dd, J=8.0 and 1.3 Hz, 5' -H); oc (100 MHz; CDCh) 
25.3 (C-12), 25.8 (C-16), 30.9 (C-13), 50.1 (C-4a), 65.9 (C-2), 99.9 (C-9a), 117.5 (C-5), 
118.1 (C-7'), 120.0 (C-10a), 120.3 (C-4a' ), 122.9 (C-6), 123.5 (C-8a' ), 125.8 (C-8'), 
126.1 (C-5' ), 128.0 (C-7), 133.6 (C-17), 134.2 (C-6' ), 136.1 (C-8), 136.6 (C-3), 136.7 
(C-4), 139.1 (C-14), 154.1 (C-2' ), 155.9 (C-3'), 157.0 (C-8a), 175.6 (C-4'), 191.5 (C-
10), 196.9 (C-11 ) and 199.0 (C-15); mlz 470 (~, 24%) and 185 (100). 
Note: 
i) When DABCO (0.38 g, 2.9mmol) was used as catalyst and 1-NMP (3mL) as solvent, 
work-up afforded 9-[11-acetyl-(15-oxo-butyl)-1 O-dihydro-3H-pyrano (9,2a)]chromen-3-
one 231 as a light brown viscous oil (0.82 g, 45%). 
9-[11-Acetyl-(15-oxo-butyl)-1 O-dihydro-3H-pyrano(9,2a)]-5-chloro-chromen-3-one 232 
and the corresponding dimer 242 
The experimental procedure employed for the synthesis of 9-[11-Acetyl-(15-oxo-butyl)-
1 O-dihydro-3H-pyrano(9,2a)]chromen-3-one 231 and the chromone dimer 241 was 
followed, using 6-chlorochromone-3-carbaldehyde 184 (1.0 g, 4.8 mmol), methyl vinyl 
ketone (0.48 mL, 7.2 mmol), 3-hydroxyquinuclidine (3 .1 g, 24 mmol) and CHCh (7.0 
mL). Work-up and flash chromatography afforded two fractions. 
i) 9-[11 acetyl-(1 5-oxo-butyl)-1 O-dihydro-3H-pyrano(9.2a)]-5-chloro-chromen-3-one 
232 as a reddish oil (1.3 g, 80%), (Found MW: 349.0843. Calc. for c18H1735Cl0s, M: 
349.0848); Vmax (KBr)/cm-1 1717, 1699 and 1674 (3 x C=O); OH (400 MHz; CDCh) 2.13 
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(3H, s, CH2CH2COCH3), 2.15-2.25 (2H, 2 x m, CH2CH2CO), 2.31 (3H, s, COCH3), 
2.46-2.59 (2H, 2xm, CH2CH2CO), 4.48 (1H, dd, 1=17.1 and 2.0 Hz, 10-Ha), 4.63 (1H, 
dd, 1=17.0 and 1.5 Hz, 10-Hb), 5.40 (1H, s, 8a-H), 6.65 (1H, br s, 2-H), 6.69 (IH, d, 
1=8.8 Hz, 7-H), 7.48 (1H, dd, 1=8.8 and 2.7 Hz, 6-H) and 7.80 (1H, d, 1=2.7 Hz, 4-H); 
oc (IOOMHz; CDCh) 25.2 (CH2CH2COCH3), 27.6 (CH2CH2COCH3), 30.0 (COCH3), 
37.6 (CH2CH2COCH3), 48.8 (C-9), 62.7 (C-10), 99.6 (C-8a), 118.8 (C-2a), 120.0 (C-7), 
126.6 (C-4), 135.4 (C-6), 136.9 (C-2), 139.4 (C-3a), 143.5 (C-5), 155.9 (C-7a), 192.0 (3-
C=O), 196.4 (15-C=O) and 205.3 (11-C=O); m/z 349 (MH+, 9%) and 154 (100). 
ii) The chromone dimer 242 as a yellow solid (0.80 g, 33%), m.p. 112-114°C, (Found 
M+:538.0587. Calc. for C2sH21Cl07, M: 538.0586); Vmax (KBr)/cm·1, 1653,1678, 1684 
and 1701 (4 x C=O); OH (400 MHz; CDCh) 2.31 and 2.44 (6H, 2xs, 12-and 16-CH3), 
3.00 (2H, 2xd, 1=14.7 Hz, B-CH2), 5.16 (2H, dd, 1=17 and 1.7 and Hz, 2-CH2 ), 5.39 
(IH, s, 9a-H), 6.93 (1H, s, 4-H), 7.12 (IH, d, 1=8.9 Hz, 8-H), 7.30 (1H, s, 17-H), 7.44 
(IH, d, 1=8.9 Hz, 8' -H), 7.45 (1H, d, 1=8.9 and 2.0 Hz, 7'-H), 7.76 (1H, dd, 1=8.0 and 
2.0 Hz, 7-H), 8.08 (1H, d, 1=2.0 Hz, 5-H), 8.66 (1H, s, 2'-H), and 8.18 (lH, d, 1=1.3 Hz, 
5' -H); oc(lOO MHz; CDCl3) 25.4 (C-12), 25.9 (C-16), 31.2 (C-13), 50.5 (C-4a), 66.l(C-
2), 100.2 (C-9a), 116.6 (C-5), 118.0 (C-7'), 121.6 (C-lOa), 122.2 (C-4a'), 124.4 (C-5'), 
128.4 (C-8'), 128.5 (C-7), 133.6 (C-17), 134.0 (C-6), 136.6 (C-3), 136.7 (C-8), 139.3 
(C-14), 141.4 (C-6' ), 143.7 (C-4), 148.6 (C-8a' ), 154.2 (C-2'), 156.2 (C-3'), 158.5 (C-
8a), 174.8 (C-4'), 190.8 (C-10), 196.9 (C-11) and 199.0 (C-15); mlz (~,%)and (100). 
Note: 
i) When DABCO (0.31 g, 2.4 mmol) was used as the catalyst and 1-NMP (3 mL) as 
solvent, work-up afforded 9-[11-acetyl-(1 5-oxo-butyl)-1 O-dihydro-3H-pyrano(9,2a)]-5-
chloro-chromen-3-one 232 as a light brown viscous oil (0.67 g, 40%). 
214 
Experimental 
9-[ 11-acetyl-(15-oxo-butyl)-1 O-dihydro-3H -pyrano (9, 2a) }-5 -bromo-chromen-3 -one 233 
and the corresponding dimer 243 
The experimental procedure employed for the synthesis of 9-[11-acetyl-(15-oxo-butyl)-
10-dihydro-3H-pyrano(9,2a)]chromen-3-one 231 and the corresponding dimer 241 was 
followed, using 6-bromochromone-3-carbaldehyde 177 (1.0 g, 4.0 mmol), methyl vinyl 
ketone (0.48 mL, 5.93 mmol), 3-hydroxyquinuclidine (2.51 g, 19.8 mmol) and CHCh 
(7.0 mL). Work-up and flash chromatography afforded two fractions. 
i) 9-[1 1 acetyl-(15-oxo-butyl)-1 O-dihydro-3H-pyrano(9.2a)}-5-bromo-chromen-3-one 
233 as a reddish oil (0.98 g, 63%), (Found: M+, 392.9466. Calc. for C1sH17Br05, M: 
391.9446), Vmax (KBr)/cm·1, 1600, 1674 and 1716 (3 x C=O); OH (400 MHz; CDCh) 
1.94-2.24 ( 2H, 2xm, CH2CH2CO), 2.08 (3H, s, CH2CH2COCH3), 2.26-2.58 (2H, m, 
CH2CH2CO), 2.39 ( 3H, s, COCH3), 4.58 (lH, dd, J=17.2 and 1.7 Hz, 1 0-Ha), 4.79 (lH, 
dd, J=17.2 and 1.5 Hz, 1 0-Hb), 5.1 1 (IH, s, 8a-H), 6.73 (lH, m, 2-H), 7.02 (1H, d, 
J=8.81 Hz, 7-H), 7.64 (1H, dd, J=8.8 and 2.5 Hz, 6-H) and 7.99 (1H, d, J=2.4 Hz, 4-H); 
oc (100 MHz; CDCb) 24.7 (C-13), 25.5 (C-16), 30.0 (C-12), 37.6 (C-14), 49.0 (C-9), 
65.9 (C-10), 100.0 (C-8a), 118.1 (C-2a), 120.2 (C-7), 130.3 (C-4), 134.8 (C-6), 139.4 
(C-2), 138.4 (C-3a), 143.5 (C-5), 156.5 (C-7a), 191.4 (3-C=O), 196.4 (15-C=O) and 
206.5 (11-C=O); m/z 392 (M+, 2%) and 194 (100). 
ii) The chromone dimer 243 as a yellow solid oil (0.62 g, 28%), (Found W:625.9579 
Calc. for C2sH21Br07, M: 625.9576); Vmax (KBr)/cm·1, 1600, 1670, 1675 and 1710 (4 x 
C=O); OH (400 MHz; CDCh) 2.31 and 2.44 (6H, 2 x s, 12-and 16-CHJ), 3.50 (2H, 2xd, 
J=14.7 Hz, 13-CH2), 5.17 (2H, dd, J= 17 and 1.7 and Hz, 2-CH2 ), 5.81 (1H, s, 9a-H), 
7.16 (1H, s, 4-H), 7.28 (IH, s, 17-H), 7.38 (1H, d, J=8.9 Hz, 8'-H), 7.61 (1H, d, J=8.9 
Hz, 8-H), 7.62 (1H, d, J=8.9 and 2.0 Hz, 7'-H), 7.79 (lH, s, 2'-H), 8.00 (lH, dd, J=8.0 
and 2.0 Hz, 7-H), 8.35 (lH, d, J=2.0 Hz, 5-H), and 8.32 (1H, d, J=1.3 Hz, 5'-H); 8c(100 
MHz; CDCh) 25.5 (C-12), 26.1 (C-16), 31.6 (C-13), 50.8 (C-4a), 66.8 (C-2), 100.4 (C-
9a), 118.8 (C-10a), 119.3 (C-4a'), 120.3 (C-5), 121.3 (C-7'), 123.2 (C-6), 128.9 (C-5'), 
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130.1 (C-8'), 131.1 (C-7), 133.7 (C-17), 133.8 (C-6'), 136.7 (C-3), 138.5 (C-8), 139.2 
(C-14), 143.7 (C-4), 149.2 (C-8a' ), 154.6 (C-2'), 156.2 (C-3 ' ), 157.9 (C-8a), 174.6 (C-
4 '), 190.6 (C-10), 196.6 (C-11) and 197.8 (C-15); rn/z 626 (M+, 16%) and 136 (100). 
Note: 
i) When DABCO (0.26 g, 2.0 mmol) was used as the catalyst and 1-NMP (3 mL) as 
solvent, work-up afforded 9-[11-acetyl-(15-oxo-butyl)-1 O-dihydro-3H-pyrano(9,2a)] -5-
bromo-chromen-3-one 233 as a light brown viscous oil (0.51 g, 33%). 
9-[11-acetyl-(15-oxo-butyl)-1 O-dihydro-3H-pyrano(9,2a)]-5-fluoro-chromen-3-one 234 
and the corresponding dimer 244 
The experimental procedure employed for the synthesis of 9-[11-Acetyl-(15-oxo-butyl)-
1 O-dihydro-3H-pyrano(9,2a)]chromen-3-one 231 and the corresponding dimer 241 was 
followed, using 6-fluorochromone-3-carbaldehyde 178 (1.0 g, 4.0 mmol), methyl vinyl 
ketone (0.48 mL, 5.9 mmol), 3-hydroxyquinuclidine (2.5 g, 20 mmol) and CHCh (7.0 
mL). Work-up and flash chromatography afforded two fractions. 
i) 9-[11 acetyl-(15-oxo-butyl)-1 O-dihydro-3H-pyrano(9.2a)]-5-jluoro-chromen-3-one 234 
as a light brown oil (0.79 g, 60%), (Found: M+W , 332.1051. Calc. for C18H17F0 5, 
M:332.1060), Vmax (K.Br)/cm-1, 1674, 1687 and 1699 (3 x C=O); OH (400 MHz; CDCIJ) 
1.97-2.23 ( 2H, 2xm, CH2CH2CO), 2.08 (3H, s, CH2CH2COCH3), 2.35-2.45 (2H, 2xm, 
CH2CH2CO), 2.39 (3H, s, COCH3), 4.57 (1H, dd, J= 17.2 and 1.9 Hz, 10-Ha), 4.79 (1H, 
dd, J=l7.2 and 1.7 Hz, 10-Hb), 5.11 (lH, s, 8a-H), 7.12 (1H, dd, J=9.1 and 4.2 Hz, 7-H), 
7.27 (lH, br s, 2-H), 7.30 (lH, m, 6-H) and 7.54 (1H, dd, J=8.0 and 3.1 Hz, 4-H); 8c 
(lOOMHz; CDCh) 24.7 (C1hCH2CO), 25.5 (CH2CH2COCH3), 30.0 (COCH3), 37.6 
(CH2CH2CO), 49.0 (C-9), 65.9 (C-10), 100.1 (C-8a), 113.0 (JcF=24.0 Hz, C-7), 119.93 
(JcF=7.6 Hz, C-4), 124.4 (JcF=24.6 Hz, C-6), 126.2 (C-2a), 134.9 (C-2), 138.4 (C-3a), 
147.7 (C-5), 153.8 (C-7a), 191.9 (3-C=O), 196.5 (15-C=O) and 206.5 (11-C=O); mlz 
392 (M+, 2%) and 154 (100). 
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ii) The chromone dimer 243 as a yellow solid oil (0.45 g, 23%), (Found M+: 507.1251. 
Calc. for C2sH21F07, M: 507.1255); Vmax (KBr)/cm-1, 1674, 1683, 1699 and 1717 (4 x 
C=O); 8H (400 MHz; CDCh) 2.32 and 2.45 (6H, 2 x s, 12-and 16-CH3), 3.52 (2H, 2xd, 
J=14.7 Hz, 13-CH2), 5.18 (2H, dd, J=17 and 1.7 and Hz, 2-CH2 ), 5.85 (1H, s, 9a-H), 
7.17 (1H, s, 4-H), 7.26 (lH, d, J=8.9 and 2.0 Hz, 7'-H), 7.30 (1H, s, 17-H), 7.48 (lH, d, 
J=8.9 Hz, 8' -H), 7.72 (lH, d, J=8.9 Hz, 8-H), 7.64 (lH, dd, J=8.0 and 2.0 Hz, 7-H), 7.93 
(lH, s, 2' -H), 7.94 (1H, d, J=2.0 Hz, 5-H), and 7.96 (lH, d, J=l.3 Hz, 5'-H); 8c (100 
MHz; CDCh) 25.6 (C-12), 25.9 (C-16), 31.6 (C-13), 52.5 (C-4a), 66.9 (C-2), 100.3 (C-
9a), 119.6 (C-5), 119.9 (C-5'), 120.3 (C-7'), 121.0 (C-4a'), 121.9 (C-10a), 129.2 (C-8'), 
130.5 (C-7), 133.8 (C-17), 136.7 (C-3), 138.4 (C-8), 139.1 (C-14), 143.7 (C-4), 144.7 
(C-8a'), 154.6 (C-2'), 156.6 (C-3'), 157.2 (C-8a), 163.5 (C-6), 164.3 (C-6'), and 174.7, 
190.5, 196.6, 197.8 (4 x C=O); m/z 507 (M\ 30%) and (100). 
Note: 
i) When DABCO (0.26 g, 2.0mmol) was used as catalyst and 1-NMP (3mL) as solvent, 
work-up afforded 9-[11-acetyl-(15-oxo-butyl)-1 O-dihydro-3H-pyrano(9,2a)]-5-bromo-
chromen-3-one 234 as a light brown viscous oil (0.40 g, 30%). 
9-[11-acetyl-(15-oxo-butyl)-1 O-dihydro-3H-pyrano(9, 2a) ]-5-methoxy-chromen-3-one 
235 and the corresponding dimer 245 
The experimental procedure employed for the synthesis of 9-[11-Acetyl-(15-oxo-butyl)-
1 O-dihydro-3H-pyrano(9,2a)]chromen-3-one 231 and the corresponding dimer 241 was 
followed, using 6-bromochromone-3-carbaldehyde 187 (1.0 g, 4.9 mmol), methyl vinyl 
ketone (0.60 mL, 7.4 mmol), 3-hydroxyquinuclidine (3.1 g, 25 mmol) and CHCh (7.0 
mL).Work-up and flash chromatography afforded. 
i) 9-[11 acetyl-(15-oxo-butyl)-1 O-dihydro-3H-pyrano(9.2a)}-5-methoxy-chromen-3-one 
235 as a reddish oil (1.23 g, 73%), (Found: W , 344.1252. Calc. for C19H2o06, M: 
344.1259), Vmax (K.Br)/cm-1, 1652, 1665 and 1674 (3 x C=O); OH (400 MHz; CDCh) 
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2.09-2.23 ( 2H, 2xm, CH2CH2CO), 2.15 (3H, s, CH2CH2COCH3), 2.39-2.51 (2H, 2xrn, 
CH2CH2CO), 2.44 ( 3H, s, COCH3), 3.91 (3H, s, 6-0CH3), 4.55 (1H, dd, 10-Ha and Hb), 
4.94 (1H, s, 8a-H), 6.69 (1H, br s, 2-H), 7.08 (1H, d, 1=9.11 Hz, 7-H), 7.33 (1H, dd, 
1=2.32 and 9.11 Hz, 6-H) and 7.85 (1H, d, 1=2.32 Hz, 4-H); 8c (100MHz; CDCh) 24.7 
(C-13), 25.5 (C-16), 30.0 (C-12), 37.6 (C-14), 50.1 (C-9), 55.9 (OCH3), 65.9 (C-10), 
99.8 (C-8a), 118.5 (C-2a), 119.4 (C-7), 124.1 (C-4), 133.9 (C-6), 137.3 (C-2), 139.0 (C-
3a), 143.5 (C-5), 154.8 (C-7a), 191.4 (3-C=O), 197.1 (15-C=O) and 199.2 (11-C=O); 
m/z 344 (M+, 33%) and 193 (1 00). 
ii) The chromone dimer 245 as a yellow solid oil (0.52 g, 20%), m.p. °C, (Found W: 
530.1578. Calc. for C3oH2609, M:530.1576); Vmax (KBr)/cm-1, 1653, 1674, 1677 and 
1700 (4 x C=O); oH (400 MHz; CDCl3) 2.28 and 2.33 (6H, 2x s, 12-and 16-CH3), 3.14 
(2H, 2xd, 1=14.7 Hz, 13-CH2), 3.68 and 3.80 (6H, 2xs, 6-and 6' -0CH3), 5.09 (2H, dd, 
1=17 and 1.7 and Hz, 2-CH2 ), 5.25 (1H, s, 9a-H), 6.95 (1H, s, 4-H), 6.98 (lH, d, 1=8.9 
Hz, 8-H), 7.27 (lH, s, 17-H), 7.44 (IH, d, 1=8.9 and 2.0 Hz, 7'-H), 7.64 (lH, d, 1=8.9 
Hz, 8' -H), 7.73 (1H, dd, 1=8.0 and 2.0 Hz, 7-H), and 8.16 (1H, d, 1=1.3 Hz, 5'-H), 8.33 
(1H, d, 1=2.0 Hz, 5-H), and 8.70 (1H, s, 2'-H); 8c (100 MHz; CDCh) 25.3 (C-12), 25.9 
(C-16), 31.4 (C-13), 50.3 (C-4a), 55.7(6-0CH3), 55.8(6' -0CH3), 66.4(C-2), 100.5 (C-
9a), 114.5 (C-5), 116.1 (C-7), 116.3 (C-7'), 120.7 (C-5'), 121.3 (C-4a'), 123.9 (C-10a), 
128.7 (C-8'), 133.6 (C-17), 136.3 (C-8), 136.6 (C-3), 139.4 (C-14), 143.8 (C-4), 143.9 
(C-8a'), 154.4 (C-2'), 158.5 (C-8a), 159.4 (C-6), 161.4 (C-6'), 156.2 (C-3 '), and 174.9, 
190.9, 196.8, 199.3 (C=O); m/z 530 (~, 15%) and 43 (100). 
Note: 
i) When DABCO (0.32 g, 2.5 mmol) was used as the catalyst and 1-NMP (3 mL) as 
solvent, work-up afforded 9-[11-acetyl-(15-oxo-butyl)-1 O-dihydro-3H-pyrano(9,2a)]-5-
methoxy-chromen-3-one 235 as a light brown viscous oil (0.6 g, 37%). 
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3.4 Baylis-Hillman reactions of chromone-2-carbaldehydes 
3.4.1 Reactions of chromone-2-carbaldehydes with methyl vinyl ketone 
3" 
1' 
OH 0 
5-Acetyl-6-(4H-I-benzopyran-4-on-2-yl)-6-hydroxy-3-(methylene)hexane-2-one 247 and 
the MVK dimer 246 
Methyl vinyl ketone (0.36 mL, 4.3 mmol) was added to a stirred solution of chromone-2-
carbaldehyde 91 (0.50 g, 2.9 mmol) and 3-hydroxyquinuclidine (1.8 g, 14 mmol) in 
CHCh (7.0 mL). The resulting mixture was stirred vigorously at room temperature for 
24h. Evaporation of solvent in vacuo gave a brown oily residue which was purified by 
flash chromatography [on silica; elution with hexane-EtOAc (1:2)] to afford MVK dimer 
246 as yellow oil (0.24 g, 40%) and as brown oil5-acetyl-6-(4H-l-benzopyran-4-on-2-
yl)-6-hydroxy-3-(methylene)hexane-2-one 247 in a mixture of the 2:3 anti-and syn-
diastereomers as (0.63 g, 70%). 
0 0 
7 
I' 
3 -(Methylene )heptane-2, 6-dione 246 
Vmax(KBr)/cm-1 ,1736 and 1694 (2 X C=O); OH (400 MHz; CDCh) 2.09 ( 3H, s, 7-CHJ), 
2.30 ( 3H, s, 1-CH3), 2.49 ( 2H, m, 4-H), 2.57 (2H, m, 5-H), 5.81 and 6.00 (2H, 2xs, 1 '-
CH2); 8c (lOOMHz; CDCh) 25.2 (C-4), 25.8 (C-7), 29.8 (C-1), 42.4 (C-5), 126.2 (C-1 '), 
147.6 (C-3), and 199.4 , 207.8 (2 x C=O). 
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5-Acetyl-6-( 4H -1-benzopyran-4-on-2 -yl)-6-hydroxy-3-(methylene) hexane-2 -one (syn-
247a): 
(Calc. for C1sH1sOs, M: 314.1154); Vmax(KBr)/cm-1, (br, OH), and (3 x C=O); OH (400 
MHz; CDCb) 2.18 (3H, s, 1-CH3), 2.37 ( 3H, s, 5'-COCHJ), 2.46-2.60 ( 2H, m, 4 '-H), 
3.38 (1H, m, 5' -H), 3.37 ( 1H, br s, 6'-0H), 4.56 (1H, d, 6' -H), 5.79 and 5.99 (2H, 2xs, 
3"-CH2=C), 6.48 (1H, s, 3-H), 7.34-7.42 (2H, m, 6-H and 8-H), 7.64 (1H, t, J=7.8 Hz, 
7-H) and 8.15 (1H, m, 5-H); 8c (100MHz; CDCh) 25.6 (1 ' -COCH3), 27.8 (C-4'), 30.1 
(5'- COCH3), 52.2 (C-5'), 69.3 (C-6'), 109.4 (C-3), 117.7 (C-8), 123.9(C-4a), 125.3 (C-
5), 125.9 (C-6 ), 129.2 (C-3"), 133.8 (C-7), 144.8 (C-3 '), 155.7 (C-2), 167.2(C-8a), 
177.9, 199.5 and 211.4 (3xC=O); mlz 314 (M+, 25%) and 149(100). 
5 -Acetyl-6-( 4H-1-benzopyran-4-on-2 -yl)-6-hydroxy-3-(methylene) hexane-2 -one (anti-
247b): 
Vmax (KBr)/cm-1, (br, OH), and (3 x C=O); OH ( 400 MHz; CDCb) 2.08 (3H, s, 1 '-
COCH3), 2.31 (3H, s, 5'-COCH3), 2.61-2.78 (2H, m, 4'-H), 3.44 (1H, m, 5'-H), 4.05 ( 
1H, br s, 6'-0H), 4.92 (1H, m, 6'-H), 5.82 and 6.14(1H, 2xs, 3"-H), 6.57 (lH, s, 3-H), 
7.34-7.42 (2H, m, 6-H and 8-H), 7.64 (1H, t, J=7.8 Hz, 7-H) and 8.17 (1H, m, 5-H); 8c 
(100 MHz; CDCb) 25.8 (1 '-COCfh), 30.3 (C-4'), 31.3 (5 ' -COCH3), 52.3 (C-5'), 
71.2(C-6'), 109.5 (C-3), 117.8 (C-8), 125.4(C-4a), 125.4 (C-5), 125.9 (C-6 ), 129.5 (C-
3"), 133.9 (C-7), 145.1 (C-3'), 155.9 (C-2), 168.0 (C-8a), 180.0, 199.6 and 212.1 
(3xC=O); mlz and (1 00). 
Note: 
i) When reaction was repeated using CH2Ch as solvent, workup afforded 5-acetyl-6-(4H-
1-benzopyran-4-on-2-yl)-6-hydroxy-3-(methylene)hexane-2-one 247 in a mixture of the 
2:3 syn-and anti-diastereomers (0.56 g, 65%) and the MVK dimer 246 (0.21 g, 35%). 
ii) When DABCO (1.6 g, 14 mmol) was used as the catalyst and CHCb (7 mL) as the 
solvent, work-up afforded 5-acetyl-6-(4H-J-benzopyran-4-on-2-yl)-6-hydroxy-3-
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(methylene)hexane-2-one 247 in a mixture of the 2:3 syn and anti diastereomers as 
yellow thick oil (0.47 g, 55%) and the MVK dimer 246 (0.22 g, 37%). 
iii) However, when DABCO (1.6 g, 14 mmol) was used as the catalyst and CH2Ch (7 
mL) was used as solvent the work-up afforded 5-acetyl-6-(4H-1-benzopyran-4-on-2-yl)-
6-hydroxy-3-(methylene)hexane-2-one 247 as a mixture of the 2:3 syn-and anti-
diastereomers (0.39 g, 45%) and the MVK dimer 246 (0.14 g, 23%). 
5-Acetyl-6-(6-bromo-4H-l-benzopyran-4-on-2-yl)-6-hydroxy-3-(methylene)hexane-2-
one 248 and the MVK dimer 246 
The experimental procedure employed for the synthesis of 5-acetyl-6-(4H-l-
benzopyran-4-on-2-yl)-6-hydroxy-3-(methylene)hexane-2-one 247 and the MVK dimer 
246 was followed, using 6-bromochromone-2-carbaldehyde 202 (1.0 g, 4.0 mmol), 
methyl vinyl ketone (0.48 mL, 5.92 mmol), 3-hydroxyquinuclidine (2.5 g, 20 mmol) and 
CHCh (7.0 mL).Work-up and flash chromatography afforded MVK dimer 246 as a pale 
yellow oil (0.31 g, 37%) and 5-acetyl-6-(6-bromo-4H-l-benzopyran-4-on-2-yl)-6-
hydroxy-3-(methylene)hexane-2-one 248 in a mixture of the 2 :3 syn-and anti-
diastereomers as brown oil (0.98 g, 63%). 
5-acetyl-6-(6-bromo-4H-l-benzopyran-4-on-2-yl)-6-hydroxy-3-(methylene)hexane-2-one 
(syn 248a): 
(Calc. for C1sH17Br05 requires, M: 329.0259); Vmax(KBr)/cm-1, (br, OH), and (3 x C=O); 
8H (400 MHz; CDCh) 2.27 ( 3H, s, 1 '-COCH3), 2.31 ( 3H, s, 9'-COCH3), 2.53-2.77 ( 
2H, m, 4'-H), 3.40 (1H, m, 5' -H), 3.89 ( 1H, br s, 6'-0H), 4.54 (1H, br d, J=3.6 Hz, 6'-
H), 5.79 and 6.02 (2H, 2xs, 3"-CH2=C), 6.50 (1H, s, 3-H), 7.29 (1H, d, J=7.5 Hz, 8-H), 
7.73 (lH, dd, J =8.9 and 2.2 Hz, 7-H) and 8.29 (1H, d, J=2.48 Hz, 5-H); 8c (100MHz; 
CDCh) 25.7 (1 '-COCH3), 27.9 (C-4'), 30.4 (5' -COCH3), 52.0 (C-5'), 69.2 (C-6'), 109.4 
221 
Experimental 
(C-3), 119.6 (C-8), 128.6 (C-5), 129.4 (C-4a), 130.0 ( C-3')141.7 (C-3"), 143.9 (C-7), 
150.1 (C-6), 153.6 (C-8a), 155.7 (C-2), 169.5 ,179.8 and 194.0 (3xC=O); 
5-acetyl-6-(6-bromo-4H-l-benzopyran-4-on-2-yl)-6-hydroxy-3-(methylene)hexane-2-one 
(anti 248b): 
Vmax (KBr)/cm-1, (br, OH), and (3 x C=O); OH ( 400 MHz; CDCl3) 2.05 (3H, s, 1 '-
COCH3), 2.31 (3H, s, 9' -COCHJ), 2.53-2.77 (2H, m, 4'-H), 3.46 (lH, m, 5'-H), 4.15 
(1H, br s, 6' -OH), 4.90 (1H, br d, 1=2.51 Hz, 6' -H), 5.86 and 6.17 (2H, 2xs, 3 " -CH2=C), 
6.59 (1H, s, 3-H), 7.31(1H, d, 1=7.47 Hz, 8-H), 7.74 (1H, dd, 1=2.20 and 8.94 Hz, 7-H) 
and 8.30 (1H, d, 1=2.46 Hz, 5-H); oc (lOOMHz; CDCh) 25.8 (1 '-COCH3), 30.2 (C-4'), 
31.3 (5'-COCHJ), 52.1 (C-5'), 71.0 (C-6'), 109.5 (C -3), 119.8 (C-8), 128.6 (C-5), 129.7 
(C-4a), 130.8 (C-3 ' ), 146.4 (C-7), 147.9 (C-3"), 150.1 (C-6), 153.7 (C-8a), 155.9 (C-2), 
170.4,179.8 and203.1 (3xC=O); 
Note: 
i) This reaction was repeated using CH2Cb as solvent, work-up afforded 5-acetyl-6-(6-
bromo-4H-1-benzopyran-4-on-2-yl)-6-hydroxy-3-(methylene)hexane-2-one 248, in a 
mixture of the 2:3 syn-and anti-diastereomers as a brown oil (0.78 g, 50%) and the MVK 
dimer 246 as (0.23 g, 28%). 
ii) When DABCO (2.2 g, 20 mmol) was used as the catalyst and CHCh (7 mL) as 
solvent, work-up afforded 5-acetyl-6-(6-bromo-4H-1-benzopyran-4-on-2-yl)-6-hydroxy-
3-(methylene)hexane-2-one 248, in a mixture of the 2:3 syn and anti diastereomers as 
brown oil (0.73 g, 47%) and the MVK dimer 246 (0.16 g,19%). 
iii) When DABCO (2.2 g, 20 mmol) was used as the catalyst and CH2Cb (7 mL) as 
solvent, work-up afforded 5-acetyl-6-(6-bromo-4H-l-benzopyran-4-on-2-yl)-6-hydroxy-
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3-(methylene)hexane-2-one 248, in a mixture of the 2:3 syn and anti diastereomers as 
brown oil (0.55 g, 35%) and the MVK dimer 246 (0.14 g, 17%). 
5-Acetyl-6-(6-methoxy-4H-l-benzopyran-4-on-2-yl)-6-hydroxy-3-(methylene)hexane-2-
one 249 and the MVK dimer 246 
The experimental procedure employed for the synthesis of 5-acetyl-6-(4H-1-
benzopyran-4-on-2-yl)-6-hydroxy-3-(methylene)hexane-2-one 247 and the MVK dimer 
246 was followed, using 6-methoxychromone-2-carbaldehyde 204 (1.0 g, 4.9 mmol), 
methyl vinyl ketone (0.60 mL, 7.35mmol), 3-hydroxyquinuclidine (3.1 g, 25 mmol) and 
CHCh (7.0 mL). Work-up and flash chromatography afforded MVK dimer 246 as pale 
yellow oil (0.24 g, 23%) and the 5-acetyl-6-(6-methoxy-4H-l-benzopyran-4-on-2-yl)-6-
hydroxy-3-(methylene)hexane-2-one 249 in a mixture of the 2:3 syn-and anti-
diastereomers as brown oil (0.92 g, 55%). 
5-Acetyl-6-(6-methoxy-4H-l-benzopyran-4-on-2-yl)-6-hydroxy-3-(methylene)hexane-2-
one (syn 249a): 
(Found: ~ 344.1247. Calc. for cl9H2o06 'M: 344.1259); Vmax (K.Br)/cm'1' (br, OH), and 
(3 x C=O); 8H ( 400 MHz; CDCh) 2.20 ( 3H, s, 1 ' -COCH3), 2.31 ( 3H, s, 9' -COCH3), 
2.60-2.75 ( 2H, m, 4'-H), 3.46 (1H, m, 5'-H), 3.78 (3H, s, 6-0CH3), 4.83 ( 1H, br s, 6'-
0H), 4.94 (lH, br s, 6'-H), 5.76 and 6.04 (2H,2 x s, 3"-CH2=C), 6.50 (1H, s, 3-H), 7.13 
(2H, d, J= 8.9 Hz, 8-H), 7.32 (1H, dd, J=8.9 and 3.1 Hz, 7-H) and 7.54 ( IH, d, J= 3.1 
Hz, 5-H); 8c (lOOMHz; CDCb) 25.3 (1 '-COCH3), 26.2 (C-4'), 28.0 (S'-COCH3), 46.1 
(C-5'), 62.2 (6-0CI-h), 69.2 (C-6'), 104.6 (C-3), 113.7 (C-8), 120.2 (C-5), 123.3 (C-4a), 
124.8 (C-6), 129.7 ( C-3'), 134.0 (C-3"), 147.7 (C-7), 149.7 (C-2), 152.0 (C-8a), 178.3, 
180.8 and 193.3 (3xC=O); m/z 344 (M+, 25%) and 248 (100). 
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5-Ace tyl-6-(6-methoxy-4H -1-benzopyran-4-on-2 -yl)-6-hydroxy-3-(methylene) hexane-2-
one (anti 249b): 
Vmax(KBr)/cm-1 (br, OH), and (3 x C=O); OH (400 MHz; CDCh) 2.02 (3H, s, 1 ' -COCH3), 
2.31 (3H, s, 9' -COCH3) , 2.53-2.77 (2H, s, 4'-H), 3.51 (1H, m, 5' -H), 3.89 (3H, s, 6-
0CH3), 4.90 ( lH, br s, 6'-0H), 4.99 (lH, br s, 6' -H), 5.86 and 6.21 (2H, 2xs, 3" 
CH2=C), 6.59 (1H, s, 3-H), 7.13 (2H, d, J=8.9 Hz, 8-H), 7.32 (1H, dd, J=8.9 and 3.1 Hz, 
7-H) and 7.54 (1H, d, J=3.1 Hz, 5-H); oc (lOOMHz; CDCh) 25.8 (1 ' -COCH3), 29.9 (5'-
COCHJ), 40.8 (C-4'), 56.0 (C-5'), 62.5 (6-0CH3)?l.O (C-6'), 104.6 (C-3), 113.8 (C-8), 
120.2 (C-5), 123.3 (C-4a), 125.0 (C-6), 129.7 (C-3 ' ), 141.8 (C-3'), 147.7 (C-7), 150.8 
(C-2), 157.50 (C-8a), 178.3, 181.8 and 201.0 (3xC=O);. 
Note: 
i) when this reaction was repeated using CH2Cb as solvent, workup afforded 5-acetyl-6-
( 4H-1-benzopyran-4-on-2-yl)-6-hydroxy-6-methoxy-3-(methylene )hexane-2-one 249, in 
a mixture of the 2:3 syn-and anti-diastereomers as a brown oil (0.95 g, 57%) and the 
MVK dimer 246 as (0.29 g, 28%). 
ii) When DABCO (2.8 g, 25 mmol) was used as the catalyst and CHCh (7 mL) as the 
solvent, work-up afforded 5-acetyl-6-(6-methoxy-4H-1-benzopyran-4-on-2-yl)-6-
hydroxy-3-(methylene)hexane-2-one 249 in a mixture of the 2 :3 syn-and anti-
diastereomers as brown oil (0.67 g, 40%) and MVK dimer 246 (0.16 g, 15%). 
iii) When DABCO (2.8 g, 25 mmol) was used as the catalyst and CH2Ch (7 mL) as 
solvent, work-up afforded 5-acetyl-6-(6-methoxy-4H-l-benzopyran-4-on-2-yl)-6-
hydroxy-3-(methylene)hexane-2-one 249 (0.50 g, 30%) in a 2:3 mixture of syn-and anti-
diastereomers as brown oil and the MVK dimer 246 (0.16 g, 15%). 
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3.4.2 Reactions of chromone-2-carbaldehydes with methyl acrylate 
0 
8 
I ' OMe 
3' 
Methyl-2 -(6-methoxy-4H -1-benzopyran-4-one-2-yl)-2-methylpropanoate 250 
Methyl acrylate (0.19 mL, 2.2 mmol) was added to a stirred solution of 6-
methoxychromone-2-carbaldehyde 204 (0.3 g, 1.5 mmol), and 3-hydroxyquinuclidine 
(0.88 g, 7.3 mmol) in CHCh (4.0 mL). The resulting mixture was stirred vigorously at 
room temperature for 24h. Evaporation of solvent in vacuo gave a brown oily residue 
which was purified by flash chromatography [on silica; elution with hexane-EtOAc 
(1 :2)] to afford Methyl-2-(6-methoxy-4H-1-benzopyran-4-one-2-yl)-2-methylpropanoate 
250 as white solid (0.17 g, 45 %). Vmax(KBr)lcm"1, 1684 and 1653 (2 x C=O); OH (400 
MHz; CDCh) 1.56 (3H, d, J=7.1 Hz, 3' -CHJ), 3.75 (3H, s, 6-0CH3), 3.93 (3H, s, 1 '-
OCH3), 4.31 (IH, q, J=7.1 Hz, 2 ' -H), 7.04 (IH, s, 3-H), 7.37 (IH, dd, 1=9.2 and 3.1 
Hz, 7-H), 7.47 (1H, d, J=9.2 Hz, 8-H) and 7.58 (lH, d, 1=3.1 Hz, 5-H); oc (IOOMHz; 
CDCh) 12.6 (C-3'), 48.0 (C-2'), 56.0 (6-0CH3), 64.0 (CO.OCH3), 104.9 (C-3), 111.1 
(C-8), 119.8 (C-5), 125.2 (C-4a), 125.4 (C-7), 150.1 (C-2), 155.6 (C-6), 157.8 (C-8a), 
178.3 (4-C=O), 190.4 (1 ' -C=O), m/z259 (W,10 %) and 69 (100). 
Note: 
(i) When this reaction was repeated using CH2Ch as solvent, work-up afforded methyl-2-
(6-methoxy-4H-1-benzopyran-4-one-2-yl)-2-methylpropanoate 250 as a brown oil (0.06 
g, 12%). 
225 
Experimental 
3.4.3 Reactions of chromone-2-carbaldehydes with acrylonitrile 
0 
255 
4-Ethyl-2 -hydroxy-5, 2 -dihydro-4-oxa-3 -aza-cyclo buta[b} naphthalene-6-one 255 
Acrylonitrile (0.37 mL, 4.3 mmol) was added to a stirred solution of chromone-2-
carbaldehyde 91 (0.5 g, 2.9 mmol), and 3-hydroxyquinuclidine (1.7 g, 14 mmol) in 
CHCh (7.0 mL). The resulting mixture was stirred vigorously at room temperature for 
24h. Evaporation of solvent in vacuo gave a brown oily residue which was purified by 
flash chromatography [on silica; elution with hexane-EtOAc (1 :2)] to afford 4-ethyl-2-
hydroxy-5,2-dihydro-4-oxa-3-aza-cyclobuta[b}naphthalene-6-one 255 as a white oil 
(0.38 g, 47 %). (Found: M+ 218.1632. Calc. for C12H1102N, M: 218.1630); Vmax 
(KBr)/cm-1, 1465 (C=N); 1658 (C=O); 3397 (OH); oH (400 MHz; CDCh) 1.42 ( 3H, t, 
J =7.1 Hz, 2'-CH3), 4.45 ( 2H, q, J= 7.1, 1 '-H), 7.10 (lH, s, 5-H), 7.36 (1H, br peak, 2-
0H), 7.43 (1H, t, J=7.5 Hz, 8-H), 7.60 ( 1H, d, J =8.6 Hz, 10-H), 7.73 ( lH, t, J=6.7 Hz, 
9-H), 8.80 (lH, d, J=7.9 Hz, 7-H); oc (IOOMHz; CDCb) 14.1 (C-2 '), 63.0 (C-1 ' ), 114.8 
(C-5), 118.8 (C-10), 124.4 (C-6a), 125.7 (C-8), 125.9 (C-7), 134.7 (C-9), 152.2 (C-
1 Oa), 156.0 (C-2), 160.5 (C-4), 178.4 (C=O), m/z 218 (M+,42 %) and 89(1 00). 
Note: 
(i) When this reaction was repeated using CH2Ch (7 mL) as solvent, work-up afforded 
4-ethyl-2-hydroxy-5, 2-dihydro-4-oxa-3 -aza-cyclobuta[b }naphthalene-6-one 255 as 
white oil (0.18 g, 22 %). 
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8-Bromo-4-ethyl-2 -hydroxy-5, 2 -dihydro-4-oxa-3 -aza-cycl obuta[b} naphthalene-6-one 
256 
The experimental procedure employed for the synthesis of 4-ethyl-2-hydroxy-5,2-
dihydro-4-oxa-3-aza-cyclobuta[b}naphthalene-6-one 255 was followed, using 6-
bromochromone-2-carbaldehyde 202 (0.5 g, 1.98 mmol), acrylonitrile (0.25 mL, 2.97 
mmol), 3-hydroxyquinuclidine (1.26 g, 9.90 mmol) and CHCh (7.0 mL).Work-up and 
flash chromatography afforded 8-bromo-4-ethyl-2-hydroxy-5,2-hydro-4-oxa-3-aza-
cyclobuta[b]naphthalene-6-one 256 as brown oil (0.22 g, 40%). (Found: M+ + H20, 
297.9679, C12H10Br02N requires, M, 280.1173); Vmax (KBr)/cm-1, 1558 (C=N); 1653 
(C=O); 3430 (OH); OH (400 MHz; CDCb) 1.43 ( 3H, t, J=7.1 Hz, 2' -CH3), 4.46 ( 2H, q, 
J=7. 1, 1 ' -H), 7.11 (1H, s, 5-H), 7.49 (1H, br peak, 2-0H), 7.51 (lH, d, J =8.9 Hz, 10-H), 
7.81 (1H, dd, J=8.9 and 2.5 Hz, 9-H), 8.32 (lH, d, J=2.4 Hz, 7-H); oc (lOOMHz; CDCh) 
14.1 (C-2'), 63 .2 (C-1 '), 114.8 (C-5), 119.5 (C-6a), 120.7 (C-10), 128.4 (C-7), 129.4 (C-
8), 137.7 (C-9), 152.4 (C-lOa), 154.7 (C-2), 163.9 (C-4), 177.0 (C=O), m/z 29 (M+, 
84%) and 298 (100). 
Note: 
(i) This reaction was repeated using CH2Ch (7.0 mL) as solvent and the workup 
afforded 8-bromo 4-ethyl-2 -hydroxy-5, 2-hydro-4-oxa-3-aza-cyclobuta[b] naphthalene-6-
one 256 as brown solid (0.08 g, 15%). 
4-Ethyl-2 -hydroxy-8 -me thoxy-5, 2 -dihydro-4-oxa-3 -aza-cycl obuta[b] naphthalene-6-one 
257 
The experimental procedure employed for the synthesis of 4-ethyl-2-hydroxy-5,2-
dihydro-4-oxa-3-aza-cyclobuta[b}naphthalene-6-one 255 was followed, using 6-
methoxychromone-2-carbaldehyde 204 (0.5 g, 2.5 mmol), acrylonitrile (0.31 rnL, 
3.68mmol), 3-hydroxyquinuclidine (1.6 g, 12 mmol) and CHCh (7.0 mL). Work-up and 
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flash chromatography afforded 4 -e thy!-2 -hydroxy-8 -me thoxy-5, 2 -dihydro-4-oxa-3 -aza-
cyclobuta[b}naphthalene-6-one 257 as a brown oil (0.31 g, 55%). (Calc. for C13H 130 3N, 
M: 231.2478); Vmax (K.Br)/cm-I, 1465 (C=N); 1653 (C=O); 3435 (OH); bH (400 MHz; 
CDCh) 1.42 (3H, t, 1= 7.1 Hz, 2' -CHJ), 3.89 ( 3H, s, 8-0CH3), 4.45 (2H, q, 1=7.1 , 1 ' -
H), 7.09 (1H, s, 5-H), 7.27 (1H, d, 1=3.2 Hz, 7-H), 7.32 (1H, dd, 1=9.2 and 3.0 Hz, 9-H), 
7.49 (lH, br peak, 2-0H), 8.02 (lH, d, 1=8.02 Hz, 10-H); 8c (lOOMHz; CDCh) 17.0 (C-
2'), 56.0 (8-0Cfi]), 64.4 (C-1'), 110.0 (C-5), 119.2 (C-6a), 120.7 (C-10) 128.9 (C-7), 
130.5 (C-8), 132.4 (C-9), 158.6 (C-10a), 159.1 (C-2), 162.1 (C-4), 178.5 (C=O). 
Note: 
(i) When this reaction was repeated using CH2Ch (7.0 mL) as solvent and the workup 
afforded 4-ethyl-2 hydroxy-8me thoxy-5, 2 -dihydro-4-oxa-3 -aza-cyclob ita[b} naphthalene-
6-one 257 as brown oil (0.14 g, 25%). 
3.5 aza-Michael reaction of Baylis-Hillman products with 
amine derivatives 
3.5.1 Reactions of Baylis-Hillman products with S-benzylcysteamine 
hydrochloride 
6 CN ~II' 10' ~ 12' 
, I 4'~S 2 ~ 13' 
N 7' H 6' s· 14' 
7 
l-(4H-l-Benzopyran-4-on-3-yl)-2-cyano-8-phenyl-4-aza-7-thiaoctanol 258 
3-(2-cyano-3-hydroxy-1-propen-3-yl)-4H-1-benzopyran-4-one 212 (100 mg, 0.44 mmol) 
was added to a stirred solution of (S)-benzylcystearnine hydrochloride (179 mg, 
0.88mmol) and sodium acetate (73 mg, 0.88 mmol) in EtOH (4 ml). The resulting 
mixture was stirred at room temperature for 6 weeks. Evaporation of the solvent in 
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vacuo gave a brown oily residue which was purified by flash chromatography [on silica; 
elution with hexane:EtOAc (3:2)] to afford l-(4H-l-benzopyran-4-on-3-yl)-2-cyano-8-
phenyl-4-aza-7-thiaoctanol258 as brown solid (89 mg, 51%), m.p. 90-92 °C, (Found: 
Mir: 395.1425. Calc. for c 22H220 3N2S M: 394.1351); Vmax (KBr)/cm-1 3300-3394 (OH 
and NH), 2360 (CN) and 1652 (C=O); DH (400 MHz; CDCh) 2.64 (2H, t, J=6.9 Hz, 6' -
CH2), 3.15 (lH, m, 2' -H), 3.21 (2H, m, S' -CH2), 3.24 (1H, dd, J =12.9 and 3.7 Hz, 3 ' -
CH2) 3.53 (1H, br s, NH), 3.57 (lH, dd, J =12.9 and 3.7 Hz, 3 ' -CH2), 3.73 (2H, s, 8'-
CH2), 4.98 (lH, d, J =2.71 Hz, 1 '-H), 6.86 (IH, t, J=7.53 Hz, 6-H), 7.01 (1H, d, J=8.29 
Hz, 8-H), 7.19 (lH, s, 2-H), 7.21-7.27 (5H, m, Ar-H), 7.41 (1H, t, 7.8 Hz, 7-H), 7.50 
(1H, d, J=7.8 Hz, 5-H), and 10.93 (lH, br s, OH); De (100MHz; CDCh) 30.1 (C-6'), 30.2 
(C-2'), 36.7 (C-8 '), 43 .2 (C-3'), 55.9 (C-5'), 61.1 (C-1 '), 107.4 (CN), 117.6 (C-3), 120.1 
(C-4a), 118.1 (C-8), 118.5 (C-6), 128.7 (C- 11' and C-13 '), 128.8 (C-12'), 128.9 (C-10' 
and C-14'), 130.8 ( C-5), 133.9 (C-7), 138.0 (C-9'), 151.1 (C-2), 160.6 (C-8a) and 195.3 
(C=O) ; m/z 395 (W, 17%) and 154 (100%). 
Note: 
(i) When the reaction was run for 6 weeks using 3-(2-cyano-3-hydroxy-1-propen-3-yl)-
4H-1-benzopyran-4-one 212 (100 mg, 0.44 nunol), (S)-benzylcysteamine (148 mg, 0.88 
mmol) as free amine, and sodium acetate (73 mg, 0.88 mmol) in EtOH (4 ml), work-up 
and purification afforded l-(4H-l-benzopyran-4-on-3-yl)-2-cyano-8-phenyl-4-aza-7-
thiaoctano/258 as a brown solid (0.079 g, 45 %). 
(ii) When the reaction was run for 6 weeks using 3-(2-cyano-3-hydroxy-1-propen-3-yl)-
4H-1-benzopyran-4-one 201 (100 mg, 0.44 mmol), (S)-benzylcysteamine (179 mg, 0.88 
mmol) as free amine, TBAB (284 mg, 0.88 mmol ) as the catalyst and sodium acetate 
(73 mg, 0.88 mmol) in EtOH (4 ml), work-up and purification afforded J-(4H-l-
benzopyran-4-on-3-yl)-2-cyano-8-phenyl-4-aza-7-thiaoctanol 258 as a brown solid 
(0.089 g, 51%). 
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(iii) When the reaction was run for 6 weeks using using 3-(2-cyano-3-hydroxy-1-propen-
3-yl)-4H-1-benzopyran-4-one 212 (100 mg, 0.44 mmol), (S)-benzylcysteamine (179 mg, 
0.88 mmol) as free amine, and BmimBF4 (2.0 mL) as the catalyst in EtOH (4 ml), work-
up and purification afforded 1-(4H-1-benzopyran-4-on-3-yl)-2-cyano-8-phenyl-4-aza-7-
thiaoctanol258 as a brown solid (0.12 g, 68%). 
1-(6-chloro-4H-1-benzopyran-4-on-3-yl)-2-cyano-8-phenyl-4-aza-7-thiaoctanol259 
The experimental procedure employed for the synthesis of l-(4H-1-benzopyran-4-on-3-
yl)-2-cyano-8-phenyl-4-aza-7-thiaoctanol258 was followed, using 6-chloro-3-(2-cyano-
3-hydroxy-1-propen-3-yl)-4H-l-benzopyran-4-one 213 (100 mg, 0.382 mmol), 
(S)-benzylcysteamine hydrochloride (128 mg, 0.76 mmol), and sodium acetate (63 mg, 
0.76 mmol) in EtOH (4ml). The resulting mixture was stirred for 6 weeks and work-up 
afforded 1-(6-chloro-4H-1-benzopyran-4-on-3-yl)-2-cyano-8-phenyl-4-aza-7-thiaoctanol 
259 as yellow viscous oil (75 mg, 46 %), m.p. 117-119°C, (Found MH+: 429.1040. Calc 
for c22H2103N2SC1, M: 428.0961); Vmax K.Br)/cm-1 3300-3394 (OH and NH), 2379 (CN) 
and 1684 (C=O); 8H (400 MHz; CDCh) 2.65 (2H, m, 6'- CH2), 2.83 (1H, m, 2'-H), 3.20 
(2H, m, 5'- CH2), 3.26 (1H, br s, NH), 3.58 (2H, dd, J=12.7 and 3.6 Hz, 3' -CH2), 3.75 
(2H, s, 8'-H), 4.99 (1H, d, J=10.5 Hz, 1 '-H), 6.97 (1H, dd, J=8.8 and 3.5 Hz, 8-H), 7.14 
(IH, s, 2-H), 7.20-7.23 (5H, m, Ar-H), 7.41 (1H, m, 7-H), 7.51 (1H, d, 1=5.7 Hz, 5-H), 
and 10.86 (lH, br s,-OH); 8c (100MHz; CDCh) 30.1 (C-6'), 30.2 (C-2'), 36.7 (C-8'), 
43.2 (C-3'), 55.9 (C-5'), 61.6 (C-1 '), 107.9 (CN), 117.6 (C-3), 120.5 (C-8), 122.0 (C-
4a), 124.8 (C-6), 128.7 (C- 11' and C-13'), 128.8 (C-12'), 128.9 (C-10' and C-14'), 
129.0 (C-5), 133.8 (C-7), 138.0 (C-9'), 151.2 (C-2), 158.7 (C-8'a) and 195.2 (C=O); m!z 
429 (M+, 35%) and 154 (100%). 
Note: 
(i) When the reaction was run for 6 weeks using 6-chloro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 213 (100 mg, 0.382 mmol), (S)-benzylcysteamine 
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(64 mg, 0.38 mmol) as free amine, and sodium acetate (63 mg, 0.76 mmol) in EtOH (4 
ml), work-up and purification afforded 1-(6-chloro-4H-1-benzopyran-4-on-3-yl)-2-
cyano-8-phenyl-4-aza-7-thiaoctanol259 as brown solid (66 mg, 40 %). 
(ii) When the reaction was run for 5 days using 6-chloro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-l-benzopyran-4-one 213 (100 mg, 0.382 mmol), (S)-benzylcysteamine 
hydrochloride (128 mg, 0.76 mmol) as free amine, TBAB (246 mg, 0.764 mmol) as the 
catalyst and sodium acetate (63.1 mg, 0.764 mmol) in EtOH (4 ml), work-up and 
purification afforded 1-(6-chloro-4H-1-benzopyran-4-on-3-yl)-2-cyano-8-phenyl-4-aza-
7-thiaoctanol259 as brown solid (79 mg, 48%). 
(iii) When the reaction was run for 5 days using 6-chloro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 213 (100 mg, 0.382 mmol), (S)-benzylcysteamine 
hydrochloride (127 mg, 0.764 mmol) as free amine, and BmimBF4 (2.0 mL ) as the 
catalyst in EtOH (4 ml), work-up and purification afforded 1-(6-chloro-4H-1-
benzopyran-4-on-3-yl)-2-cyano-8-phenyl-4-aza-7-thiaoctanol 259 as brown solid (1 05 
mg, 64%). 
1-(6-bromo- 4H-1-benzopyran-4-on-3-yl)-2-cyano-8-phenyl-4-aza-7 -thiaoctano/260 
The experimental procedure employed for the synthesis of 1-(4H-1-benzopyran-4-on-3-
yl)-2-cyano-8-phenyl-4-aza-7-thiaoctanol258 was followed, using 6-bromo-3-(2-cyano-
3-hydroxy-1-propen-3-yl)-4H-1-benzopyran-4-one 214 (100 mg, 0.40 mmol), (S)-
benzylcysteamine hydrochloride (163 mg, 0.80 mmol), sodium acetate (66 mg, 0.80 
mmol) in EtOH (4ml). Work-up afforded 1-(6-bromo- 4H-1-benzopyran-4-on-3-yl)-2-
cyano-8-phenyl-4-aza-7-thiaoctanol 260 as brown solid oil ( 80 mg, 42%); (Found 
MW: 473.0535. Calc. for C22H2103N2SBr, M: 472.0456); Vmax (KBr)/cm-1 3300-3394 
(OH and NH), 2360 (CN) and 1685(C=O); 8H (400 MHz; CDCh) 2.67 (2H, m, 6'- CH2), 
2.82 (lH, m, 2'-H), 3.20 (2H, m, 5'-CH2), 3.47 (IH, br s, NH), 3.59 (2H, m, 3'-CH2), 
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3.80 (2H, s, 8'- CH2), 4.99 (lH, d, J=2.4 Hz, 1 ' -H), 6.92 (1H, d, J=8.8 Hz, 8-H), 7.14 
(1H, s, 2-H), 7.20-7.32 (5H, m, Ar-H), 7.50 (1H, m, 7-H), 7.64 (1H, dd, J=12.3 and 2.5 
Hz, 5-H), and 10.02 (1H, br s, OH); &c(lOOMHz; CDCb) 30.1 (C-6'), 30.2 (C-2'), 36.7 
(C-8'), 43.2 (C-3'), 55.9 (C-5'), 62.8 (C-1'), 107.1 (CN), 117.5 (C-6), 117.8 (C-3), 119.0 
(C-4a), 122.2 (C-8), 128.7 (C- 11 ' and C- 13 '), 128.8 (C-12'), 128.9 (C-10' and C-14'), 
133.7 (C-5), 137.1 (C-7), 138.5 (C-9'), 151.4 (C-2), 158.6 (C-8a) and 195.3 (C=O); m/z 
473 (M+, 5%) and 136 (100). 
Note: 
(i) When the reaction was run for 6 weeks using 6-bromo-3-(2-cyano-3-hydroxy-1 -
propen-3-yl)-4H-1-benzopyran-4-one 214 (100 mg, 0.40 mmol), (S)-benzylcysteamine 
(135 mg, 0.80 mmol) as free amine, and sodium acetate (66 mg, 0.80 mmol) in EtOH 
(4 ml), work-up and purification afforded 1-(6-bromo-4H-1-benzopyran-4-on-3-yl)-2-
cyano-8-phenyl-4-aza-7-thiaoctanol260 as a brown solid (63 mg, 33%). 
(ii) When the reaction was run for 5 days using 6-bromo-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 214 (1 00 mg, 0.40 mmol), (S)-benzylcysteamine 
hydrochloride (163 mg, 0.80 mmol), TBAB (258 mg, 0.80 mmol) as the catalyst and 
sodium acetate (66 mg, 0.80 mmol) in EtOH (4 ml), work-up and purification afforded 
l-(6-bromo-4H -1-benzopyran-4-on-3 -yl)-2 -cyano-8-phenyl-4-aza-7 -thiaoctanol 260 as a 
brown solid (82 mg, 43%). 
(iii) When the reaction was run for 5 days using 6-bromo-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 214 (100 mg, 0.40 mmol), (S)-benzylcysteamine 
hydrochloride (163 mg, 0.80 mmol), and BmimBF4 (2.0 mL) as the catalyst in EtOH (4 
ml), work-up and purification afforded J-(6-bromo-4H-1-benzopyran-4-on-3-yl)-2-
cyano-8-phenyl-4-aza-7-thiaoctanol 260 as a brown solid (107 mg, 56%). 
232 
Experimental 
1- (6-jluoro-4H-1-benzopyran-4-on-3-yl)- -2-cyano-8-phenyl-4-aza-7-thiaoctanol261 
The experimental procedure employed for the synthesis of 1-[4H-1-benzopyran-4-on-3-
yl)-2-cyano-8-phenyl-(4-aza-7-thiaoctanol) 258 was followed, using 6-fluoro-3-(2-
cyano-3-hydroxy-1-propen-3-yl)-4H-1-benzopyran-4-one 215 (1 00 mg, 0.52 mmol), (S)-
benzyl cysteamine hydrochloride ( 211.9 mg, 1.04 mmol), and sodium acetate (85.9 mg, 
1.04 mmol) in EtOH (4ml). Work-up afforded 1- (6-fluoro-4H-1-benzopyran-4-on-3-
yl)-2-cyano-8-phenyl-4-aza-7-thiaoctanol 261 as brown solid oil (75 mg, 35%); Found 
MH+: 413.1335. Calc. for c22H2103N2SF M: 412.1257); Vmax (K.Br)/cm"1 3300-3394 
(OH and NH), 2360 (CN) and 1653(C=O); 8H (400 MHz; CDC~)) 2.64 (2H, m, 6'-CH2), 
2.85 (lH, m, 2 '-H), 3.02 (2H, m, 5'-CH2), 3.42 (lH, br s, NH), 3.45-3.63 (2H,m, 3'-
CH2), 3.72 (2H, s, 8'-CH2), 4.99 (lH, d, 1=2.0 Hz, 1 ' -H), 7.01 (1H, d, J=8.3 Hz, 8-H), 
7.24 (1H, s, 2-H), 7.41 (lH, t, 1=3.7 Hz, 7-H), 7.50 (1H, d, 1=5.7 Hz, 7-H), 7.23-7.28 
(5H, m, Ar-H), and 10.27 (1H, br s, OH); 8c (lOOMHz; CDCh) 30.5 (C-6'), 30.3 (C-2'), 
36.5 (C-8'), 43 .5 (C-3'), 56.0 (C-5'), 61.3 (C-1'), 108.1 (CN), 117.2 (C-3), 17.6 (C-5), 
121.3 (C-8), 120.7 (C-4a), 121.9.8 (C-7), 128.6 (C- 11' and C-13'), 128.8 (C-12'), 129.0 
(C-10' and C-14'), 138.0 (C-9'), 151.3 (C-2), 155.8 (C-6), 158.9 (C-8 ' a) and 195.1 
(C=O); mlz 413 (M+, 12%) and 154 (100%). 
Note: 
(i) When the reaction was run for 6 weeks using 6-fluoro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 215 (100 mg, 0.52 mmol), (S)-benzylcysteamine 
(175 mg, 1.0 mmol), and sodium acetate (86 mg, 1.0 mmol) in EtOH (4 ml), work-up 
and purification gave 1-(6-jluoro-4H-1-benzopyran-4-on-3-yl}-2-cyano-8-phenyl-4-aza-
7-thiaoctanol261 as a brown solid (32 mg, 15%). 
(ii) When the reaction was run for 5 days using 6-fluoro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 215 (100 mg, 0.52 mmol), (S)-benzylcysteamine 
hydrochloride (212 mg, 1.0 mmol), TBAB (335 mg, 1.0 mmol) as the catalyst and 
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sodium acetate (86 mg, 1.0 mmol) in EtOH (4 ml), work-up and purification afforded l-
(6-jluoro-4H -1-benzopyran-4-on-3-yl)-2-cyano-8-phenyl-4-aza-7 -thiaoctanol 261 as 
brown solid (85.3 mg, 40%). 
(iii) When this reaction was run for 5 days using 6-fluoro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 215 (100 mg, 0.52 mmol), (S)-benzylcysteamine 
hydrochloride (211.9 mg, 1.04 mmol), and BmimBF4 (2.0 mL) as the catalyst in EtOH 
(4 ml), work-up and purification afforded l-(6-jluoro-4H-l-benzopyran-4-on-3-yl)-2-
cyano-8-phenyl-4-aza-7-thiaoctanol261 as a brown solid (106.7 mg, 50%). 
I-[6-methoxy-4H-J-benzopyran-4-on-3-yl)-2-cyano-8-phenyl-4-aza-7 -thiaoctano/262 
The experimental procedure employed for the synthesis of l-(4H-l-benzopyran-4-on-3-
yl)-2-cyano-8-phenyl-4-aza-7-thiaoctanol 258 was followed, using 3-(2-cyano-3-
hydroxy-1-propen-3-yl)-6-methoxy-4H-1-benzopyran-4-one 216 (1 00 mg, 0.35 mrnol), 
S-benzylcysteamine hydrochloride (143 mg, 0.70 mmol), and sodium acetate (58 mg, 
0.70 mmol) in EtOH (4ml). Work-up afforded J-[6-methoxy-4H-l-benzopyran-4-on-3-
yl)-2-cyano-8-phenyl-4-aza-7-thiaoctanol262 as brown solid oil (70 mg, 47 %); Found: 
MW: 391.1539. Calc. for c23H2404N2S, M: 390.1579); Vmax (KBr)/cm-1 3300-3394 (OH 
and NH), 2360 (CN) and 1623(C=O); 8H (400 MHz; CDCb) 2.64 (2H, t, J =6.8 Hz, 6'-
CH2), 3.15 (1H, m, 2'-H), 3.18 (2H, m, 5'- CH2), 3.44 (1H, br s, NH), 3.57 (2H, dd, 
J=12.9 and 3.6 Hz, 3'-CH2), 3.73 (2H, s, 6'-CH2), 3.75 (3H, s, OCH3), 4.99 (lH, d, 
J=2.7 Hz, 1 ' -H), 7.01 (1H, d, J=8.3 Hz, 8-H), 7.24 (IH, s, 2-H), 7.41 (1H, t, J=3.7 Hz, 7-
H), 7.50 (lH, d, J=5.7 Hz, 7-H), 7.23-7.28 (5H, m, Ar-H), and 10.27 (1H, br s, OH); 8c 
(100MHz; CDC~)) 29.9 (C-6'), 30.1 (C-2'), 36.4 (C-8'), 43.2 (C-3'), 58.7 (6-0CH3), 
60.0 (C-5'), 61.2 (C-1 '), 107.2 (CN), 117.6 (C-3), 117.8 (C-5), 118.2 (C-4a), 122.5 (C-
8), 128.7 (C- 11' and C-13'), 128.8 (C-12' ), 128.9 (C-10' and C-14'), 131.2 (C-7), 135.2 
(C-9), 140.3 (C-6), 146.8 (C-2), 158.6 (C-8a) and 195.3 (C=O); mlz 391 (M+, 10%) and 
154 (100). 
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Note: 
(i) When the reaction was run for 6 weeks using 3-(2-cyano-3-hydroxy-1-propen-3-yl)-
6-methoxy-4H-1-benzopyran-4-one 216 (100 mg, 0.35 mmol), S-benzylcysteamine (118 
mg, 0.70 mmol), and sodium acetate (58 mg, 0.70 mmol) in EtOH (4 ml), work-up and 
purification 1-[6-methoxy-4 H-1-benzopyran-4-on-3 -yl)-2-cyano-8-phenyl-4-aza-7-
thiaoctanol262 as a brown solid ( 40 mg, 27 %). 
(ii) When this reaction was run for 5 days using 3-(2-cyano-3-hydroxy-1-propen-3-yl)-6-
methoxy-4H-l-benzopyran-4-one 216 (1 00 mg, 0.52 mmol), S-benzylcysteamine 
hydrochloride (143 mg, 0.70 mmol), TBAB (226 mg, 0.70 mmol ) as the catalyst and 
sodium acetate (58 mg, 0.70 mmol) in EtOH (4 ml), work-up and purification afforded 
1-[6-methoxy-4H-1-benzopyran-4-on-3-yl)-2-cyano-8-phenyl-4-aza-7 -thiaoctano/262 as 
a brown solid (89 mg, 60%). 
(iii) When this reaction was run for 5 days using 3-(2-cyano-3-hydroxy-1-propen-3-yl)-
6-methoxy-4H-1-benzopyran-4-one 216 (1 00 mg, 0.52 mmol), S-benzylcysteamine 
hydrochloride (143 mg, 0.70 mmol), and BmimBF4 (2.0 mL) as the catalyst in EtOH (4 
ml), work-up and purification afforded 1-[6-methoxy-4H-l-benzopyran-4-on-3-yl)-2-
cyano-8-phenyl-4-aza-7-thiaoctanol 262 as a brown solid ( 99 mg, 66%). 
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3.5.2 Reactions of Baylis-Hillman products with ethyl glycine 
hydrochloride 
0 OH 
6 
CN 
7 3' I' 0 4' ~ ~2· ~ II I" 
0 
Ethyl 5-cyano-6-( 4H -1-benzopyran-4-on-3 -yl)-6-hydroxy-3 -azahexanoate 263 
3-(2-Cyano-3-hydroxy-1-propen-3-yl)-4H-1-benzopyran-4-one 212 (1 00 mg, 0.44 
mmol) was added to a stirred solution of ethyl glycine hydrochloride (124 mg, 0.88 
mmol) and sodium acetate (73 mg, 0.88 mmol) in EtOH (4 ml). The resulting mixture 
was stirred at room temperature for 48 hours. Evaporation of the solvent in vacuo gave a 
brown oily residue which was purified by flash chromatography [on silica; elution with 
hexane: EtOAc (1 :2)] to afford ethyl 5-cyano-6-(4H-1-benzopyran-4-on-3-yl)-6-
hydroxy-3-azahexanoate 263 as brown crystalline solid (79.9 mg, 55%), m.p. 70-76°C, 
(Found ~: 330.13007. Calc. for cl7HlsOsN2, M: 330.12157); Vmax (KBr)/cm-1 3200-
3500 (OH and NH), 2346 (C=N), and 1700 and 1658 (2x C=O); 8H (400 MHz; CDCh) 
1.29 (3H, t, J=7.1 Hz, 2"CH3), 3.21 (IH, m, 5' -H), 3.38 (IH, dd, J=l2.6 and 1.7 Hz, 4' -
CH2), 3.61 (lH, br s, NH), 3.79 (1H, dd, J=l2.5 and 3.8 Hz, 4'- CH2), 4.02 (2H, q, 
1=17.7 Hz, 2'- CH2), 4.24 (2H, q, J=7.2 Hz, 1 " - CH2), 4.99 (lH, s, 6' -H), 6.85 (lH, t, 
J=7.6 Hz, 6-H), 6.98 (lH, d, J=8.3 Hz, 8-H), 7.24 (IH, s, 2-H), 7.39 (1H, t, J=7.8 Hz, 7-
H), 7.52 (1H, d, J=7.8 Hz, 5-H), and 10.92 (IH, br s, OH); 8c (100MHz; CDCh) 14.2 
(C-2"), 30.3 (C-5'), 44.2 (C-4' ), 57.12 (C-2 ' ), 6l.O(C-6'), 62.2 (C-1 "), 108.9 (C-4a), 
117.7 (C=N), 118.1 (C-8), 118.5 (C-6), 119.8 (C-3), 130.9 (C-5), 134.2 (C-7), 156.2 (C-
8a), 160.6 (C-2), 167.9 (1 ' -C=O) and 195.9 (4'-C=O); mlz 330 (~, 4%) and 225 (100). 
Note: 
(i) When the reaction was run for 6 weeks using 3-(2-cyano-3-hydroxy-1-propen-3-yl)-
4H-l-benzopyran-4-one 212 (lOOmg, 0.44 mmol), ethyl glycine (57 mg, 0.88 mmol), 
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and sodium acetate (73mg, 0.88 mmol) in EtOH (4 ml), work-up and purification 
afforded ethyl 5 -cyano-6-( 4H -1-benzopyran-4 -on-3 -yl) -6-hydroxy-3 -azahexanoate 263 
as a brown crystalline solid as (69.7 mg, 48%). 
(ii) When the reaction was run for 5 days using 3-(2-cyano-3-hydroxy-1-propen-3-yl)-
4H-1-benzopyran-4-one 212 (100.0 mg, 0.44 mmol), ethyl glycine hydrochloride (124 
mg, 0.88 mrnol), TBAB (367 mg, 1.1 mrnol ) as the catalyst and sodium acetate (73 mg, 
0.88 mmol) in EtOH (4 ml), work-up and purification afforded ethyl 5-cyano-6-(4H-1-
benzopyran-4-on-3-yl)-6-hydroxy-3-azahexanoate 263 as a brown crystalline solid as 
(84.2 mg, 58%). 
(iii) When the reaction was run for 5 days using 3-(2-cyano-3-hydroxy-1-propen-3-yl)-
4H-1-benzopyran-4-one 212 (100 mg, 0.44 mmol), ethyl glycine ester hydrochloride 
(124 mg, 0.88 mrnol), and BmimBF4 (2.0 mL) as the catalyst in EtOH (4 ml), work-up 
and purification afforded ethyl 5-cyano-6-( 4H -1-benzopyran-4-on-3-yl)-6-hydroxy-3-
azahexanoate 263 as a brown crystalline solid as (99 mg, 68%). 
Ethyl 5-cyano-6-(6-chloro-4H-1-benzopyran-4-on-3-yl) -6-hydroxy-3-azahexanoate 264 
The experimental procedure employed for the synthesis of ethyl-6-(4H-1-benzopyran-4-
on-3-yl)-5-cyano-6-hydroxy-3-azahexanoate 263 was followed, using 6-chloro-3-(2-
cyano-3-hydroxy-l-propen-3-yl)-4H-1-benzopyran-4-one 213 (100 mg, 0.38 mmol), 
sodium acetate (62.7 mg, 0.76 mmol) and ethyl glycine ester hydrochloride ( 107.0 mg, 
0.76 mrnol) in EtOH (4ml). Work-up afforded ethyl 5-cyano-6-(6-chloro-4H-1-
benzopyran-4-on-3-yl)- 6-hydroxy-3-azahexanoate 264 as brown solid (51.3 mg, 37%), 
(Found MH+: 365.0902, C17H170sN2Cl, M: 364.0826); Vmax (KBr)/cm-1 3200-3500 (OH 
and NH), 2348 (C=N), 1654 (2x C=O); 1.34 (3H, t, J= 8.8 Hz, 2"-CHJ), 3.08 (2H, m, 
2 ' - CH2), 3.24 (1H, br s, NH), 3.71 (1H, m, 5'-H), 4.12 (2H, dd, J=9.0 and 3.8 Hz, 4'-
H), 5.07 (1H, d, J=7.1 Hz, 6' -H), 6.94 (1H, t, J=9.4 Hz, 7-H), 6.98 (lH, d, J=8.7 Hz, 8-
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H), 7.49 (1H, d, J=2.5 Hz, 5-H), 7.53 (1H, s, 2-H) and 10.74 (1H, br s, OH); 8c 
(100MHz; CDCh) 14.1 (C-2"), 30.5 (C-5'), 44.6 (C-4'), 57.4 (C-2'), 61.3 (C-6'), 62.6 
(C-7'), 110.6 (C-4a), 117.7 (C=N), 119.8 (C-3), 120.5 (C-8), 129.1 (C-5), 131.5 (C-6), 
134.0 (C-7), 153.7 (C-8a), 160.7 (C-2), 167.9 (1'-C=O) and 195.7 (4'-C=O); m/z 365 
(M+, 18%) and 147 (100). 
Note: 
(i) When the reaction was run for 6 weeks using 6-chloro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 213 (100 mg, 0.38 mrnol), ethyl glycine ester (49 
mg, 0.76 mrnol), as free amine, and sodium acetate (63 mg, 0.76 mmol) in EtOH (4 ml), 
work-up and purification afforded ethyl 5-cyano-6-(6-chloro-4H-l-benzopyran-4-on-3-
yl)- 6-hydroxy-3-azahexanoate 264 as a brown crystalline solid (74.9 mg, 54%). 
(ii) When the reaction was run for 5 days using 6-chloro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 213 (100 mg, 0.38 mmol), ethylglycine 
hydrochloride (107 mg, 0.76 mrnol), TBAB (245 mg, 0.76 mrnol) as the catalyst and 
sodium acetate (63 mg, 0.76 mmol) in EtOH (4 ml), work-up and purification afforded 
ethyl 5-cyano-6-(6-chloro-4H-l-benzopyran-4-on-3-yl)- 6-hydroxy-3-azahexanoate 264 
as a brown crystalline solid (90.2 mg, 65%). 
(iii) When the reaction was run for 5 days using 6-chloro-3-(2-cyano-3-hydroxy-1 -
propen-3-yl)-4H-1-benzopyran-4-one 213 (100 mg, 0.38 mmol), ethylglycine 
hydrochloride (107 mg, 0.76 mmol), and BmimBF4 (2.0 mL) as the catalyst in EtOH (4 
ml), work-up and purification afforded ethyl 5-cyano-6-(6-chloro-4H-l-benzopyran-4-
on-3-yl)- 6-hydroxy-3-azahexanoate 264 as a brown crystalline solid (89 mg, 64%). 
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Ethyl 5-cyano-6-(6-jluoro-4H-l-benzopyran-4-on-3-yl)-6-hydroxy-3-azahexanoate 265 
The experimental procedure employed for the synthesis of ethyl 6-{4H-1-benzopyran-4-
on-3-yl)-5-cyano-6-hydroxy-3-azahexanoate 263 was followed, using 6-fluoro-3-(2-
cyano-3-hydroxy-1-propen-3-yl)-4H-1-benzopyran-4-one 215 ( 100 mg, 0.41 mmol), 
ethylglycine ester hydrochloride (1.5 mg, 0.82 mmol), TBAB (264 mg, 0.82 mmol )and 
sodium acetate (68 mg, 0.82 mmol) in EtOH (4ml). Work-up afforded ethyl 5-cyano-6-
(6-jluoro-4H-1-benzopyran-4-on-3-yl)-6-hydroxy-3-azahexanoate 265 as a brown oil 
(21.4 mg, 15%), (Found M +: 34 , C17H170sN2F, M: 348.1121); Vmax (KBr)/cm-1 3200-
3500 (OH and NH), 2348 (C=N) and 1658 (2x C=O); 1.34 (3H, t, J=8.9 Hz, 1 "-CH3), 
3.08 (2H, m, 2'-CH2), 3.24 (1H, br s, NH), 3.71 (lH, m, 5'-H), 4.12 (2H, dd, J= 9.0 and 
1.7 Hz, 4'- CH2), 5.07 (1H, d, J=7.1, 6' -H), 6.94 (1H, t, 1=9.4 Hz, 7-H), 6.98 (lH, d, 
J=8.7 Hz, 8-H), 7.49 (lH, d, J=2.5 Hz, 5-H), 7.53 (1H, s, 2-H) and 10.74 (1H, br s, OH); 
8c (100MHz; CDCb) 14.3 (C-2"), 30.7 (C-5 '), 44.7 (C-4' ), 57.7 (C-2'), 61.0 (C-6'), 
62.4 (C-1 " ), 109.4 (C-4a), 117.6 (C=N), 117.7 (C-5), 119.8 (C-3), 121.3 (C-8), 131.5 
(C-6), 149.8 (C-8a), 160.6 (C-2), 161.9 (C-7), 167.8 (1 '-C=O) and 195.6 (4'-C=O); mlz 
344 (M+, 30%) and 303 (100). 
Note: 
(i) When the reaction was run for 6 week using 6-fluoro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 215 (100 mg, 0.41 mmol), ethyl glycine (53 mg, 
0.82 mmol), as free amine, and sodium acetate (68 mg, 0.82 mmol) in EtOH (4 ml), 
work-up and purification afforded ethyl 5-cyano-6-(6-jluoro-4H-J-benzopyran-4-on-3-
yl)-6-hydroxy-3-azahexanoate 265 as a brown crystals (59 mg, 41 %). 
(ii) When the reaction was run for 5 days using 6-fluoro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)AH-1-benzopyran-4-one 215 (1 00 mg, 0.41 mmol) ethyl glycine 
hydrochloride (1.5 mg, 0.82 mmol), TBAB (367 mg, 1.1 mmol ) as the catalyst and 
sodium acetate (68 mg, 0.82 mmol) in EtOH (4 ml), work-up and purification afforded 
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ethyl 5-cyano-6-(6-jluoro-4H -1-benzopyran-4-on-3-yl)-6-hydroxy-3 -azahexanoate 265 
as a brown crystals (71.3 mg, 50%). 
(iii) When the reaction was run for 5 days using 6-fluoro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 215 (100 mg, 0.41 mmol), ethyl glycine ester 
hydrochloride (1.5 mg, 0.82 mmol), and BmimBF4 (2.0 mL) as the catalyst in EtOH 
(4 ml), work-up and purification afforded ethyl5-cyano-6-(6-jluoro-4H-1-benzopyran-4-
on-3-yl)-6-hydroxy-3-azahexanoate 265 as a brown crystals (80.0 mg, 56%). 
3.5.3 Reactions of Baylis-Hillman products with D-serine methyl ester 
hydrochloride 
-
4' 3'~: 1' 0 N 2' .......__ 
H 
0 
Methyl 5-cyano-6-( 4H -1-benzopyran-4-on-3 -yl)-6-hydroxy-3 -azahexanoate 266 
3-(3-Hydroxy-2-cyanopropen-3-yl)-4H-1-benzopyran-4-one 212 (100 mg, 0.44 mmol) 
was added to a stirred solution of D-serine methyl ester hydrochloride (137 mg, 
0.88mmol), and sodium acetate (73 mg, 0.88 mmol) in EtOH (4 ml). The resulting 
mixture was stirred at room temperature for 6 weeks. Evaporation in vacuo gave a brown 
oily residue which was purified by flash chromatography [on silica gel and elution with 
hexane: EtOAc (3:2)] to afford methyl 5-cyano-6-(4H-1-benzopyran-4-on-3-yl)-6-
hydroxy-3-azahexanoate 266 as yellow solid (47.2 mg, 31%), (Found M+:345.1045. 
Calc for C11His06N2, M: 346.1164); Vmax (KBr)/cm-1 3420 (OH and NH), 2349 (CN), 
1653 and 1652 (2xC=O); 8H (400 MHz; CDCb) 2.21 (lH, m, CH20H), 2.64 (lH, t, 
J=7.0 Hz, 4'-H), 3.02 (lH, t, J=7.5 Hz, 4'-H), 3.16 (lH, br s, 3'-NH), 3.21 (lH, m, 5'-
H), 3.31-3.45 (3H, m, 2'-H and CH20H ), 3.72 (3H, m, OCH3), 4.98 (1H, br s, 6'-H), 
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6.84 (IH, t, J=8.5 Hz, 6-H), 7.01 (1H, d, J=8.5 Hz, 8-H), 7.13(1H, s, 2-H), 7.41 (1H, t, 
7.5 Hz, 7-H), 7.50 (1H, d, J=7.8 Hz, 5-H), and 10.98 (1H, br s, 1 '-OH); oc (lOOMHz; 
CDCb) 31.3 (C-5'), 43.1 (C-4'), 45.0 (C-2'), 55.5 (CB20H-8'), 59.8 (C-2' and 7'-
OCB3), 118.1 (C-8), 118.4 (CN), 127.7 (C-3), 128.8 (C-6), 128.9 (C-7), 130.6 (C-8), 
133.9 (C-4a), 151.1 (C-2), 160.7 (C-8a), 172.0 (1 ' -C=O) and 189.7 (4-C=O); m/z 
345(W, 14%) and 121 (100). 
Note: 
(i) When the reaction was run for 5 days using 3-(3-hdroxy-2-cyanopropen-3-yl)-4H-1-
benzopyran-4-one 212 (100 mg, 0.44 rnrnol), D-serine methyl ester hydrochloride (137 
mg, 0.88mrnol), TBAB (284 mg, 0.88 mmol) as the catalyst and sodium acetate (73 mg, 
0.88 rnrnol) in EtOH (4 ml), work-up and purification afforded methyl 5-cyano-6-(4H-1-
benzopyran-4-on-3-yl)-6-hydroxy-2-(hydroxymethyl)-3-azahexanoate 266 as yellow 
solid oil (61 mg, 40%). 
Methyl 
267 
5 -cyano-6-( 6-chloro-4H -1-benzopyran-4-on-3-yl)-6-hydroxy-3 -azahexanoate 
The experimental procedure employed for the synthesis of methyl 5-cyano-6-(4H-l-
benzopyran-4-on-3-yl)- 6-hydroxy-2-(hydroxymethyl)-3-zahexanoate 266 was followed, 
using 6-chloro-3-(3-hydroxy-2-cyanopropen-3-yl)-4H-1-benzopyran-4-one 213 (1 00 mg, 
0.38 mmol), sodium acetate (63 mg, 0.76 mmol) and D-serine methyl ester 
hydrochloride (118 mg, 0.76 rnrnol) in EtOH (4ml). Work-up afforded methy/5-cyano-
6-(6-chloro-4H-l-benzopyran-4-on-3-yl)-6-hydroxy-3-azahexanoate 267 as brown oil 
(22 mg, 15%), (Found: MH+, 381.0859, CnH1706N2Cl requires M: 380.7751); Vmax 
(KBr)/cm-1 3421 (OH and NH), 2353 (CN), 1654 and 1653 (2xC=O); oH (400 MHz; 
CDCh) 3.09 (IH, m, 5'-H), 3.57 (2H, dd, J= 3.36 and 12.83 Hz, 4'-H), 3.65 (2H, dd, J= 
3.81 and 12.42 Hz, 8'-H), 3.75 (1H, m, 5'-H), 3.79 (1H, br s, 3'-NH), 3.81 (1H, br s, 8'-
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OH), 3.85 (lH, m, 2'-H), 4.13 (3H, s, 7'-0CHJ), 5.15 (1H, m, 6' -H), 6.92 and 6.93 (2 x 
1H, d, J= 8.82 Hz, 8-H), 7.32 and 7.35 (2 x 1H, t, 7-H), 7.36 (lH, s, 5-H), 7.44 and 7.48 
(2 x lH, d, J= 2.61 Hz, 7-H), 7.51 (1H, s, 5-H), and 10.8 (lH, br s,6'-0H); 8c (l OOMHz; 
CDCh) 31.4 (C-5 '), 43.2 (C-4'), 45.3 (C-2'), 55.8 (C-8'), 60.0 (7'-0CI-1]), 61.3 (C-2'), 
118.5 (CN), 127.1 (C-5), 127.9 (CN), 131.4 (C-8), 135.7 (C-6), 137.2 (C-4a), 145.9 (C-
7), 151.1 (C-2), 158.2 (C-8a), 172.2 (1 '-C=O) and 189.8 (4-C=O); mlz 381 (~, 10%) 
and 149 (100). 
Note: 
(i) When the reaction was run for 5 days using 6-chloro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 213 (1 00 mg, 0.3 8 mmol), D-serine methyl ester 
hydrochloride(118.2 mg, 0.76 mmol), TBAB (284 mg, 0.76mmol) as the catalyst and 
sodium acetate (63 mg, 0.76 mmol) in EtOH (4 ml), work-up and purification afforded 
methyl 5-cyano-6-(6-chloro-4H-J-benzopyran-4-on-3-yl)-6-hydroxy-3-azahexanoate 267 
as a yellow solid oil ( 29 mg, 20%). 
Methyl 5 -cyano-6-(6-methoxy-4H -1-benzopyran-4-on-3-yl)-6-hydroxy-3 -azahexanoate 
268 
The experimental procedure employed for the synthesis of methyl 6-(4H-1-benzopyran-
4-on-3-yl)-5-cyano-6-hydroxy-2-(hydroxymethyl)-3-azahexanoate 266 was followed, 
using 6-methoxy-3-(3-hydroxy-2-cyanopropen-3-yl)-4H-1-benzopyran-4-one 216 (1 00 
mg, 0.39 mmol), sodium acetate (64 mg, 0.78 mmol) and D-serine methyl ester 
hydrochloride (121 mg, 0.78 mmol) in EtOH (4ml). Work-up afforded methyl 5-cyano-
6-(6-methoxy-4H-1-benzopyran-4-on-3 -yl)-6-hydroxy-3-azahexanoate 268 as brown oil 
(40 mg, 27%), (Found: M+:376.0967. Calc for C,sH2o0 1N2, M: 376.1271); Vmax 
(KBr)/cm·' 3200-3421 (OH and NH), 2350(CN), 1654 and 1653 (2xC=O); 8H (400 
MHz; CDCh) 2.73 (1H, m, 5'-H), 3.53 (2H, dd, 1=12.83 and 3.36 Hz, 4'-H), 3.64 (2H, 
dd, J=I2.4 and 3.8 Hz, 8' -H), 3.75 (1H, m, 5'-H), 3.79 (lH, br s, 3' -NH), 3.81 (1H, br s, 
8' -0H), 3.85 (lH, m, 2'-H), 3.76 (3H, s, 7'-0CH3) , 3.87 (3H, s, 6-0CH3) , 4.96 (1H, m, 
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6'-H), 6.97 and 6.99 (2 x lH, d, J=8.8 Hz, 8-H), 7.38 and 7.43 (2 x lH, t, 7-H), 8.07 and 
8.27(2x1H, s, 5-H), and 10.23 (lH, br s, 6'-0H); 8c(100MHz; CDCl3) 31.2 (C-5'), 43.0 
(C-4'), 45.2 (C-2'), 55.6 (C-8'), 59.8 (7'-0Cti)), 61.1 (C-2'), 107.8 (CN), 111.8 (C-5), 
131.1 (C-8), 137.0 (C-4a), 139.5 (C-7), 161.9 (C-6), 162.1 (C-2), 164.2 (C-8a), 171.8 
(1'-C=O) and 189.1 (4-C=O); mlz 376 (M+, 15%) and 151 (100). 
Note: 
(i) When the reaction was run for 5 days using 6-methoxy-3-(3-hydroxy-2-
cyanopropen-3-yl)-4H-1-benzopyran-4-one 216 (100 mg, 0.39 mmol), D-serine methyl 
ester hydrochloride (121 mg, 0.78 mmol), TBAB (291 mg, 0.78 mmol) as the catalyst 
and sodium acetate (64 mg, 0.78 mmol) in EtOH (4 ml), work-up and purification 
afforded methyl 5-cyano-6-(6-methoxy-4H-1-benzopyran-4-on-3-yl)-6-hydroxy-3-
azahexanoate 268 as yellow solid oil (48 mg, 33%). 
3.5.4 Reaction of Baylis-Hillman products with L-Serine ethyl ester 
hydrochloride 
0 OH 
s· CN40H 9' 3' 1' 0~ / N 2' ~ s· H T 
0 
Ethyl 5-cyano-6-( 4H -1-benzopyran-4-on-3 -yl)-6-hydroxy-2 -hydroxymethyl-3-
azahexanoate 269 
3-(2-cyano-3-hydroxy-1-propen-3-yl)-4H-l -benzopyran-4-one 212 (1 00 mg, 0.44 mmol) 
was added to a stirred solution of L-serine ethyl ester hydrochloride (149 mg, 
0.88mmol), and sodium acetate (73 mg, 0.88 mmol) in EtOH (4 ml). The resulting 
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mixture was stirred at room temperature for 6 weeks. Evaporation in vacuo gave a brown 
oily residue which was purified by flash chromatography [on silica gel and elution with 
hexane: EtOAc (3:2)] to afford ethyl 5-cyano-6-(4H-1-benzopyran-4-on-3-yl)-6-
hydroxy-2-hydroxymethyl-3-azahexanoate 269 as yellow solid oil (41 mg, 26%), (Found 
Mir: 
391.14606, C1sH2o06N2, Calc forM: 390.1427); Vmax (KBr)/cm-1 3200-3421 (OH and 
NH), 2355 (CN), 1676 and 1654 (2xC=O); 8H (400 MHz; CDCh) 2.73 (3H, t, J= 7.2 Hz, 
8' -CH3), 3.81 (1H, br s, 3'-NH), 3.57 (2H, m, 4'-H), 3.72 (2H, m, 8'-H), 3.80 (1H, m, 
5'-H), 4.06 (1H, br s, 9'-0H), 4.08 (lH, m, 2'-H), 4.28 (1H, q, 7'-H), 5.03 (1H, d, J=7.0 
Hz, 6'-H), 6.85 (1H, m, 8-H), 6.90 (lH, m, 8-H), 7.04 (1H, m, 7-H), 7.38 (lH, d, J=8.4 
Hz, 5-H), 8.25 (1H, s, 2-H) and 10.87 (lH, br s, 6'-0H); 8c (100MHz; CDCh) 14.2 (C-
8'), 47.4 (C-5'), 53.4 (C-4'), 60.4 (C-7'), 62.8 (C-9'), 68.3 (C-2'), 68.4 (C-6'), 108.5 
(CN), 118.1 (C-3), 118.2 (C-8), 118.4 (C-6), 119.7 (C-4a), 130.4 (C-5), 138.5 (C-7), 
153.8 (C-2), 161.3 (C-8a), 167.2 (1 ' -C=O) and 191.6 (4-C=O); mlz 391 (M+, 51%) and 
149 (1 00). 
Note: 
(i) When the reaction was run for 5 days using 3-(2-cyano-3-hydroxy-1-propen-3-yl)-
4H-l-benzopyran-4-one 212 (100 mg, 0.44 mmol), L-serine ethyl ester hydrochloride 
(149.3 mg, 0.88mmol), TBAB (283.6 mg, 0.88 mmol ) as the catalyst and sodium 
acetate (72.7 mg, 0.88 mmol) in EtOH (4 ml). The workup and purification afforded 
ethyl 5-cyano-6-( 4H -1-benzopyran-4-on-3 -yV-6-hydroxy-2 -hydroxymethyl-3-
azahexanoate 269 as yellow solid crystals (47.5 mg, 30%). 
Ethyl 5-cyano-6-(-6-chloro-4H -1-benzopyran-4-on-3-yl)-6-hydroxy-2 -hydroxyme thy!-3-
azahexanoate 270 
The experimental procedure employed for the synthesis of ethyl-2-methanol-6-(4H-1-
benzopyran-4-on-3-yl)-5-cyano-6-hydroxy-3-azahexanoate 269 was followed, using 6-
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chloro-3-(2-cyano-3-hydroxy-1-propen-3-yl)-4H-1-benzopyran-4-one 213 (1 00 mg, 0.38 
mmol), sodium acetate (63 mg, 0.76 mmol) and L-serine ethyl ester hydrochloride 
(129mg, 0.76 mmol) in EtOH (4ml). Work-up afforded ethyl 5-cyano-6-(-6-chloro-4H-
1-benzopyran-4-on-3-yl)-6-hydroxy-2-hydroxymethyl-3-azahexanoate 270 as brown oil 
(44 mg, 29%). Vmax (KBr)/cm·1 3200-3421 (OH and NH), 2926 (CN), 1676 and 1654 
(2xC=O); DH (400 MHz; CDCh) 1.31 (3H, t, 1=7.15 Hz, 8' -CH3), 3.23 (IH, m, 5'-H), 
3.38 (1H, br s, 3'-NH), 3.41 (1H, br s, 9'-0H), 3.81 (2H, dd, 1=12.7 and 3.6 Hz, 4'-H), 
4.08 (1H, m, 2'-H), 4.25 (2H, m, 9' -H), 5.01 (IH, d, 1=2.7 Hz, 9'-H), 6.93 (1H, d, 1=8.8 
Hz, 8-H), 7.19 (1H, m, 7-H), 7.42 (1H, d, 1=2.4 Hz, 5-H), 8.42 (1H, s, 2-H) and 10.7 
(lH, br s, 6' -0H); 8c (IOOMHz; CDCh) 14.3 (C-8'), 47.5 (C-5'), 53 .7 (C-4'), 60.6 (C-
7'), 62.9 (C-9'), 68.5 (C-2'), 68.7 (C-6' ), 108.8 (CN), 118.6 (C-3), 120.6 (C-8), 124.6 
(C-4a), 128.6 (C-5), 129.2 (C-6), 138.7 (C-7), 153.9 (C-2), 163.5 (C-8a), 167.0 (1 '-C=O) 
and 191.4 (4-C=O); m/z 395(M+,15%) and 149(100). 
Note: 
(i) When this reaction was run for 5 days using 6-chloro-3-(2-cyano-3-hydroxy-1-
propen-3-yl)-4H-1-benzopyran-4-one 213, L-serine ethyl ester hydrochloride (129 mg, 
0.76 mmol)), TBAB (245 mg, 0.76 mmol) as the catalyst and sodium acetate (63 mg, 
0.76 mmol) in EtOH (4 ml). The workup and purification afforded ethyl 5-cyano-6-(-6-
chloro-4H-l-benzopyran-4-on-3-yl)-6-hydroxy-2-hydroxymethyl-3 -azahexanoate 270 as 
yellow solid crystals (68 mg, 45%). 
Ethyl 5 -cyano-6-( 6-methoxy-4H -1-benzopyran-4-on-3 -yl}-6-hydroxy-2-hydroxymethyl-3-
azahexanoate 271 
The experimental procedure employed for the synthesis of ethyl-2-methanol-6-(4H-1-
benzopyran-4-on-3-yl)-5-cyano-6-hydroxy-3-azahexanoate 269 was followed, using 6-
methoxy-3-(3-hydroxy-2-cyanopropen-3-yl)-4H-1-benzopyran-4-one 216 (100 mg, 0.39 
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mmol), sodium acetate (64 mg, 0.78 mmol) and L-serine ethyl ester hydrochloride (132 
mg, 0.78 mmol) in EtOH (4ml). Work-up afforded ethyl 5-cyano-6-(-6-methoxy-4H-1-
benzopyran-4-on-3-yl)-6-hydroxy-2-hydroxymethyl-3-azahexanoate 271 as brown oil (40 
mg, 27%); Vmax (K.Br)/cm-1 3200-3421 (OH and NH), 2355 (CN), 1645 and 1636 
(2xC=O); 8H (400 MHz; CDCh) 1.32 (3H, t, 1=7.2 Hz, 8'-CH3), 3.01 (1H, m, 5'-H), 
3.96 (1H, br s, 3 ' -NH), 4.00 (3H, s, 6-0CH3), 4.02 (2H, m, 4' -H), 4.11 (1H, m, 2' -H), 
4.26 (2H, m, 9'-H), 4.28 (2H, q, 9' -H), 4.81 (lH, br s, 6'-H), 5.04 (2H, br s, 9' and 6'-
0H), 6.95 (lH, d, 1=8.8 Hz, 8-H), 7.21 (1H, m, 7-H), 7.42 (lH, d, 1=2.4 Hz, 5-H), and 
8.48 (lH, s, 2-H) 8c (100MHz; CDCh) 14.1 (C-8 '), 47.2 (C-5 '), 53.5 (C-4' ), 60.3 (C-7'), 
62.5 (C-9'), 68.8 (C-2'), 68.9 (C-6'), 108.9 (CN), 113.1 (C-5), 118.9 (C-3), 120.9 (C-8), 
124.8 (C-4a), 132.7 (C-7), 154.1 (C-6), 154.3 (C-2), 158.7 (C-8a), 167.0 (1 ' -C=O) and 
191.4 (4-C=O); mlz 376 (W,12 %) and 155 (100). 
Note: 
(i) When this reaction was run for 5 days using 3-(2-cyano-3-hydroxy-l-propen-3-yl)-6-
methoxy-4H-l -benzopyran-4-one 216, L-serine ethyl ester hydrochloride (128.9 mg, 
0.76 mmol)), TBAB (244.9 mg, 0.76 mmol ) as the catalyst and sodium acetate 
(132.3 mg, 0.78 mmol) in EtOH (4 ml). The workup and purification afforded ethyl 5-
cyano-6-( 6-methoxy-4H -1-benzopyran-4-on-3 -yl)-6-hydroxy-2 -hydroxymethyl-3-
azahexanoate 271 as yellow solid crystals (49 mg, 33%). 
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3.5.5 Reaction of Baylis-Hillman products with L-Threonine methyl ester 
hydrochloride 
0 
Methyl 5-cyano-6-(4H-l-benzopyran-4-on-3-yl)-6-hydroxy-2-hydroxyethyl-3-
azahexanoate 272 
3-(3-Hydroxy-2-cyanopropen-3-yl)-4H-1-benzopyran-4-one 212 (100 mg, 0.44 mmol) 
was added to a stirred solution of L-threonine methyl ester hydrochloride (149 mg, 
0.88mmol), and sodium acetate (72.7 mg, 0.88 mmol) in EtOH (4 ml). The resulting 
mixture was stirred at room temperature for 6 weeks. Evaporation in vacuo gave a brown 
oily residue which was purified by flash chromatography [on silica gel and elution with 
hexane: EtOAc (3:2)] to afford 7-methyl-2-methanol-(8-methyl)-6-{4H-1-benzopyran-4-
on-3-yl}-5-cyano-6-hydroxy-3-azahexanoate 272 as yellow oil (41.2 mg, 25%); Vmax 
(KBr)/cm-1 3200-3421 (OH and NH), 2956 (CN), 1653 and 1712 (2xC=O); oH (400 
MHz; CDCb) 1.27 (9H, m, 9'-CH3), 2.78 (2H, br peak, OH), 3.21 (1H, br s, 3' -NH), 
3.58 (lH, m, 4'-H), 3.65 (2H, m, 4'-H and 5'-H), 3.79 (3H, s, 7'-0CH3), 4.24 (2H, m, 
8'-H), 4.44 (lH, m, 2'-H), 5.11(2H, m, 6'-H), 6.70 (4H, m, 6-H and 8-H), 7.34 (2H, m, 
7-H), 7.89 (2H, 2xs, 2-H), 8.02 (2H, J=8.2 and 1.4 Hz, 5-H) and oc (100MHz; CDCh) 
15.3 and 18.5 (2xC-9'), 29.1 (C-8'), 31.3 (C-5 '), 53.2 (C-2'), 62.0 (C-6'), 63.3 (C-4'), 
68.4 (C-7'), 108.8 (CN), 118.5 (C-8), 126.6 (C-6), 126.9 (C-3), 127.1 (C-4a), 127.4 (C-
5), 129.7 (C-7), 133.2 (C-2), 158.9 (C-8a), 167.3 (1 ' -C=O) and 173.4 (4-C=O); 
The 1H NMR (Figure 75) of a new aza-Michael product 256 reveals a multiplet at 1.29 
ppm which correspond to 9'- methyl diastereotopic protons three isomers, a broad peak 
at 2.99 ppm which correspond to OH, a multiplet at 3.21 ppm which correspond to 5 ' -
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methine proton, a broad singlet at 2.63 ppm which correspond to 3 '-amine proton, a 
multiplet at 3.64 ppm which correspond to one proton of 4'-methylene diastereotopic 
protons, a multiplet of 2' -methine proton (overlapping to another proton of 4 ' -methylene 
diastereotopic protons) at 3.76 ppm, a singlet at 3.82 ppm which correspond to 7'-
methoxy protons, a multiplet at 4.29 ppm which correspond to 8' -methine proton of 
three isomers, a multiplet at 4.44 which correspond to 2' -methine proton, a broad peak 
which correspond to 6' -methine proton. 
Note: 
(i) When this reaction was run for 5 days using 3-(3-Hydroxy-2-cyanopropen-3-yl)-4H-
1-benzopyran-4-one 212 (1 00 mg, 0.44 mmol), L-threonine methyl ester hydrochloride 
(149 mg, 0.88mmol), TBAB (284 mg, 0.88 mmol) as the catalyst and sodium acetate (73 
mg, 0.88 mmol) in EtOH (4 ml). The workup and purification afforded 7-methyl-2-
methanol-(8-methyl)-6-{ 4H-l-benzopyran-4-on-3-yl }-5-cyano-6-hydroxy-3-
azahexanoate 272 as yellow solid crystals (61 mg, 37%). 
7-Methyl-2-methanol-(8-methyl)-6-{4H-1-benzopyran-4-on-3-yl-6-chloro}-5-cyano-6-
hydroxy-3-azahexanoate 273 
The experimental procedure employed for the synthesis of ethyl-2-methanol-6-(4H-1-
benzopyran-4-on-3-yl)-5-cyano-6-hydroxy-3-azahexanoate 272 was followed, using 6-
chloro-3-(3-hydroxy-2-cyanopropen-3-yl)-4H-1-benzopyran-4-one 213 (100 mg, 0.38 
mmol), sodium acetate (63 mg, 0.76 mmol) and L-threonine methyl ester hydrochloride 
(129 mg, 0.76 mmol) in EtOH (4ml). Work-up afforded 7-methyl-2-methanol-(8-
methy 1 )-6-{ 4 H -1-benzopyran -4-on-3-yl-6-chloro}-5 -cyano-6-hydroxy-3 -azahexanoate 
272 as brown oil (48.2 mg, 31%), m.p., (Found: Mir:395.0928 C1sH190 6N2Cl requires 
M: 394.0931); Vmax (KBr)/cm·1 3200-3421 (OH and NH), 2956 (CN), 1653 and 1712 
(2xC=O); oH (400 MHz; CDCh) 1.29 (9H, m, 9' -CH3), 2.99 (2H, br peak, OH), 3.21 
(1H, br s, 3' -NH), 3.64 (lH, m, 4'-H), 3.76 (2H, m, 4' -H and 5'-H), 3.82 (3H, s, 7'-
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OCH3), 4.29 (2H, m, 8'-H), 4.44 (1H, m, 2'-H), 6.82 (2H, m, 6-H), 6.97 (2H, dd, J=8.8 
and 1.0 Hz, 8-H), 7.48 (2H, m, 7-H), 8.07 (2H, 2xs, 2-H), 8.18 (2H, m, 5-H) and oc 
(lOOMHz; CDCIJ) 15.5 and 19.8 (2xC-9'), 29.2 (C-8'), 31.2 (C-5'), 53.5 (C-2'), 62.0 
(C-6'), 63.3 (C-4' ), 68.3 (C-7'), 109.2 (CN), 118.9 (C-3), 120.5 (C-8), 124.5 (C-5), 
124.8 (C-4a), 129.6 (C-7), 133.6 (C-6), 133.9 (C-2), 158.3 (C-8a), 167.3 (I '-C=O) and 
173.4 (4-C=O); m/z 395 (M+,10 %) and 149 (100). 
Note: 
When the reaction was run for 5 days using 6-chloro-3-(3-hydroxy-2-cyanopropen-3-
yl)-4H-1-benzopyran-4-one 213 (100 mg, 0.38 mmol), L-threonine methyl ester 
hydrochloride (129 mg, 0.76 mmol), TBAB (245 mg, 0.76 mmol) as the catalyst and 
sodium acetate (63 mg, 0.76 mmol) in EtOH (4 ml), work-up and purification afforded 
7 -methyl-2-methanol-(8-methyl)-6-{ 4H-1-benzopyran-4-on-3-yl-6-chloro} -5-cyano-6-
hydroxy-3-azahexanoate 272 as a brown oil (70 mg, 45%). 
3.6 HIV -1 Protease Inhibition Kinetics 
Enzyme inhibition studies were conducted using a Perkin Elmer Lambda 35 UVNis 
Spectrometer with HIV -1 protease and HIV protease Substrate III having the sequence:-
H-His-Lys-Ala-Arg-Val-Leu-Nitroph-Glu-Ala-Nli-Ser-NH2. The enzyme and substrate 
were purchased from Bachem AG and Biosciences (Philadelphia, USA), respectively, 
and were used without further purification. Glacial acetic acid, sodium acetate trihydrate, 
NaCl and glycerol were purchased from Saarchem or Merck, while 1 ,4-dithiothreitol 
(DTT) was obtained from Roche. 
3.6.1 HIV-1 Protease Linearity Assays 
A certain volume of assay buffer [50mM NaOAc, 200mM NaCl, 10% (v/v) glycerol, pH 
4.9, 5mM DTT] was added to a solution ofHIV substrate III (lOj..tL, 760j..tM) in a UV 
cuvette, followed by the addition of aliquots (0 to 1 Oj..tL) of an aqueous solution ofHIV-
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1 protease (3.8~M) which started the reaction. The assay buffer volumes were adjusted 
to give a constant total assay volume (411~L). The spectrophotometer was set to 
measure the decrease in absorbance at 300nm, at 5 min intervals, at 25°C. All of the 
HIV -1 protease linearity assays were carried out in duplicate. 
3. 6.2 HIV Protease Substrate III Dependence Assays 
An aqueous solution of HIV protease substrate III (0 to 40~L, 760~M) was added to a 
certain volume of assay buffer in a UV cuvette, followed by the addition of protease ( 4 
J..I.L, 3.8J..1.M) which started the reaction. The assay buffer volumes were adjusted to give a 
constant total assay volume (411J..I.L). The spectrophotometer was set to measure the 
decrease in absorbance at 300nm, at 5 min. intervals, at 25°C. All of the HIV -1 protease 
substrate dependence assays were carried out in triplicate. 
3. 6.3 Inhibition Assay using Chromone Derivatives 
An aqueous solution of HIV protease substrate III (1 O~L, 760~M) was mixed with 
varying volumes of a 254 ~M stock solution of the chromone derivative 258 in DMSO. 
Aliquots (16 ~L, 32 ~L, 35 ~L and 41 ~L) were added to a cetiain volume of assay 
buffer (adjusted to give a constant total assay volume of 411~L) in a UV cuvette, 
followed by an aqueous solution of HIV-1 protease (4 ~L, 3.8~M) to start the reaction. 
The buffer solution (411~L) was used as the blank and DMSO (40~L) was used as the 
control. The spectrophotometer was set to measure the decrease in absorbance at 300nm, 
at 5 min. intervals, at 25°C. Each assay was carried out in triplicate. Inhibition assays 
were also carried out using the same method for the chromone derivative 263 (0 - 40 ~L, 
303 ~M) and the chromone derivative 266 (lOjlL, 20jlLand 30jlL, 289!-lM). 
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3.6.4 Evaluation of K"" V max and K; 
The kinetic data obtained from the HIV -1 protease inhibition assays for the chromone 
derivatives 258, 263 and 266 were processed using the UV Kinlab software and the 
Grafit 5 programme was used to plot all the graphs. Lineweaver-Burk plots were 
constructed from the data to obtain the Michaelis constant (Km) and maximum initial 
velocity (V max) as well as to determine type of inhibition occurring in each case. Dixon 
plots were also constructed to determine the inhibition constants (Ki) of the specific 
inhibitors. 
The experimental data obtained from the above assays and used to plot the graphs in 
Figures 66 - are tabulated in the pages which follow. 
Data used for Figure 66. Linearity dependence Plot. 
Volume [HIV-1 PR] vo 
~L ~M units/minute 
0 0 0 
0 0 0 
2 0.018491 84.53164776 
2 0.018491 101.9501186 
4 0.036983 236.1262102 
4 0.036983 202.7072705 
6 0.055474 264.6157509 
6 0.055474 259.1745169 
8 0.073966 207.3544017 
8 0.073966 340.8836437 
10 0.092457 191.7226177 
10 0.092457 340.3877679 
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Data used for Figure 67a. Michaelis-Menten Plot 
Volume [HIV-1 PRJ vo 
J.!L J.!M units/minute 
0 0 0 
0 0 0 
0 0 0 
5 9.245742 76.62 
5 9.245742 94.68 
5 9.245742 86.76 
10 18.49148 124.62 
10 18.49148 124.62 
10 18.49148 126.48 
15 27.73723 155.34 
15 27.73723 142.26 
15 27.73723 160.38 
20 36.98297 195.3 
20 36.98297 178.26 
20 36.98297 192.54 
40 73.96594 225.06 
40 73.96594 226.08 
40 73.96594 256.44 
Data used for Figure 67b. Lineweaver-Burk Plot 
Volume [HIV-1 PRJ 1/ [HIV -1 PR] vo 1/vo 
J.!L J.!M J.!M-1 units/minute minute/ units 
0 0 - 0 2.229654 
0 0 - 0 1.80538 
0 0 - 0 217.3913 
5 9.245742 0.108158 76.62 7.830854 
5 9.245742 0.108158 94.68 6.337136 
5 9.245742 0.108158 86.76 6.915629 
10 18.49148 0.054079 124.62 4.814636 
10 18.49148 0.054079 124.62 4.8 14636 
10 18.49148 0.054079 126.48 4.743833 
15 27.73723 0.036053 155.34 3.862495 
15 27.73723 0.036053 142.26 4.21763 
15 27.73723 0.036053 160.38 3.741115 
20 36.98297 0.027039 195.3 3.072197 
20 36.98297 0.027039 178.26 3.36587 
20 36.98297 0.027039 192.54 3.116236 
40 73.96594 0.01352 225.06 2.665956 
40 73 .96594 0.01352 226.08 2.653928 
40 73.96594 0.01352 256.44 2.339729 
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Data used for Figure 67c. Hanes-WoolfPlot 
Volume [HIV-1 PRJ va [HIV-1 PRJ I vo 
J.tL J.tM units/minute J,tM.minute.units·1 
0 0 0 -
0 0 0 -
0 0 0 -
5 9.245742 76.62 0.12067 
5 9.245742 94.68 0.097653 
5 9.245742 86.76 0.106567 
10 18.49148 124.62 0.148383 
10 18.49148 124.62 0.148383 
10 18.49148 126.48 0.146201 
15 27.73723 155.34 0.178558 
15 27.73723 142.26 0.194976 
15 27.73723 160.38 0.172947 
20 36.98297 195.3 0.189365 
20 36.98297 178.26 0.207466 
20 36.98297 192.54 0.192079 
40 73.96594 225.06 0.32865 
40 73 .96594 226.08 0.327167 
40 73.96594 256.44 0.288434 
Data used for Figures 68 a and b 
[Compound 252J Enzyme Enzyme [Compound 260J Enzyme Enzyme 
J.tM Activity Activity J.tM Activity Activity 
units/min. (%) units/min. (%) 
0 0.0027 100 0 0.0015 100 
0 0.0022 100 0 0.0015 100 
0 0.0025 100 0 0.0016 100 
19.78 0.0016 59.26 3.52 0.0013 83.85 
19.78 0.0016 59.26 3.52 0.0013 84.21 
19.78 0.0014 51.85 3.52 0.0014 88.15 
22.25 0.0013 48.15 7.03 0.0014 73.48 
22.25 0.0011 40.74 7.03 0.0010 68.15 
24.72 0.0013 48.15 7.03 0.0011 69.38 
24.72 0.0016 59.26 10.88 0.0012 79.25 
24.72 0.0013 48.15 10.88 0.00 I 1 70.43 
25.96 0.0009 33.33 10.88 0.0010 65.09 
25.96 0.0013 48.15 14.50 0.0010 64.20 
25.96 0.0013 48.15 14.50 0.0008 52.08 
29.05 0.0009 33.33 14.50 0.0008 51.89 
29.05 0.0006 33.33 18.13 0.0007 47.60 
29.05 0.0013 22.22 18.13 0.0007 47.45 
32.75 0.0009 48.15 18.13 0.0009 58.36 
32.75 0.0007 33.33 21.75 0.0008 52.53 
32.75 0.0007 25.93 21.75 0.0007 48.19 
37.08 0.0008 25.93 21.75 0.0007 47.09 
37.08 0.0011 40.74 29.00 0.00038 25.16 
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37.08 0.00012 4.44 29.00 0.0002 13.44 
29.00 0.0002 11.47 
36.25 0.0009 57.26 
36.25 62.43 
Data used for Figure 69a. Lineweaver-Burk plot when [chromone derivative 252] is 
011M 
1/ [HIV -1 PR substrate III] vo 1/vo 
!J.M-1 units/minute minute/units 
0.00 8.1291142 0.1230146 
0.108158 85.374339 0.0117131 
0.054079 125.23389 0.0079851 
0.036053 152.26829 0.0065674 
0.027039 188.3968 0.0053079 
0.01 352 234.99884 0.0042553 
Data used for Figure 69a. Lineweaver-Burk plot when [chromone derivative 252] is 
101-f.M 
1/ [HIV -1 PR substrate III] vo llvo 
!J.M-1 units/minute minute/units 
0.00 3.723309 0.268578 
0.108158 66.1032 0.01 5128 
0.054079 116.1418 0.00861 
0.036053 108.1852 0.009243 
0.027039 167.236 0.00598 
0.01352 186.0281 0.005376 
Data used for Figure 69a. Lineweaver-Burk plot when [chromone derivative 252] is 
221-f.M 
II [HIV -1 PR substrate III] vo 1/vo 
1-lM-1 units/minute minute/units 
0.00 40.80228 0.024508 
0.108158 42.36827 0.023603 
0.054079 64.65627 0.015466 
0.036053 129.7364 0.007708 
0.027039 107.1587 0.010835 
0.01352 92.29456 0.009332 
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Data used for Figure 69b. Dixon plot 
[ chromone derivative 252] 1/vo llvo 
llM-1 minute/units minute/units 
when [substrate] is when [substrate] is 
9.25JlM 18.251-lM 
0.00 0.01 0.01 
10.00 0.15 0.09 
20.00 0.16 0.09 
22.00 0.24 0.15 
25.00 0.25 0.15 
Data used for Figure 70a. Lineweaver-Burk plot when [chromone derivative 260] is 
011M 
11 [HIV -1 PR substrate III] vo 1/vo 
llM-1 units/minute minute/units 
0.00 8.1291142 0.1230146 
0.108158 85.374339 0.0117131 
0.054079 125.23389 0.0079851 
0.036053 152.26829 0.0065674 
0.027039 188.3968 0.0053079 
0.01352 234.99884 0.0042553 
Data used for Figure 70a. Lineweaver-Burk plot when [ chromone derivative 260] is 
7.03!lM 
1/ [HIV-1 PR substrate III] vo 1/vo 
llM-1 units/minute minute/units 
0.00 2.478043 0.403544 
0.108158 42.15914 0.02372 
0.054079 71.93778 0.013901 
0.036053 88.91899 0.011246 
0.027039 101.1136 0.00989 
0.01352 128.7195 0.007769 
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Data used for Figure 70a. Lineweaver-Burk plot when [chromone derivative 260] is 
14.5~M 
11 [HIV -1 PR substrate III] vo 1/vo 
~M-1 units/minute minute/units 
0.00 7.40171 0.135104 
0.108158 49.96784 0.02001 3 
0.054079 I 01.4901 0.009853 
0.036053 95.60087 0.01046 
0.027039 II 0.0482 0.009087 
0.01352 
Data used for Figure 70b. Dixon plot 
[chromone derivative 260] llvo l lvo 
~M-1 minute/units minute/units 
when [substrate] is when [substrate] is 
18.49~M 27.73~M 
0.00 0.010347 0.006009 
7.03 0.013901 0.011246 
14.5 0.009853 0.01046 
21.75 0.036977 0.017709 
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3. 7 Computer Modelling 
Molecular modelling was performed on a Silicon Graphics 0 2 work-station using the 
CERIUS2 version 4.5 modelling platform; the Drieding force field was used for energy 
minimization and the LigandFit module was used to explore the interactions between the 
HIV -1 protease receptor cavity and the synthetic inhibitors during docking. 
The binding energies (kcal.mor1) for each of the twenty conformers of compounds 2, 
222, 222, 241, 258, 260, 266, 269, 272 and 274 that were scored in the HIV-1 protease 
t "t t b 1 t db 1 recep1 or cav1 y, are au a e eow. 
No. of Comp. Comp. Comp. Comp. Comp. Comp. Comp. 
222 245 263 266 269 272 274 
score 
1 252.2 204.7 156.4 155.2 160.3 139.9 156.1 
2 243.8 203.2 154.8 140.4 133.0 108.1 154.4 
3 241.9 197.5 119.7 114.3 117.8 83.3 153.0 
4 240.8 193.3 116.2 103.1 104.1 81.9 152.7 
5 234.3 191.3 114.9 97.9 103.0 70.0 152.4 
6 222.6 188.9 109.3 90.4 88.3 69.7 149.7 
7 222.3 186.0 108.7 89.6 84.2 60.0 145.6 
8 218.4 179.1 108.0 87.6 83.7 57.5 141.6 
9 213.2 174.7 107.6 83.2 79.7 57.3 140.5 
10 198.1 163.9 105.3 76.8 78.4 54.9 140.1 
11 195.9 160.7 105.0 74.1 78.1 48.3 139.8 
12 190.9 150.2 103.8 71.6 77.4 45.1 137.0 
13 184.2 141.8 101.9 71.1 69.6 40.5 135.2 
14 181.0 136.3 101.8 70.8 67.5 36.6 133.9 
15 169.1 131.3 99.4 69.9 60.2 36.4 133.7 
16 165.8 115.1 97.3 69.7 58.6 34.9 133.5 
17 149.3 106.3 93.4 66.7 55.1 32.4 132.3 
18 128.3 88.8 93.0 65. 1 53.9 31.3 131.4 
19 127.4 76.5 90.2 64.1 48.8 29.6 131.3 
20 97.2 61.6 87.8 60.9 46.7 29.5 129.4 
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3.8 CHEMICAL KINETIC STUDIES 
1H-NMR spectroscopic data, obtained on a Bruker Avance 400MHz spectrometer, at 
298K, were used for the kinetic studies. Reactants were weighed and then transferred 
into 1ml graduated NMR tube in the order: 3-methoxy-2-nitrobenzaldehyde, 
trimethoxybenzene (TMB), DABCO and, finally, CDCl). The resulting mixture was 
allowed to dissolve completely which normally takes about 5min, and the methyl vinyl 
ketone (MVK) was then added to increase the volume of the solution to 1.0 mL. The 
resulting sample was then placed in the NMR spectrometer to run the first spectrum; 
subsequent spectra were run at 1 Omin intervals for a period of 14 hours. 
The experimental procedures for each of these four aryl aldehydes examined reaction 
mixtures were as follows: 
1. Methyl vinyl ketone (0.370 mL, 4.44 mmol) was added to a solution of 3-methoxy-2-
nitrobenzaldehyde (0.119 g, 0.657 mmol), trimethoxybenzene (0.0172 g, 0.105 mmol), 
DABCO (0.0353 g, 0.315 mmol) and CDCh (0.53rnL,). The reaction mixture was 
placed in the NMR and allowed to run for 14hours. The data obtained was converted 
into concentration using the trimethoxybenzene (TMB) as the standard. The results 
obtained gave linear first-order plot with respect to 3-methoxy-2-nitrobenzaldehyde and 
second-order plot with respect to MVK, the entire reaction was found to be pseudo 
second -order. 
2. The procedure used in experiment 1 was followed using: 3-methoxy-2-
nitrobenzaldehyde (0.238 g, 1.11 mmol), trimethoxybenzene (0.014g, 0.0832mmol), 
DABCO (0.0366g, 0.326mmol), CDCb (0.53mL) and MVK (0.37mL, 4.44 mmol) to 
make the total volume of 1 rnL. The results obtained gave linear first-order plot with 
respect to 3-methoxy-2-nitrobenzaldehyde and second-order plot with respect to MVK, 
the entire reaction was found to be pseudo second-order. 
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3. The procedure used in experiment 1 was followed usmg: 3-methoxy-2-
nitrobenzaldehyde (0.119g, 0.657 mmol), trimethoxybenzene (0.014g, 0.0832mmol), 
DABCO (0.0366g, 0.326mmol), CDCb (0.16mL) and MVK (0.74mL, 8.89 mmol) to 
make the total volume of 1 mL. The results obtained gave linear first-order plot with 
respect to 3-methoxy-2-nitrobenzaldehyde and second-order plot with respect to MVK, 
the entire reaction was found to be pseudo second-order. 
4. The procedure used m experiment 1 was followed usmg: 2-chloro-6-
nitrobenzaldehyde (0.101g, 0.544mmol), trimethoxybenzene (0.0126g, 0.0749mmol), 
DABCO (0.0316g, 0.282mmol), CDCb (0.53mL) and MVK (0.37mL, 4.44 mmol) to 
make the total volume of 1 mL. The results obtained gave linear first-order plot with 
respect to 3-methoxy-2-nitrobenzaldehyde and second-order plot with respect to MVK, 
the entire reaction was found to be pseudo second-order. 
5. The procedure used m experiment 1 was followed usmg: 5-chloro-6-
nitrobenzaldehyde (0.101g, 0.545mmol), trimethoxybenzene (0.0126g, 0.0749mmol), 
DABCO (0.0320g, 0.285mmol), CDCb (0.53mL) and MVK (0.37mL, 4.44 mmol) to 
make the total volume of 1 mL. The results obtained gave linear first-order plot with 
respect to 3-methoxy-2-nitrobenzaldehyde and second-order plot with respect to MVK, 
the entire reaction was found to be pseudo second-order. 
6. The procedure used in experiment 1 was followed usmg: 4-nitrobenzaldehyde 
(0.102g, 0.672mmol), trimethoxybenzene (0.0193g, 0.0115mmol), DABCO (0.0375g, 
0.334mmol), CDCh (0.53mL) and MVK (0.37mL, 4.44 mmol) to make the total volume 
of 1 mL. The results obtained gave linear first-order plot with respect to 3-methoxy-2-
nitrobenzaldehyde and second-order plot with respect to MVK, the entire reaction was 
found to be pseudo second-order. 
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The experimenta data obtained from NMR studies and used to plot the graphs in Figures 
106 - 116 and for the determination of rate constants for compounds 275a, 275f, 280 and 
281 are tabulated below. 
Data used for Figures 108, 110 and 112 
time [A] [B] [E] [F]syn [F]anti [H] [R] + [P] 
sec. M M M M M M M 
0 0.7305 4.9387 0.0000 0.0000 0.0000 0.0000 0.7305 
420 0.48 14 3.7800 0.0469 0.0574 0.0969 0.0174 0.7831 
1051 0.3930 3.6672 0.0682 0.0969 0.1043 0.0343 0.7970 
1684 0.3104 3.5765 0.0973 0.1209 0.0984 0.0375 0.7854 
2316 0.2360 3.3521 0.1085 0.1399 0.1008 0.0497 0.7598 
2953 0.1942 3.4102 0.1267 0.1593 0.1070 0.0718 0.7837 
3584 0.1546 3.3707 0.1337 0.1701 0.1085 0.0727 0.7732 
4217 0.1174 3.3358 0.13 10 0.1856 0.1136 0.0826 0.7627 
4848 0.0872 3.2765 0.1500 0.1949 0.1163 0.0921 0.7790 
5481 0.0674 3.3544 0.1546 0.1973 0.1112 0.1064 0.7622 
6113 0.0535 3.1288 0.1546 0.2015 0.1174 0.1148 0.7639 
6746 0.0233 3.1602 0.1546 0.2019 0.1263 0.1256 0.7476 
7378 0.0233 3.0835 0.1543 0.2093 0.1333 0.1267 0.7685 
8010 0.0105 3.0719 0.1554 0.2035 0.1260 0.1401 0.7377 
8644 0.0000 2.8556 0.1581 0.2147 0.1325 0.1503 0.7581 
9277 0.0000 2.9254 0.1597 0.2182 0.1368 0.1692 0.7720 
9910 0.0000 2.9137 0.1608 0.2136 0.1364 0.1686 0.7662 
10543 0.0000 2.9544 0.1570 0.2147 0.1457 0.1866 0.7761 
11176 0.0000 2.7963 0.1558 0.2136 0.1411 0.1886 0.7656 
11809 0.0000 2.9230 0.1535 0.2147 0.1422 0.1916 0.7656 
12442 0.0000 2.9463 0.1597 0.2174 0.1411 0.2093 0.7773 
13076 0.0000 2.9219 0.1543 0.2190 0.1453 0.2154 0.7779 
13709 0.0000 2.8242 0.1492 0.2104 0.1535 0.2244 0.7697 
14343 0.0000 2.8033 0.1496 0.2186 0.1481 0.2317 0.7744 
14974 0.0000 2.8265 0.1438 0.2070 0.1558 0.2357 0.7598 
15607 0.0000 2.7742 0.1461 0.2112 0.1593 0.2453 0.7749 
16240 0.0000 2.7742 0.1422 0.2104 0.1601 0.2535 0.7691 
16873 0.0000 2.7184 0.1446 0.2136 0.1647 0.2610 0.7842 
17505 0.0000 2.7033 0.1395 0.2101 0.1659 0.2651 0.7732 
18138 0.0000 2.7754 0.1384 0.2120 0.1744 0.2793 0.7872 
18772 0.0000 2.6928 0.1426 0.2093 0.1709 0.2825 0.7842 
19406 0.0000 2.6859 0.1349 0.2108 0.1732 0.2892 0.7784 
20039 0.0000 2.6138 0.1302 0.2116 0.1806 0.3003 0.7837 
0.0000 
260 
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20672 0.0000 2.5766 0.1353 0.2042 0.1756 0.3035 0.7726 
21305 0.0000 2.7149 0.1329 0.2089 0.1802 0.3119 0.7831 
21937 0.0000 2.6103 0.1298 0.2035 0.1818 0.3200 0.7726 
22571 0.0000 2.5963 0.1298 0.2062 0.1845 0.3293 0.7808 
23204 0.0000 2.5905 0.1287 0.2066 0.1829 0.3282 0.7773 
23836 0.0000 2.5940 0.1267 0.1996 0.1899 0.3535 0.7744 
24470 0.0000 2.5731 0.1178 0.2062 0.1907 0.3471 0.7720 
25103 0.0000 2.5638 0.1205 0.2073 0.1887 0.3622 0.7749 
25737 0.0000 2.5417 0.1186 0.1957 0.1934 0.3712 0.7616 
26370 0.0000 2.5091 0.1201 0.2031 0.1977 0.3741 0.7813 
27003 0.0000 2.5126 0.1232 0.2062 0.2000 0.3628 0.7941 
27635 0.0000 2.4894 0.1186 0.2019 0.1980 0.3817 0.7779 
28267 0.0000 2.4463 0.1163 0.2054 0.1992 0.3901 0.7813 
28867 0.0000 2.4545 0.1085 0.2031 0.2097 0.3982 0.7819 
29533 0.0000 2.4173 0.1167 0.2027 0.2077 0.4043 0.7906 
30167 0.0000 2.4266 0.1136 0.2035 0.2066 0.4084 0.7854 
30799 0.0000 2.3394 0.1 132 0.2035 0.2128 0.4194 0.7941 
31434 0.0000 2.4138 0.1139 0.2019 0.2124 0.4200 0.7924 
32066 0.0000 2.4115 0.1105 0.2023 0.2201 0.4264 0.7994 
32700 0.0000 2.3812 0.1116 0.2004 0.2186 0.4276 0.7959 
33333 0.0000 2.3975 0.1112 0.201 5 0.2198 0.4357 0.7988 
33966 0.0000 2.3417 0.1039 0.2042 0.2170 0.4427 0.7877 
34599 0.0000 2.3696 0.1046 0.2008 0.2236 0.4442 0.7935 
35231 0.0000 2.2975 0.1008 0.1988 0.2178 0.4549 0.7761 
35865 0.0000 2.3231 0.1050 0.1992 0.2182 0.4587 0.7837 
36497 0.0000 2.2754 0.1050 0.1969 0.2244 0.4662 0.7895 
37131 0.0000 2.2696 0.1015 0.1980 0.2248 0.4535 0.7866 
37764 0.0000 2.2696 0.1043 0.2050 0.2314 0.4753 0.8110 
38397 0.0000 2.2545 0.1039 0.1922 0.2314 0.4808 0.7912 
39030 0.0000 2.2557 0.0992 0.1949 0.2302 0.4715 0.7866 
39662 0.0000 2.1998 0.0992 0.1996 0.2376 0.4933 0.8046 
40295 0.0000 2.1894 0.0973 0.2011 0.2372 0.5005 0.8034 
40929 0.0000 2.2301 0.0853 0.1996 0.2418 0.4988 0.7901 
41563 0.0000 2.1638 0.0969 0.1973 0.2380 0.5020 0.7982 
42197 0.0000 2.1010 0.0942 0.1957 0.2395 0.5066 0.7941 
42831 0.0000 2.1487 0.0942 0.1965 0.2407 0.4982 0.7970 
43465 0.0000 2.0998 0.0915 0.1973 0.2426 0.5017 0.7970 
44099 0.0000 2.1138 0.0903 0.1938 0.2426 0.5035 0.7901 
44733 0.0000 2.1150 0.0934 0.1980 0.2446 0.5142 0.8040 
45367 0.0000 2.0405 0.0810 0.1965 0.2442 0.5235 0.7825 
46001 0.0000 2.0743 0.0868 0.1930 0.2477 0.5255 0.7912 
46635 0.0000 2.0650 0.0857 0.1965 0.2511 0.5409 0.7999 
47269 0.0000 2.0394 0.0868 0.1946 0.2477 0.5284 0.7935 
47903 0.0000 2.0533 0.0895 0.1922 0.2496 0.5296 0.7970 
48537 0.0000 2.0603 0.0864 0.2008 0.2577 0.5459 0.8174 
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49171 0.0000 2.0405 0.0864 0.1949 0.2542 0.5337 0.8034 
49805 0.0000 2.0068 0.0868 0.1930 0.2573 0.5607 0.8058 
50439 0.0000 1.9975 0.0822 0.1806 0.2558 0.5505 0.7779 
51073 0.0000 2.1801 0.0814 0.2004 0.2554 0.5636 0.8058 
51707 0.0000 1.9929 0.0779 0.1946 0.2612 0.5572 0.8005 
52341 0.0000 1.9092 0.0826 0.1810 0.2608 0.5700 0.7866 
52975 1.9557 0.0818 0.1926 0.2581 0.5689 0.7988 
D t a a use or Igure 106 d 107 an 
Uncorrected Corrected [A] (M) -In[ A] -In[ A] 
time (s) time (s) Exp. Calc. 
0 0 0.7305 0.3140 0.3138 
631 420 0.4814 0.7311 0.5130 
1051 1051 0.3930 0.9340 0.8123 
1684 1684 0.3104 1.1698 1.1126 
2316 2316 0.2360 1.4438 1.4123 
2953 2953 0.1942 1.6390 1.7145 
3584 3584 0.1546 1.8667 2.0138 
4217 4217 0.1174 2.1419 2.3141 
4848 4848 0.0872 2.4395 2.6134 
5481 5481 0.0674 2.6966 2.9136 
6113 6113 0.0535 2.9284 3.2134 
6746 6746 0.0233 3.7613 3.5137 
7378 7378 0.0233 3.7613 3.8134 
8010 8010 0.0105 4.5598 4.1132 
D t a a use or 1gure 109 
time (s) [E] (M) [Ecorr] (M) [E] - [E]moct (M) 
0 0.0000 0.2570 0.0000 
420 0.0469 0.2559 0.0715 
1051 0.0682 0.2542 0.1052 
1684 0.0973 0.2524 0.1505 
2316 0.1085 0.2507 0.1691 
2953 0.1267 0.2490 0.1982 
3584 0.1337 0.2472 0.2104 
4217 0.1310 0.2455 0.2080 
4848 0.1500 0.2438 0.2382 
5481 0.1546 0.2421 0.2469 
6113 0.1546 0.2403 0.2487 
6746 0.1546 0.2386 0.2504 
7378 0.1543 0.2369 0.2515 
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8010 0.1554 0.2352 0.2550 
8644 0.1581 0.2334 0.2608 
9277 0.1597 0.2317 0.2649 
9910 0.1608 0.2300 0.2683 
10543 0.1570 0.2282 0.2643 
11176 0.1558 0.2265 0.2642 
11809 0.1535 0.2248 0.2625 
12442 0.1597 0.2230 0.2735 
13076 0.1543 0.2213 0.2671 
13709 0.1492 0.2196 0.2613 
14343 0.1496 0.2179 0.2636 
14974 0.1438 0.2161 0.2566 
15607 0.1461 0.2144 0.2618 
16240 0.1422 0.2127 0.2577 
16873 0.1446 0.2109 0.2629 
17505 0.1395 0.2092 0.2571 
18138 0.1384 0.2075 0.2571 
18772 0.1426 0.2058 0.2652 
19406 0.1349 0.2040 0.2553 
20039 0.1302 0.2023 0.2501 
20672 0.1353 0.2006 0.2594 
21305 0.1329 0.1988 0.2576 
21937 0.1298 0.1971 0.2547 
22571 0.1298 0.1954 0.2564 
23204 0.1287 0.1936 0.2564 
23836 0.1267 0.1919 0.2552 
24470 0.1178 0.1902 0.2436 
25103 0.1205 0.1885 0.2494 
25737 0.1186 0.1867 0.2482 
26370 0.1201 0.1850 0.2523 
27003 0.1232 0.1833 0.2586 
27635 0.1186 0.1815 0.2534 
28267 0.1163 0.1798 0.2516 
28867 0.1085 0.1782 0.2416 
29533 0.1167 0.1764 0.2557 
30167 0.1136 0.1746 0.2528 
30799 0.1132 0.1729 0.2539 
31434 0.1139 0.1712 0.2568 
32066 0.1105 0.1694 0.2533 
32700 0.1116 0.1677 0.2568 
33333 0.1112 0.1660 0.2579 
33966 0.1039 0.1642 0.2486 
34599 0.1046 0.1625 0.2515 
35231 0.1008 0.1608 0.2474 
35865 0.1050 0.1591 0.2555 
263 
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36497 0.1050 0.1573 0.2573 
37131 0.1015 0.1556 0.2538 
37764 0.1043 0.1539 0.2596 
38397 0.1039 0.1521 0.2607 
39030 0.0992 0.1504 0.2555 
39662 0.0992 0.1487 0.2572 
40295 0.0973 0.1469 0.2560 
40929 0.0853 0.1452 0.2397 
41563 0.0969 0.1435 0.2589 
42197 0.0942 0.1418 0.2566 
42831 0.0942 0.1400 0.2583 
43465 0.0915 0.1383 0.2560 
44099 0.0903 0.1366 0.2559 
44733 0.0934 0.1348 0.2623 
45367 0.0810 0.1331 0.2455 
46001 0.0868 0.1314 0.2559 
46635 0.0857 0.1296 0.2559 
47269 0.0868 0.1279 0.2594 
47903 0.0895 0.1262 0.2652 
48537 0.0864 0.1244 0.2623 
49171 0.0864 0.1227 0.2640 
49805 0.0868 0.1210 0.2663 
50439 0.0822 0.1192 0.2611 
51073 0.0814 0.1175 0.2616 
51707 0.0779 0.1158 0.2581 
52341 0.0826 0.1140 0.2668 
52975 0.0818 0.1123 0.2674 
E = [Ecorr] initial - [Ecorr ]final 
D ata use or 1gures 113 d 114 an 
time [E] (M) [F]syn (M) [F]anti (M) [F]tot(M) (F]tot - [E] (M) 
sec. 
0 0.0000 0.0000 0.0000 0.0000 0.0000 
420 0.0469 0.0574 0.0969 0.2314 0.1610 
1051 0.0682 0.0969 0.1043 0.3017 0.1994 
1684 0.0973 0.1209 0.0984 0.3290 0.1831 
2316 0.1085 0.1399 0.1008 0.3610 0.1982 
2953 0.1267 0.1593 0.1070 0.3994 0.2093 
3584 0.1337 0.1701 0.1085 0.4180 0.2174 
4217 0.1310 0.1856 0.1136 0.4488 0.2523 
4848 0.1500 0.1949 0.1163 0.4668 0.2418 
5481 0.1546 0.1973 0.1112 0.4628 0.2308 
6113 0.1546 0.2015 0.1174 0.4785 0.2465 
6746 0.1546 0.2019 0.1263 0.4924 0.2604 
7378 0.1543 0.2093 0.1333 0.5139 0.2825 
264 
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8010 0.1554 0.2035 0.1260 0.4942 0.2610 
8644 0.1581 0.2147 0.1325 0.5209 0.2837 
9277 0.1597 0.2182 0.1368 0.5325 0.2930 
9910 0.1608 0.2136 0.1364 0.5250 0.2837 
10543 0.1570 0.2147 0.1457 0.5407 0.3052 
11176 0.1558 0.2136 0.1411 0.5319 0.2982 
11809 0.1535 0.2147 0.1422 0.5354 0.3052 
12442 0.1597 0.2174 0.1411 0.5378 0.2982 
13076 0.1543 0.2190 0.1453 0.5465 0.3151 
13709 0.1492 0.2104 0.1535 0.5459 0.3221 
14343 0.1496 0.2186 0.1481 0.5500 0.3256 
14974 0.1438 0.2070 0.1558 0.5441 0.3285 
15607 0.1461 0.2112 0.1593 0.5558 0.3366 
16240 0.1422 0.2104 0.1601 0.5558 0.3424 
16873 0.1446 0.2136 0.1647 0.5674 0.3506 
17505 0.1395 0.2101 0.1659 0.5639 0.3546 
18138 0.1384 0.2120 0.1744 0.5796 0.3721 
18772 0.1426 0.2093 0.1709 0.5703 0.3564 
19406 0.1349 0.2108 0.1732 0.5761 0.3738 
20039 0.1302 0.2116 0.1806 0.5883 0.3930 
20672 0.1353 0.2042 0.1756 0.5697 0.3668 
21305 0.1329 0.2089 0.1802 0.5837 0.3843 
21937 0.1298 0.2035 0.1818 0.5779 0.3831 
22571 0.1298 0.2062 0.1845 0.5860 0.3913 
23204 0.1287 0.2066 0.1829 0.5843 0.3913 
23836 0.1267 0.1996 0.1899 0.5843 0.3942 
24470 0.1178 0.2062 0.1907 0.5953 0.4186 
25103 0.1205 0.2073 0.1887 0.5941 0.4133 
25737 0.1186 0.1957 0.1934 0.5837 0.4058 
26370 0.1201 0.2031 0.1977 0.6011 0.4209 
27003 0.1232 0.2062 0.2000 0.6093 0.4244 
27635 0.1186 0.2019 0.1980 0.6000 0.4221 
28267 0.1163 0.2054 0.1992 0.6069 0.4325 
28867 0.1085 0.2031 0.2097 0.6191 0.4564 
29533 0.1167 0.2027 0.2077 0.6157 0.4407 
30167 0.1136 0.2035 0.2066 0.6151 0.4447 
30799 0.11 32 0.2035 0.2128 0.6244 0.4546 
31434 0.1139 0.2019 0.2124 0.6215 0.4505 
32066 0.1105 0.2023 0.2201 0.6337 0.4680 
32700 0.1116 0.2004 0.2186 0.6284 0.4610 
33333 0.1112 0.2015 0.2198 0.6319 0.4651 
33966 0.1039 0.2042 0.2170 0.6319 0.4761 
34599 0.1046 0.2008 0.2236 0.6366 0.4796 
35231 0.1008 0.1988 0.2178 0.6250 0.4738 
35865 0.1050 0.1992 0.2182 0.6261 0.4686 
265 
E t 1 xpenmen a 
36497 0.1050 0.1969 0.2244 0.6319 0.4744 
37131 0.1015 0.1980 0.2248 0.6343 0.4819 
37764 0.1043 0.2050 0.2314 0.6546 0.4982 
38397 0.1039 0.1922 0.2314 0.6354 0.4796 
39030 0.0992 0.1949 0.2302 0.6377 0.4889 
39662 0.0992 0.1996 0.2376 0.6558 0.5069 
40295 0.0973 0.2011 0.2372 0.6575 0.5116 
40929 0.0853 0.1996 0.2418 0.6622 0.5343 
41563 0.0969 0.1973 0.2380 0.6529 0.5075 
42197 0.0942 0.1957 0.2395 0.6529 0.5116 
42831 0.0942 0.1965 0.2407 0.6558 0.5145 
43465 0.0915 0.1973 0.2426 0.6598 0.5226 
44099 0.0903 0.1938 0.2426 0.6546 0.5191 
44733 0.0934 0.1980 0.2446 0.6639 0.5238 
45367 0.0810 0.1965 0.2442 0.6610 0.5395 
46001 0.0868 0.1930 0.2477 0.6610 0.5308 
46635 0.0857 0.1965 0.2511 0.6715 0.5430 
47269 0.0868 0.1946 0.2477 0.6633 0.5331 
47903 0.0895 0.1922 0.2496 0.6627 0.5284 
48537 0.0864 0.2008 0.2577 0.6877 0.5581 
49171 0.0864 0.1949 0.2542 0.6738 0.5441 
49805 0.0868 0.1930 0.2573 0.6755 0.5453 
50439 0.0822 0.1806 0.2558 0.6546 0.5314 
51073 0.0814 0.2004 0.2554 0.6837 0.5616 
51707 0.0779 0.1946 0.2612 0.6837 0.5668 
52341 0.0826 0.1810 0.2608 0.6627 0.5389 
52975 0.0818 0.1926 0.2581 0.6761 0.5534 
D t a a use d f F. or 1gure 115 
time [B] (M) 1/[B] (M-1) 
sec. 
0 4.9387 0.2025 
420 3.7800 0.2646 
1051 3.6672 0.2727 
1684 3.5765 0.2796 
2316 3.3521 0.2983 
2953 3.4102 0.2932 
3584 3.3707 0.2967 
4217 3.3358 0.2998 
4848 3.2765 0.3052 
5481 3.3544 0.2981 
6113 3.1288 0.3196 
6746 3.1602 0.3164 
266 
E xpenmenta 
7378 3.0835 0.3243 
8010 3.0719 0.3255 
8644 2.8556 0.3502 
9277 2.9254 0.3418 
9910 2.9137 0.3432 
10543 2.9544 0.3385 
11176 2.7963 0.3576 
11809 2.9230 0.3421 
12442 2.9463 0.3394 
13076 2.9219 0.3422 
13709 2.8242 0.3541 
14343 2.8033 0.3567 
14974 2.8265 0.3538 
15607 2.7742 0.3605 
16240 2.7742 0.3605 
16873 2.7184 0.3679 
17505 2.7033 0.3699 
18138 2.7754 0.3603 
18772 2.6928 0.3714 
19406 2.6859 0.3723 
20039 2.6138 0.3826 
20672 2.5766 0.3881 
21305 2.7149 0.3683 
21937 2.6103 0.3831 
22571 2.5963 0.3852 
23204 2.5905 0.3860 
23836 2.5940 0.3855 
24470 2.5731 0.3886 
25103 2.5638 0.3901 
25737 2.5417 0.3934 
26370 2.5091 0.3985 
27003 2.5126 0.3980 
27635 2.4894 0.4017 
28267 2.4463 0.4088 
28867 2.4545 0.4074 
29533 2.4173 0.4137 
30167 2.4266 0.4121 
30799 2.3394 0.4275 
31434 2.4138 0.4143 
32066 2.4115 0.4147 
32700 2.3812 0.4200 
33333 2.3975 0.4171 
33966 2.3417 0.4270 
34599 2.3696 0.4220 
35231 2.2975 0.4353 
267 
E al xpenment 
35865 2.3231 0.4305 
36497 2.2754 0.4395 
37131 2.2696 0.4406 
37764 2.2696 0.4406 
38397 2.2545 0.4436 
39030 2.2557 0.4433 
39662 2.1998 0.4546 
40295 2.1894 0.4568 
40929 2.2301 0.4484 
41563 2.1638 0.4622 
42197 2.1010 0.4760 
42831 2.1487 0.4654 
43465 2.0998 0.4762 
44099 2.1138 0.4731 
44733 2.1150 0.4728 
45367 2.0405 0.4901 
46001 2.0743 0.4821 
46635 2.0650 0.4843 
47269 2.0394 0.4903 
47903 2.0533 0.4870 
48537 2.0603 0.4854 
49171 2.0405 0.4901 
49805 2.0068 0.4983 
50439 1.9975 0.5006 
51073 2.1801 0.4587 
51707 1.9929 0.5018 
52341 1.9092 0.5238 
52975 1.9557 0.5113 
Data for the reaction of 4-nitrobenzaldehyde 275a. 
time [A] [Flanti [B] [F]syn [E] [H] ln[A] 
sec. (M) (M) (M) (M) (M) (M) 
0 0.7470 0.0000 4.8052 0.0000 0.0000 0.0000 0.2916 
420 0.3066 0.1526 4.3652 0.0122 0.1004 0.0008 1.1821 
636 0.1934 0.1532 4.2344 0.0111 0.1371 0.0028 1.6428 
1273 0.1273 0.1607 4.2392 0.0180 0.1620 0.0033 2.0610 
1910 0.0834 0.1649 4.1046 0.0183 0.1768 0.0150 2.4836 
2546 0.0561 0.1687 4.0148 0.0153 0.1860 0.0239 2.8797 
3181 0.0386 0.1683 3.9369 0.0081 0.1888 0.0204 3.2537 
3817 0.0270 0.1737 3.8916 0.0178 0.1960 0.0378 3.6112 
4453 0.0194 0.1784 3.8465 0.0164 0.2016 0.0436 3.9448 
5089 0.0139 0.1851 3.8090 0.0209 0.2055 0.0579 4.2772 
5725 0.0099 0.1888 3.7016 0.0208 0.2069 0.0660 4 .6122 
6361 0.0076 0.1925 3.7047 0.0304 0.2081 0.0826 4.8759 
6996 0.0059 0.1 996 3.6622 0.0305 0.2106 0.0922 5.1363 
268 
E tal xpenmen 
7633 0.0044 0.2036 3.5787 0.0374 0.2087 0.1045 5.4306 
8269 0.0038 0.2053 3.5363 0.0414 0.2068 0.1124 5.5655 
8905 0.0034 0.2103 3.4978 0.0475 0.2050 0.1233 5.6937 
9540 0.0028 0.2187 3.5029 0.0539 0.2078 0.1316 5.8623 
10177 0.0026 0.2201 3.4548 0.0621 0.2030 0.1459 5.9369 
10813 0.0024 0.2313 3.4902 0.0688 0.2072 0.1589 6.0348 
11450 0.0023 0.2305 3.3960 0.0741 0.2016 0.1639 6.0790 
12085 0.0021 0.2332 3.3360 0.0795 0.1995 0.1720 6.1750 
12721 0.0018 0.2419 3.3355 0.0879 0.2042 0.1876 6.3238 
13357 0.0020 0.2452 3.3309 0.0915 0.2002 0.1957 6.1914 
13992 0.0021 0.2507 3.3076 0.0955 0.1993 0.2068 6.1821 
14628 0.0020 0.2517 3.2388 0.1020 0.1947 0.2168 6.2013 
15264 0.0016 0.2597 3.2390 0.1086 0.2008 0.2265 6.4449 
15899 0.0019 0.2633 3.2314 0.1136 0.1951 0.2404 6.2522 
16536 0.0015 0.2725 3.2234 0.1177 0.2007 0.2501 6.4736 
17173 0.0016 0.2748 3.1823 0.1218 0.1972 0.2578 6.4502 
17810 0.0015 0.2817 3.1897 0.1292 0.2002 0.2698 6.5012 
18446 0.0016 0.2836 3.1704 0.1295 0.1969 0.2760 6.4341 
19085 0.0019 0.2864 3.1390 0.1332 0.1 911 0.2860 6.2614 
19721 0.0015 0.2915 3.1000 0.1405 0.1942 0.2979 6.4997 
20358 0.0018 0.2932 3.0623 0.1399 0.1899 0.2957 6.3114 
20993 0.0015 0.2993 3.0578 0.1456 0.1918 0.3118 6.5092 
21630 0.0014 0.3025 3.0382 0.1504 0.1914 0.3204 6.5641 
22266 0.0014 0.3012 2.9598 0.1528 0.1877 0.3227 6.5690 
22922 0.0020 0.3069 2.9856 0.1563 0.1833 0.3398 6.2322 
23559 0.0013 0.3118 2.9492 0.1655 0.1889 0.3493 6.6838 
24196 0.0014 0.3172 2.9479 0.1669 0.1870 0.3590 6.5881 
24833 0.0019 0.3173 2.9152 0.1659 0.1805 0.3613 6.2536 
25468 0.0014 0.3243 2.8973 0.1760 0.1856 0.3740 6.5830 
26105 0.0013 0.3297 2.9127 0.1791 0.1878 0.3813 6.6389 
26748 0.0013 0.3320 2.8722 0.1832 0.1855 0.3897 6.6170 
27385 0.0015 0.3379 2.8777 0.1864 0.1861 0.4004 6.4923 
28022 0.0013 0.3370 2.8268 0.1888 0.1826 0.4050 6.6373 
28658 0.0020 0.3364 2.7859 0.1859 0.1740 0.4087 6.2092 
29294 0.0019 0.3414 2.7804 0.1915 0.1779 0.4100 6.2432 
29929 0.0019 0.3422 2.7373 0.1907 0.1717 0.4243 6.2535 
30566 0.0018 0.3483 2.7440 0.1969 0.1738 0.4343 6.2967 
31210 0.0019 0.3514 2.7440 0.1991 0.1758 0.4362 6.2687 
31848 0.0014 0.3594 2.7375 0.2091 0.1802 0.4498 6.5719 
32484 0.0020 0.3591 2.7135 0.2040 0.1714 0.4571 6.1900 
33121 0.0019 0.3575 2.6538 0.2046 0.1687 0.4587 6.2454 
33757 0.0018 0.3615 2.6407 0.2091 0.1698 0.4643 6.3139 
34426 0.0018 0.3677 2.6391 0.2140 0.1723 0.4734 6.3313 
35108 0.0019 0.3690 2.6130 0.2126 0.1686 0.4802 6.2923 
35768 0.0017 0.3700 2.5828 0.2160 0.1694 0.4786 6.3521 
36409 0.0018 0.3761 2.5944 0.2197 0.1681 0.4951 6.3236 
37045 0.0016 0.3768 2.5588 0.2227 0.1684 0.4958 6.4144 
37682 0.0014 0.3826 2.5646 0.2281 0.1725 0.5071 6.6057 
38319 0.0016 0.3818 2.5176 0.2261 0.1664 0.5143 6.4419 
38956 0.0016 0.3919 2.5557 0.2329 0.1725 0.5213 6.4165 
39594 0.0019 0.3885 2.5046 0.2291 0.1639 0.5263 6.2906 
40229 0.0020 0.3947 2.5137 0.2317 0.1655 0.5364 6.2228 
40867 0.0018 0.4003 2.5127 0.2340 0.1663 0.5503 6.3418 
41504 0.0018 0.4010 2.4841 0.2350 0.1640 0.5527 6.2983 
269 
E tal xpenmen 
42141 0.0019 0.3993 2.4463 0.2345 0.1628 0.5509 6.2867 
42777 0.0019 0.4031 2.4398 0.2345 0.1625 0.5584 6.2438 
43420 0.0018 0.4108 2.4420 0.2428 0.1645 0.5730 6.2962 
44057 0.0019 0.4130 2.4318 0.2404 0.1624 0.5806 6.2825 
44693 0.0016 0.4214 2.4413 0.2505 0.1703 0.5926 6.4527 
45075 0.0018 0.4154 2.3827 0.2428 0.1619 0.5863 6.3336 
Data for the reaction of 5-chloro-6-nitrobenzaldehyde 280. 
time (A] [E] [F]anti [B] [F]syn [H] ln[A] 
sec. (M) (M) (M) (M) (M) (M) 
0 0.6053 0.0000 0.0000 4.8053 0.0000 0.0000 0.5020 
420 0.2758 0.0022 0.0125 4.4088 0.0140 0.0000.2 1.2880 
636 0.2058 0.0079 0.0130 4 .3938 0.0166 0.0000.8 1.5806 
1273 0.1 584 0.0100 0.0124 4.3623 0.0194 0.00029 1.8427 
1910 0.1245 0.0105 0.0117 4.3364 0.0213 0.00093 2.0835 
2546 0.0986 0.0118 0.0111 4.2909 0.0214 0.00292 2.3168 
3181 0.0792 0.0119 0.0115 4.2666 0.0225 0.00338 2.5352 
3817 0.0631 0.0141 0.0118 4.2007 0.0234 0.00448 2.7637 
4453 0.0501 0.0147 0.0132 4.1548 0.0262 0.00290 2.9945 
5089 0.0392 0.0148 0.0137 4.0990 0.0263 0.00852 3.2394 
5725 0.0316 0.0149 0.0153 4.0553 0.0266 0.01110 3.4532 
6361 0.0255 0.0176 0.0169 4.0221 0.0305 0.01958 3.6683 
6996 0.0200 0.0185 0.0181 3.9727 0.0278 0.02730 3.9145 
7633 0.0159 0.0168 0.0182 3.9383 0.0280 0.02957 4.1420 
8269 0.0124 0.0154 0.0190 3.9213 0.0294 0.02981 4 .3940 
8905 0.0096 0.0159 0.0192 3.9010 0.0319 0.03623 4 .6509 
9540 0.0075 0.0159 0.0203 3.8981 0.0355 0.04010 4 .8987 
10177 0.0054 0.0209 0.0223 3.9026 0.0367 0.07092 5.2178 
10813 0.0045 0.0164 0.0216 3.8577 0.0374 0.07610 5.4021 
11450 0.0031 0.0231 0.0238 3.8804 0.0374 0.08183 5.7887 
12085 0.0028 0.0175 0.0232 3.8449 0.0293 0.06871 5.8819 
12721 0.0016 0.0205 0.0245 3.8405 0.0336 0.09169 6.4663 
13357 0.0008 0.0224 0.0257 3.8354 0.0356 0.09363 7.1063 
13992 0.0013 0.0173 0.0250 3.8064 0.0291 0.08635 6.6505 
14628 0.0009 0.0200 0.0264 3.8021 0.0320 0.09777 7.0597 
15264 0.0005 0.0222 0.0275 3.7999 0.0350 0.10980 7.5416 
15899 0.0001 0.0208 0.0280 3.7814 0.0327 0.11093 9.0000 
16536 0.0000 0.0199 0.0278 3.7649 0.0318 0.10984 10.3776 
17173 0.0000 0.0215 0.0289 3.7606 0.0344 0.12534 
17810 0.0000 0.0216 0.0293 3.7453 0.0337 0.12986 
18446 0.0000 0.0220 0.0298 3.7311 0.0344 0.13394 
19085 0.0000 0.0183 0.0297 3.7005 0.0283 0.13482 
19721 0.0000 0.0203 0.0310 3.7083 0.0312 0.13523 
20358 0.0000 0.0185 0.0309 3.6721 0.0278 0.13116 
20993 0.0000 0.0202 0.0320 3.6792 0.0319 0.14821 
21630 0.0000 0.0200 0.0321 3.6622 0.0304 0.15058 
22266 0.0000 0.0213 0.0331 3.6538 0.0335 0.15839 
22922 0.0000 0.0200 0.0329 3.6383 0.0308 0.15890 
23559 0.0000 0.0196 0.0336 3.6251 0.0304 0.16296 
24196 0.0000 0.0208 0.0344 3.6207 0.0318 0.16753 
270 
E tal xpenmen 
24833 0.0000 0.0205 0.0348 3.6002 0.0308 0.17279 
25468 0.0000 0.0233 0.0362 3.6135 0.0353 0.17559 
26105 0.0000 0.0206 0.0360 3.5874 0.0299 0.17864 
26748 0.0000 0.0205 0.0363 3.5830 0.0300 0.18287 
27385 0.0000 0.0204 0.0370 3.5719 0.0297 0.18715 
28022 0.0000 0.0197 0.0369 3.5651 0.0295 0.19029 
28658 0.0000 0.0205 0.0376 3.5439 0.0299 0.19435 
29294 0.0000 0.0205 0.0383 3.5463 0.0299 0.20032 
29929 0.0000 0.0202 0.0388 3.5291 0.0296 0.20416 
30566 0.0000 0.0206 0.0390 3.5235 0.0301 0.20785 
31210 0.0000 0.0209 0.0399 3.5105 0.0297 0.21245 
31848 0.0000 0.0201 0.0400 3.5031 0.0298 0.21599 
32484 0.0000 0.0202 0.0405 3.4894 0.0299 0.21979 
33121 0.0000 0.0204 0.0407 3.4846 0.0292 0.22515 
33757 0.0000 0.0198 0.0413 3.4708 0.0295 0.22741 
34426 0.0000 0.0212 0.0421 3.4677 0.0310 0.23075 
35108 0.0000 0.0208 0.0423 3.4504 0.0297 0.23573 
35768 0.0000 0.0227 0.0432 3.4598 0.0331 0.24553 
36409 0.0000 0.0205 0.0428 3.4383 0.0294 0.24684 
37045 0.0000 0.0219 0.0438 3.4354 0.0305 0.24718 
37682 0.0000 0.0212 0.0439 3.4202 0.0306 0.24863 
38319 0.0000 0.0227 0.0446 3.4287 0.0338 0.26050 
38956 0.0000 0.0213 0.0448 3.4047 0.0303 0.25748 
39594 0.0000 0.0215 0.0455 3.4020 0.0304 0.26206 
40229 0.0000 0.0217 0.0458 3.3884 0.0308 0.26552 
40867 0.0000 0.0230 0.0463 3.3788 0.0331 0.27568 
41504 0.0000 0.0219 0.0461 3.3650 0.0308 0.27250 
42141 0.0000 0.0218 0.0470 3.3562 0.0309 0.27487 
42777 0.0000 0.0221 0.0473 3.3559 0.0316 0.28138 
43420 0.0000 0.0230 0.0474 3.3465 0.0325 0.28893 
44057 0.0000 0.0226 0.0486 3.3467 0.0325 0.29384 
44693 0.0000 0.0216 0.0480 3.3210 0.0303 0.29559 
45352 0.0000 0.0218 0.0492 3.3111 0.0310 0.29877 
46000 0.0000 0.0224 0.0490 3.3020 0.0315 0.30089 
46638 0.0000 0.0215 0.0493 3.2786 0.0303 0.29830 
47274 0.0000 0.0231 0.0496 3.2797 0.0329 0.31019 
47912 0.0000 0.0221 0.0491 3.2656 0.0322 0.31084 
48549 0.0000 0.0222 0.0505 3.2519 0.0308 0.31168 
49185 0.0000 0.0222 0.0507 3.2585 0.0309 0.31462 
49822 0.0000 0.0222 0.0508 3.2513 0.0320 0.32226 
50459 0.0000 0.0221 0.0514 3.2418 0.0307 0.32752 
51096 0.0000 0.0227 0.0519 3.2287 0.0319 0.32789 
51738 0.0000 0.0226 0.0521 3.2200 0.0316 0.33016 
52376 0.0000 0.0222 0.0523 3.2094 0.0315 0.33371 
271 
Experimental 
D t £ th a a or f e reac 10n o f2 hl -c 6 •t b oro- -m ro ld h d 281 enza elY' e 
time [A] [E] [F]anti [B] [F]syn [H] ln[A] 
sec. (M) (M) (M) (M) (M) (M) 
0 0.6047 0.0000 0.0000 4 .8053 0.0000 0.0000 0.5030 
420 0.5298 0.1112 0.0464 2.1026 0.0030 0.0007 0.6352 
636 0.5164 0.1280 0.0473 2.1499 0.0045 0.0064 0.6609 
1273 0.4913 0.1353 0.0432 2.1319 0.0070 0.0132 0.7108 
1910 0.4687 0.1418 0.0430 2.1066 0.0081 0.0202 0.7578 
2546 0.4534 0.1476 0.0448 2.1046 0.0081 0.0266 0.7910 
3181 0.4243 0.1498 0.0558 2.0431 0.0133 0.0465 0.8573 
3817 0.4041 0.1492 0.0549 2.0168 0.0159 0.0486 0.9062 
4453 0.3768 0.1470 0.0640 1.9524 0.0178 0.0576 0.9761 
5089 0.3603 0.1478 0.0644 1.9342 0.0192 0.0651 1.0208 
5725 0.3417 0.1484 0.0727 1.9032 0.0219 0.0762 1.0738 
6361 0.3205 0.1485 0.0779 1.8454 0.0238 0.0875 1.1378 
6996 0.3095 0.1498 0.0837 1.8413 0.0292 0.0959 1.1728 
7633 0.2965 0.1502 0.0841 1.8123 0.0302 0.0989 1.2156 
8269 0.2891 0.1519 0.0885 1.8116 0.0348 0.1099 1.2410 
8905 0.2804 0.1515 0.0944 1. 7941 0.0339 0.1162 1.2716 
9540 0.2749 0.1527 0.0962 1.7952 0.0362 0.1223 1.2913 
10177 0.2668 0.1515 0.1004 1.7724 0.0367 0.1266 1.3211 
10813 0.2620 0.1538 0.1119 1.7790 0.0375 0.1414 1.3395 
11450 0.2520 0.1507 0.1096 1.7404 0.0376 0.1431 1.3782 
12085 0.2470 0.1486 0.1191 1.7389 0.0381 0.1545 1.3984 
12721 0.2408 0.1459 0.1217 1.7315 0.0383 0.1592 1.4237 
13357 0.2356 0.1437 0.1261 1.7227 0.0403 0.1638 1.4456 
13992 0.2314 0.1409 0.1304 1.7249 0.0397 0.1707 1.4634 
14628 0.2265 0.1394 0.1372 1.7166 0.0399 0.1766 1.4850 
15264 0.2186 0.1352 0.1431 1.6834 0.0412 0.1842 1.5204 
15899 0.2177 0.1361 0.1462 1.7115 0.0434 0.1885 1.5248 
16536 0.2124 0.1339 0.1490 1.6958 0.0429 0.1946 1.5492 
17173 0.2049 0.1290 0.1614 1.6686 0.0420 0.2071 1.5854 
17810 0.2018 0.1 287 0.1644 1.6684 0.0459 0.2103 1.6006 
18446 0.1959 0.1255 0.1723 1.6439 0.0455 0.2177 1.6304 
19085 0.1931 0.1242 0.1761 1.6493 0.0459 0.2264 1.6445 
19721 0.1875 0.1198 0.1789 1.6276 0.0431 0.2289 1.6741 
20358 0.1819 0.1139 0.1941 1.6033 0.0470 0.2424 1.7046 
20993 0.1788 0.1083 0.1997 1.5998 0.0470 0.2473 1.7213 
21630 0.1751 0.1035 0.2077 1.5901 0.0489 0.2533 1.7425 
22266 0.1705 0.0964 0.2182 1.5755 0.0477 0.2624 1.7691 
22922 0.1688 0.0948 0.2267 1.5858 0.0495 0.2724 1.7789 
23559 0.1643 0.0920 0.2362 1.5674 0.0509 0.2798 1.8059 
24196 0.1594 0.0878 0.2438 1.5442 0.0508 0.2865 1.8366 
24833 0.1581 0.0870 0.2406 1.5534 0.0493 0.2879 1.8447 
25468 0.1528 0.0806 0.2584 1.5272 0.0497 0.3029 1.8789 
26105 0.1497 0.0803 0.2623 1.5167 0.0523 0.3103 1.8992 
26748 0.1475 0.0801 0.2574 1.5111 0.0518 0.3088 1.9138 
27385 0.1422 0.0780 0.2680 1.4827 0.0497 0.3217 1.9502 
28022 0.1402 0.0759 0.2714 1.4782 0.0561 0.3266 1.9649 
28658 0.1396 0.0763 0.2774 1.4863 0.0577 0.3400 1.9689 
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E tal xpenmen 
29294 0.1366 0.0742 0.2835 1.4764 0.0584 0.3437 1.9907 
29929 0.1322 0.0733 0.2814 1.4462 0.0568 0.3455 2.0232 
30566 0.1301 0.0710 0.2947 1.4474 0.0616 0.3638 2.0393 
31210 0.1200 0.0643 0.2851 1.3883 0.0360 0.3281 2.1201 
31848 0.1249 0.0669 0.3060 1.4289 0.0605 0.3784 2.0805 
32484 0.1207 0.0646 0.3070 1.4037 0.0552 0.3749 2.1141 
33121 0.1178 0.0643 0.3073 1.3883 0.0553 0.3768 2.1386 
33757 0.1107 0.0582 0.3113 1.3616 0.0378 0.3651 2.2006 
34426 0.1076 0.0565 0.3119 1.3398 0.0377 0.3652 2.2293 
35108 0.1066 0.0575 0.3140 1.3472 0.0371 0.3734 2.2383 
35768 0.1024 0.0552 0.3190 1.3145 0.0373 0.3758 2.2792 
36409 0.1007 0.0549 0.3222 1.3076 0.0360 0.3827 2.2958 
37045 0.0982 0.0536 0.3302 1.2981 0.0342 0.3944 2.3204 
37682 0.0951 0.0522 0.3337 1.2746 0.0364 0.3989 2.3532 
38319 0.0927 0.0525 0.3309 1.2629 0.0303 0.3966 2.3785 
38956 0.0922 0.0530 0.3396 1.2676 0.0371 0.4114 2.3841 
39594 0.0915 0.0554 0.3396 1.2687 0.0461 0.4145 2.3911 
40229 0.0875 0.0525 0.3464 1.2445 0.0356 0.4190 2.4360 
40867 0.0844 0.0510 0.3438 1.2235 0.0278 0.4174 2.4722 
41504 0.0894 0.0584 0.3511 1.2700 0.0608 0.4475 2.4148 
42141 0.0877 0.0588 0.3615 1.2673 0.0688 0.4748 2.4336 
42777 0.0849 0.0571 0.3646 1.2489 0.0669 0.4790 2.4662 
43420 0.0839 0.0594 0.3654 1.2523 0.0678 0.4846 2.4779 
44057 0.0811 0.0574 0.3681 1.2324 0.0676 0.4881 2.5126 
44693 0.0796 0.0568 0.3704 1.2152 0.0602 0.4848 2.5303 
45352 0.0772 0.0565 0.3670 1.1975 0.0595 0.4802 2.5610 
46000 0.0756 0.0571 0.3696 1.1858 0.0593 0.4887 2.5824 
46638 0.0753 0.0575 0.3794 1.1937 0.0630 0.4976 2.5861 
47274 0.0724 0.0562 0.3813 1.1628 0.0614 0.4986 2.6261 
47912 0.0707 0.0561 0.3792 1.1581 0.0610 0.4999 2.6486 
48549 0.0682 0.0538 0.3829 1.1354 0.0599 0.5031 2.6855 
49185 0.0676 0.0557 0.3822 1.1281 0.0606 0.5060 2.6941 
49822 0.0656 0.0556 0.3880 1.1144 0.0608 0.5143 2.7242 
50459 0.0639 0.0544 0.3977 1.1049 0.0626 0.5251 2.7499 
51096 0.0627 0.0555 0.3957 1.0948 0.0616 0.5243 2.7696 
51738 0.0617 0.0576 0.3904 1.0939 0.0618 0.5265 2.7861 
52376 0.0603 0.0582 0.3970 1.0887 0.0607 0.5319 2.8083 
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